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“We are as forlorn as children lost in the woods. When you stand in front of me 
and look at me, what do you know of the griefs that are in me and what do I 
know of yours. And if I were to cast myself down before you and weep and tell 
you, what more would you know about me than you know about Hell when 
someone tells you it is hot and dreadful? For that reason alone we human 
beings ought to stand before one another as reverently, as reflectively, as 
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1 Summary 
Schizophrenia (SZ) is as severe and phenotypically as well as genetically 
complex neuropsychiatric disorder. Only so-called positive symptoms (e.g. 
hallucinations and delusions) are currently amenable to treatments with 
neuroleptics. Negative symptoms (such as anhedonia, social withdraw) and 
cognitive deficits, however, are not substantially improved by current therapies. 
An impaired function of the prefrontal cortex has been hypothesised as a 
potential cause for the latter symptoms. Impaired NRG1-ERBB4 signalling 
affects cortical circuits formed between inhibitory interneurons and excitatory 
pyramidal neurons. The corresponding dysbalance of inhibition and excitation is 
thought to be causative for the cognitive deficits observed in corresponding gain 
and loss-of-function mouse models. Importantly, genetic association studies 
have identified NRG1 and ERBB4 as risk factors for SZ. Therefore, NRG1-
ERBB4 signalling is among the most promising targets for the development of 
new treatments for SZ.   
This thesis describes the design and development of a split TEV-based co-
culture assay to monitor several steps of the NRG1-ERBB4 signalling cascade 
in one integrated measurement. The assay displays high sensitivity and 
robustness and is applicable to high-throughput approaches. In a proof-of-
principle, the assay was used to screen 727 FDA-approved drugs. 
Spironolactone was recovered as a major hit, acting as an inhibitor of NRG1-
ERBB4 signalling and was validated by an extensive set of secondary assays 
including several technical controls. Moreover, specificity and first mode-of-
action analyses were performed with a panel of assays with NRG and ERBB 
family members as well as different components of the signalling cascade.  
In summary, the assay monitoring proximal aspects of the inter- and 
intracellular NRG1-ERBB4 signalling cascade was successfully established and 
a first hit was validated. The assay qualifies for high-throughput screenings with 
huge libraries of diverse chemical compounds and thus holds a great promise to 




2.1 General characterisation of schizophrenia 
Schizophrenia (SZ) is a severe brain disorder ((Lewis and Lieberman, 
2000)(Lewis and Levitt, 2002), a major mental illness and a severely debilitating 
neuropsychatric disorder (Arnold and Trojanowski, 1996). The term SZ was first 
introduced in the beginning of the 20th century by Bleuler (Pratt et al., 2012). 
Kraepelin described the illness as “Dementia praecox”(Kraepelin, 1896).  
The diagnostic criteria for schizophrenia are described in the ICD 10 
(International Classification of Diseases 10) as well as DSM IV (Diagnostic and 
Statistical Manual of Mental Disorders). These literal classification schemes are 
important, since no biological marker of SZ has been identified so far. The 
classification is based on the categorization of behavioural phenotypes by 
interviews and are inherent to biases possible by the subjective evaluation of 
individual clinicians. Nontheless because our understanding of biomarkers 
based on causal genetic, biochemical or pathophysiological events remains 
scarce (Pratt et al., 2012) there is no alternative. Moreover, the term disorder is 
under debate, shifting to disease (Becker, 2005; Berganza et al., 2005; Steurer 
et al., 2006), taking in account the specific etiology and the discernable 
pathology of SZ (Tandon et al., 2008b). Further debates, to deconstruct the 
term SZ itself as it represents an artificial term for different diseases with similar 
phenotypes are on-going (Tandon et al., 2008a). 
The prevalence of SZ ranges between 0.3% and 2.0%, with an average of 0.7% 
in the population of Western Europe. Although occurring worldwide, SZ seems 
to be independent of culture, political system, or religion (Saha et al., 2005). 
The precise determination of the number of affected subjects is impossible due 
to the lack of biomarkers, valid and reliable diagnosis, and precise demarcation 
between diseased and healthy people (Eaton et al., 2007). 
The onset of the disease occurs usually after puberty or during early adulthood 
(age 15-45) (Fig. 1). Affected men are usually younger than women (average 
five-seven years earlier) when the disease starts and seem to have a slightly 
increased risk to suffer from SZ (up to 1,4 fold higher risk) (Aleman et al., 2003; 
McGrath, 2007). The onset of SZ is usually preceded by a prodromal phase 
with an average lengths of five years (Klosterkötter, 2008). The prodromal 
phase often includes the manifestation of cognitive deficits, impairments in 




After the prodromal phase chronic SZ starts mostly by a psychotic episode. The 
“phenotype” of the disease can further be classified by course (continuous or 
episodic) onset (acute, progressive or stable), and outcome (mild, severe or 
recovery). The most abundant type is an episodic course with distinct psychotic 
episodes. 
  
Figure 1: Schematic representation of the course of schizophrenia, modified from 
(Tandon et al., 2009) 
SZ is characterised by three subsets of symptoms: positive symptoms, negative 




2.3 Positive symptoms  
Positive symptoms are the prominent phenotypic symptoms during an acute 
psychotic episode where patients may suffer from different sorts of 
hallucinations (e.g. visual, audio, tactile, olfactory, or gustatory hallucinations), 
delusions or thought disorders. Patients might suffer upon e.g. hearing of a 
voice keeping up a running commentary on the persons behaviour or thoughts 
or experience olfactory hallucinations like the smell of dead people. The 
patients usually develop more complex delusions (bizarre delusions, delusions 
of control, organisations) severely altering or modifying the perception of reality. 
As a part of this, single symptoms are reported, such as the feeling of thought 
insertions or thought withdrawal, thought echos and thought broadcasting. This 
leads to feelings of suspiciousness or persecution, extending to attempts of 
suicide. In contrast, even grandiosity or hostile behaviour is observed 
depending on the perception content of the delusions. The behaviour of the 
patients is furthermore impaired by disorganised speech and/or disorganised 
behaviour, which can be catatonic, but also a complete disorganisation of 
conceptual thinking. In 75% of patients these positive symptoms can be 
reduced by the use of anti-psychotic drugs. At least 25% of patients do not 
respond to the treatment at all (Tandon et al., 2010; Tandon et al., 2009; 
Keshavan et al., 2008; Tandon et al., 2008b; Tandon et al., 2008a). 
2.4 Negative symptoms 
Negative symptoms are not as prominent as positive symptoms. However, 
negative symptoms can start years before the first psychotic episode and often 
persist after the decline of the psychotic episode. Patients may suffer from 
social withdrawal, reduced, flat or inappropriate affect, alogia (poverty of 
speech), avolition (generalized lack of motivation to perform tasks or undertake 
activities), emotional withdrawal, and poor rapport. All these symptoms distract 
the patients to live a normal social life i.e. they may not be integrated in 
networks of relationships, friends, colleagues, and even medical care personal. 
In particular solitude has been reported by patients to be one of the major 
symptoms ruining the quality of their life. The negative symptoms are poorly 
targeted by classical drugs (Tandon et al., 2009; Tandon et al., 2010). 
2.5 Cognitive deficits 
Furthermore, there is an impact of the disease on the cognitive abilities of the 
patients. These cognitive deficits are the most debilitating and persistent deficits 
in SZ. A drop in performance in every-day life regularly accompanies the 
progress in the development of the negative symptoms, e.g. at school, at the 
university or in professional life. Cognitive impairments are further impaired with 
the onset of psychotic episodes. Deficits in working memory, difficulties in 
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abstract thinking or stereotyped and inflexible thinking are usually observed. 
The cognitive deficits remain impaired after fading of the psychotic episode and 
can worsen with further episodes or over time. The cognitive deficits, as the 
negative symptoms, do not respond regularly to medication and remain largely 
resistant to treatment (Arnold and Trojanowski, 1996; Pratt et al., 2012). 
Negative and cognitive symptoms are not efficiently targeted by available drugs 
and are factors which most significantly contribute to worsening of patients 
individual quality of life. SZ is laying an annual burden of 30 billion € on the 
European health care systems (33 billlion US dollars in 1999 worldwide (Bayer 
1999)) and is among the top ten leading causes of disease related disability in 
the world (WHO statistics 2001, (Tandon et al., 2008b)).  
 
Figure 2: Triade of SZ symptoms: positive symptoms, negative symptoms and 
cognitive deficits are shown with exemplary phenotypes 
2.6 Comorbidities 
Single symptoms, or even mixtures of the symptoms described above, can also 
occur in various other mental diseases. For the differential diagnosis of SZ by a 
psychiatrist, different other illnesses e.g. depression, brain tumour, have to be 
ruled out as causative for the symptoms or, if occurring in parallel, separately 
treated. The diagnosis is further complicated by a high rate of psychiatric 
comorbidity in the patients. The most frequently present psychiatric 
comorbidities are depression, suicide tendency, substance abuse, sleep 
disturbances and addiction.  
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Diabetes mellitus, autoimmune disorders and cardiac autonomic dysregulation 
are the most often described non-psychiatric comorbidities. Furthermore, the 
medications lead often to severe side effects e.g. metabolic syndrome or 
tiredness, which have to be necessarily addressed in the treatment of SZ as 
well. In general, the health state of the SZ patients is most likely impaired in 
multiple ways (Ferentinos and Dikeos, 2012; Kodesh et al., 2012). 
2.7 Residual symptoms 
There is a set of residual symptoms, which occur with an acute psychotic 
episode and remain present thereafter. This has been described for most 
negative symptoms like social withdrawal or flat affect, or mild positive 
symptoms like eccentric behaviour or odd beliefs (de Bartolomeis et al., 2012).  
Subtypes of schizophrenia 
For a better diagnosis, SZ is subdivided in different phenotypic subtypes (Tab. 
1). The usefulness of this diversion is debatable. 
Type Description 
Paranoid (F20.0) hostile or threatening auditory hallucinations, 
delusions 
Catatonic (F20.2) motoric immobility, stuporous catatonia or 
exited catatonia / excessive motor activity, 
echolalia, echopraxia 
Disorganized (F20.1) disorganized speech, disorganized behaviour, 
flat or inappropriate affect  
Undifferentiated (F20.3) mixture or emerging process of different 
subtypes 
Residual (F20.5) Absence of prominent delusions, 
hallucinations etc., presence of negative 
symptoms  
Table 1:   SZ subtypes with the most prominent behavioural phenotypes. 
Depicted are the 5 common subtypes of SZ used, when diagnosed by a psychiatrist. The 





2.8 History of schizophrenia 
The first identifications of mental illnesses and attempts to cure these are 
unknown but it´s history might be as old as human consciousness itself. 
Symptoms of a mental disease were first mentioned 3400 years BC in the Book 
of Heart, an Egyptian papyrus (Okasha, 1999; Okasha, 2001; Mohit, 2001). 
However, whether these mentions can be linked to SZ is unclear or remains 
elusive, as this medical term did not exist at that time. Other descriptions, of 
putative SZ phenotypes, were found in the Indian vedas and in some books of 
the bible e.g. Nebukadnezar written ca.1400 BC. Skulls with trepanations are 
sometimes interpreted as early attempts to cure mental diseases (Clower and 
Finger, 2001).  
The Greek philosophers Thales, Phytagoras, Galen, and Hippocrates provided 
the first theories of the mind and consciousness, and what mental diseases 
possibly could be at ca. 550 BC. The theories included natural courses and 
miss-regulations of the four humours. The function of the brain itself was poorly 
understood (Missios, 2007).  
During the dark ages mental illnesses were regarded as evil possessions and 
no progress in theories could be made. Exorcisms and witch burnings were 
regular events. In 1357, the Bethlem asylum was founded in London, where 
dangerous mental diseased patients were simply chained and locked away. 
In the 17th century, John Locke (1632-1704) came up with the theory that the 
brain is empty at birth and is filled in a process of learning by e.g. sensory input. 
Mental diseases are regarded as a disconnection of the relationship between 
the environment and the affected person. 
In the 18th century Phillippe Pinel (1745-1826) began to unchain the patients in 
the asylums.  
In the 19th century Wilhelm Griesinger (1818-1868) proposed that the brain is 
the origin / source of the mental diseases, and that these diseases are complex. 
In addition he shaped the term “unitary psychosis”. 
Emil Kraeplin (1856-1926) proposed the dichotomy between “dementia praecox” 
and “bipolar disorder”. He also observed the symptoms in longitudinal manner 
and was convinced that an organic brain disease causing SZ symptoms exists. 
In 1897 Alois Alzheimer published the first study on patients having SZ 
symptoms. 
In 1911 Eugen Bleuler (1857-1939) coined the term “schizophrenia” He based it 
on the Greek words skhizein = to split and phren = mind. 
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The first half of the 20th century was dominated by eugenic and social 
darwinistic pseudo-science, that even lead to mass murder on mentally 
diseased patients in Germany (“Action T4”). In 1952 the first international 
congress on neuropathology in Rom concluded: “There is no neuropathology of 
SZ”. 
In 1976 a computer tomography (CT) study on schizophrenic brains conducted 
by Johnstone showed an enlargement of the lateral ventricles. Meanwhile, the 
development of neuroleptics allowed for the first time to a state of control of the 
psychotic disease symptoms, which permitted ¾ of the patients to leave the 
asylums, e.g. in USA the number of patients in asylums decreased from 
600,000 to 150,000. A wide range of treatment strategies were developed 
starting from lobotomy, relaxing therapies, lithium, insulin coma, to 
psychotherapy and psychoactive drugs (Jeste et al., 1985, Ellard, 1987). For 
further readings see (Russel and Cohn 2012)  
2.9  Morphologic findings in schizophrenia  
The cause of the disease remains unknown. Although the behavioural 
phenotype is strong, the morphological abnormalities in the brain are more 
subtle and elusive. SZ is nowadays considered as a multifactorial disease 
including multiple genetic and environmental components, potentially modulated 
by epigenetic- risk factors. (Tandon et al., 2008b; Tandon et al., 2009). In detail 
the following findings are validated and discussed. 
Magnetic resonance imaging (MRI) showed in first episode SZ patients a 
reduction of the total brain volume, an enlargement of the ventricles and a 
reduction of the volume of the hippocampus. Analysis of high-risk individuals 
shows growing evidence for subtle abnormalities of hippocampal and ventricular 
volume in close relatives of SZ patients (Whalley et al., 2012). 
Only a few degenerative processes are described for SZ (Meyer-Lindenberg, 
2011). A dynamic wave of accelerated grey matter loss has been published 
(Honea et al., 2008). The loss is most prominent in the early phases of SZ. First, 
the parietal regions are affected, afterwards the temporal lobes, and 
subsequently changes in dorsolateral prefrontal cortices and superior temporal 
gyrii are observed. The yearly grey matter loss in SZ patients has a rate of 0,5% 
compared to 0,2% in healthy individuals (Rund, 2009). 
Medical findings in SZ patients using EEG recordings are not specific for SZ. 
Deficits in sensory-motor gating measured as pre-pulse inhibition are observed. 
However, again they are not specific for SZ and are present in other psychiatric 
diseases as well. Moreover, SZ patients display impairments of synchronisation 
of different brain areas (Fig 12). A disturbance in sensory gating of the p50 
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wave is often found in SZ patients. A failure in the corollary discharge system is 
hypothesized as causative for hallucinations (Ishii et al., 2012). 
Autopsies taken from post mortem brains of SZ patients show a decrease in 
brain weight and brain length, a decrease of the volume of cerebral 
hemispheres, and an enlargement of the ventricles (Kleinman et al., 2011). 
In vivo neuroimaging studies revealed alterations in the ventricular system. SZ 
brains display abnormalities in the cavum septi pellucidi, an enlargement of the 
lateral ventricles, and the third ventricle. The grey matter volume is decreased 
in the prefrontal cortex. A decrease in the thalamus, temporal lobe structures, 
medial temporal lobe (hippocampus/amygdala), and the superior temporal 
gyrus is described. The white matter integrity is decreased in all four cortical 
lobes (Fornito et al., 2012). 
At the cellular level microscopic studies of the hippocampus and prefrontal 
cortex have shown no overall change in neuron numbers, but a size reduction 
of the mean neuronal soma, and a higher package density of neurons in the 
prefrontal cortex. The thalamus displays a lower number of neurons in the 
mediodorsal, anteroventral, and anteromedial nuclei. The entorhinal cortex is 
characterised by a poorly developed layer II and a disturbance in the layer 
structure (Arnold and Trojanowski, 1996). 
Other theories in the field link findings of auto immune reactions and micro glia 
malfunctions to the disease (Monji et al., 2009). For further information, see 
(Hanisch and Kettenmann, 2007; Chen et al., 2010). 
Fast progress in individualised medicine enabled derivation of human induced 
pluripotent stem cells (hiPSC) from patients. The re-programming of patient 
fibroblasts infected with lentiviruses containing genes for the factors Oct4, 
SOX2, KLF4, cMYC, and Lin 28, lead to the growth and differentiation of 
disorder specific neurons. The SZ hiPSC display diminished neuronal 
connectivity and reduced expression of PSD95 and glutamate receptors. 
Moreover, alterations in the expression of components of cyclic AMP (cAMP) 
and the WNT signalling pathways have been reported. Furthermore, the 
neurons obtained from hiPSC of SZ patients respond to antipsychotic treatment. 
Experiments on hiPSC of SZ patients give for the first time an unique 
opportunity of investigating SZ in vitro which offers a tremendous potential to 
find new personalised treatments for SZ patients (“SZ in a box”) (Brennand et 
al., 2011). 
2.10  Genetic studies 
Adoption studies, twin studies, family-based studies, and population studies 
showed an increased risk to develop SZ depending on the degree of kinship 
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(Sullivan et al., 2003). The average prevalence in any society in any country in 
the world to develop the illness is 0,7% (Saha et al., 2005). For children of two 
SZ-positive parents, and for gene identical monozygotic twin where the other 
suffers from SZ the overall risk is increased to 40%-50% (Ayhan et al., 2009). 
The overall genetic impact on the development of SZ is estimated 70%-80% 
(Sullivan et al., 2003; Wexler and Geschwind, 2011). Family-based studies 
identified a gene that is disrupted and plays a role in the disease (disrupted in 
SZ: DISC1, Scottish family). However, genome-wide genetic association studies 
(GWAS) failed to identify a single gene or a specific subset of genes being 
causative for the disease. Nevertheless, it was possible to identify different 
single nucleotide polymorphisms (SNPs) and rare copy number variations 
(CNVs) in genes, which seem to be associated with brain changes leading to 
higher vulnerability (Sebat et al., 2009). The precise contribution of each genetic 
alteration remains unclear and combinatorial effects of different risk alleles are 
debated as effective cause (Allen et al., 2008; Jia et al., 2010). In addition, a 
current model suggests that a set of complex disease pathways, where various 
different alleles lead in different combinations to disparate neuropsychiatric 
disorders (Figure 3) (SZ, bipolar and unipolar depression, mental retardation, 
seizures and autism, no clear demarcation lines) (Karam et al., 2010). This 
model also emphasizes that the discovery of a single pharmacological 
intervention treating all symptoms at once is highly unlikely. In contrast, newly 
developed drugs probably target similar symptoms in different neuropsychiatric 
disorders (Karam et al., 2010). 
 
 
Figure 3: Model for SZ: The endpoint result is different SZ types (Tandon et al. 2008) 
Some of the most frequent SZ susceptibility genes are: 
2.10.1 DISC1  
The DISC1 (disrupted in schizophrenia 1) gene was linked to the disease by St 
Clair in 1968, when he discovered a chromosomal translocation from 
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chromosome chr.11 to chr1 in a Scottish boy. The translocation truncated a 
single gene, DISC1. The truncation was present in a half of the boy’s family that 
was diagnosed with severe mental diseases. Later linkage of DISC1 to SZ was 
confirmed in Finish, Caucasian and Asian populations.  
DISC1 is a large scaffolding protein (93kDa), prominently expressed in the 
human hippocampus. It interacts with MAP1a, GSK-3, PDE4, FEZ1, and 
NDEL1. DISC1 is also downstream of the NRG1-ERBB4 signalling cascade (St 
Clair et al., 1990; Millar et al., 2000; Kang et al., 2011; Wexler and Geschwind, 
2011). 
2.10.2 NRG1-ERBB4  
The first findings on impaired NRG1-ERBB4 (Neuregulin1 - receptor tyrosine-
protein kinase v-erb-a erythroblastic leukemia viral oncogene homolog 4) 
signalling were made by Stefansson and colleagues in the genome wide 
association studies on an Icelandic population (Stefansson et al., 2002). The 
identified SNP SNP8NRG243177 or ‘icelandic’ haplotype (HAPice) has been 
associated with several schizophrenia-like phenotypes, e.g impaired frontal and 
temporal lobe activation, deficits in cognitive functions and a predisposition for 
the development of psychotic symptoms (Hall et al., 2006).  
Until 2009, more than 80 SNPs in the NRG1-ERBB4 receptor-ligand pair have 
been associated with SZ (Sebat et al., 2009). Patients with alterations in the 
Nrg1 gene display endophenotypes like decrease in pre-puls inhibition (Hong et 
al., 2008), reduced integrity of the white matter (McIntosh et al., 2008; Winterer 
et al., 2008), hypofrontality, cognitive dysfunction and decreased IQ (Hall et al., 
2006). Most genetic polymorphisms of the Nrg1 gene are found in the 5’ region, 
the regulatory element of the Nrg1 gene (Harrison 2006). It is speculated that 
this alterations contribute to alterations in gene function and expression. A 
meta-analysis of up to 24 different studies in diverse ethnic groups successfully 
confirmed these findings (Munafò et al., 2006; Li et al., 2004; Li et al., 2006).  
The Nrg1 gene is a key player of numerous processes implicated and 
discussed in the development of SZ. NRG1 contributes to myelination, 
development of glial cells, migration of radial glial cells during cortical 
development, neuronal plasticity modulated by NMDA receptor function, 
development of GABAergic interneurons, and expression of dopamine and 
serotonin receptors and monoamine transporters (Mei and Xiong, 2008). 
Furthermore, NRG1 modulates the formation of dendritic spines (Chen et al., 
2008), and gamma oscillations in the hippocampus (Fisahn et al., 2009). Mice 
heterozygous for Nrg1 show schizophrenia-related phenotypes resembling 
symptoms observed in SZ patients (see below). 
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NRG1 has been shown to increase the expression of 7-nicotinic receptors 
(Hancock et al., 2008). It is postulated that alterations in NRG1 mediated 
signalling changes the nicotinic receptor profile in presynaptic inputs, leading to 
deficits in pre-puls inhibition by altering glutamatergic transmission from the 
ventral hippocampus to the nucleus accumbens (Karam et al., 2010). 
Additionally, the NRG1-ERBB4 signalling pathway is a major input for various 
pathways, involving PI3-kinases, PTPRZ1-RTP-phosphatase, BACE secretase, 
and the afore mentioned DISC1. Many of these are hubs at information 
processing, and may be suitable as future drug targets (Jaaro-Peled et al., 
2009; Höistad et al., 2009). 
2.11  Environmental factors 
Many studies show the importance of environmental factors in onset, cause and 
severity of the disease. The concordance for SZ in monozygotic twins is only 
50%. Therefore genes cannot be the only cause for the disease. The most 
prominent environmental factors contributing to development of SZ are 
antenatal or obstetric complications (hypoxia, maternal infections, maternal drug 
- intake) (Nicodemus et al., 2008)), migration (first reported by Odegard 1932, 
(Cantor-Graae and Selten, 2005), urbanicity (Kirkbride et al., 2006), parental 
age, malnutrition and psychotrauma (Keshavan et al., 2008). All these factors 
seem to create psychosocial stress. Just like the genetic factors, environmental 
factors alone fail to explain the disease (Fig. 3). The combination of genetic and 
environmental factors leads to the “Two Hit Hypothesis”. 
2.12  Two hit hypothesis  
The “Two Hit Hypothesis” of SZ integrates the genetic and environmental 
observations. The combination of one, or of different genetic defects, either 
inherited, or de novo mutated, generates a state of vulnerability e.g. a deficient 
neuronal network. Stressful environmental effects like viral infections, birth 
complications, or social stress as a second hit can subsequently trigger the 
outbreak of SZ by modulating the expression or function of the defective genes 
or proteins (Bayer et al., 1999; Maynard et al., 2001). 
 The proposal of a “Three Hit Hypothesis”, additionally taking in account drug 
effects like cannabinol (THC), as an additional player to genes and environment 




2.13 Findings in animal models of schizophrenia 
Animal models of diseases, reflecting the genetic findings, are highly desired 
and deliver valuable information about the disease. The problem with animal 
models of complex diseases, which cannot be associated with a single gene, or 
that are multifactorial disorders like SZ, is to generate a valid model for a 
disease.  
A valid animal model has to meet the following criteria: 
- Face validity (animal model shows the symptoms of the disease) 
- Construct validity (animal model has the same mutation or genetic 
alteration underlying the mechanisms of disease aetiology) 
- Predictive validity (animal model responds to treatments similar as 
patient) 
As the precise cause and the multi factorial interaction remains unknown, 
construct validity of the different animal models in SZ is not possible. Consistent 
with the complexity of the disease and spectrum of symptoms, genetic research 
has led to the development of several animals models that are thought to mimic 
parts of the disease. They show a broad spectrum of endophenotypes similar to 
observations of a few positive symptoms, negative symptoms, and cognitive 
deficits in SZ but “the schizophrenia model” will not be possible to generate 
(Kellendonk et al., 2009). 
The first mouse models in the field were drug induced ‘psychotic’ models. Mice 
were simply treated with Amphetamine or Phencyclidine until they show 
psychotic behaviour (such as motor hyperactivity) and were subsequently 
treated with the newlz developed putative drugs (Javitt and Zukin, 1991). 
Amphetamine leads to an over activation of the dopaminergic system and   
Phencyclidine leads to an over activation of the glutamatergic system. The 
Dopamine- and Glutamate-Hypotheses sprouted from these observations.  
Drugs could be tested afterward with these models which lead e.g. to the 
discovery of antipsychotic drugs like Haloperidol (1958), which is still used to 
treat psychotic episodes in SZ patients. However, these setup of drug discovery 
remains serendipitous (Pratt et al., 2012). 
2.13.1 Dopamine hypothesis of schizophrenia 
Dopamine belongs to the family of monoamines and acts as neurotransmitter or 
neuromodulator. It is recognised via G-protein coupled receptors, localised in 
the prefrontal cortex, nucleus acumbens, and the striatum. Decreased Dopamin 
in the prefrontal cortex and increased dopamine in the mesolimbic pathwayarer 
key findings for SZ (Goldman-Rakic et al., 2004) The classic dopamine 
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hypothesis postulates that the drug class of neuroleptics (e.g. Droperidol) act as 
dopamine receptor antagonists (van Rossum, 1966; van Rossum, 1967). There 
is a correlation between affinity of these antipsychotic drugs to the Dopamine 
D2 receptor subtype and the clinical efficiency in countering hallucinations and 
delusions(Seeman and Lee, 1975). They are hypothesized to block dopamine 
receptors in the mesolimbic dopaminergic system. This leads to the alleviation 
of the positive i.e. psychotic symptoms. Unfortunately, side effects resulting 
from dopamine blockade in the nigrostriatal and hypothalamic-pituitary systems, 
phenotypically similar to Parkinson’s disease, hyperprolactinemia, sedation and 
hypertension can be observed (Pratt et al., 2012, Vigano et al., 2009). 
In 1991, a modified dopamine hypothesis was postulated (Davis et al., 1991, 
Biedermann and Fleischhacker, 2009) .Cortical hypoactivity, leads to negative 
symptoms, therefore neuroleptics show no effect. It is based on the observation 
that humans with frontal lobe brain damages or lobotomy show symptoms 
similar to SZ negative symptoms. Subcortical hyperactivity, leads to the positive 
symptoms, which are partially reduced by neuroleptics. Only the D2 receptor 
subclass, localized in the striatum (subcortical) is targeted by all relevant 
antipsychotics (Sanyal and Van Tol, 1997). 
2.14 NRG1-ERBB4 animal models  
The finding of impairments in the NRG1-ERBB4 system by GWAS, led to an 
increased interest in the analysis of different genetically manipulated Nrg1 and 
Erbb4 mice to study neuronal and behavioural phenotypes.  
Mice that are homozygous null for Erbb4 are dying at postnatal day (P) 10,5 - 
11 because of developmental heart failure (Tidcombe et al., 2003). Heart 
rescued mice (to prevent developmental death) show defects in neuronal 
architecture. 
Heterozygous knock-out (KO) mice of Nrg1 show hyperactivity and pre-pulse 
inhibition deficits, one of endophenotypes of SZ.  
Nrg1 overexpression (Stefansson et al., 2002), altered social behaviour and 
increased anxiety (Desbonnet et al., 2009), memory deficits, reduced inhibitory 
interneuron numbers and increased ventricular volume (Chen et al., 2008). 
These findings resemble symptoms observed in SZ patients. 
Nrg1-typeIII overexpressing mouse models and the ErbB4 heterozygous mouse 
model could be used to validate effects of Nrg1-ERBB4 mediating drugs. 






Nrg1.I Overexpression Increased locomotor activity, non-significant trend 
towards decreased pre-pulse inhibition, decreased 
context depending fear learning (Kato et al., 2010). 
reduced GABAergic (parvalbumin) and myelination 
marker in the frontal cortex (Kato et al, 2008). 
Alterations in hippocampus. Hypermyelination and  
ataxia for high gene dosage (Brinkmann et al., 2008)  
 Heterozygous KO Behavioural phenotype linked to SZ phenotype 
(Stefansson et al., 2002) Fewer functional NMDA 
receptors, react to clozapine (Bjarnadottir et al., 2007) 
 Homozygous KO Die during embryogenesis, heart malformations 
(Meyer and Birchmeier, 1995) 
Nrg1.III Overexpression Hypermyelination (Velanac et al., 2012; Michailov et 
al., 2004)  ataxia for high gene dosage (Brinkmann et 
al., 2008) 
 Heterozygous KO Poor ensheathment of sensory neurons, 
disproportionately unmyelinated or hypomyelinated 
nerve fibres. Failure in myelination (Taveggia et al., 
2005; Taveggia et al., 2008). 
 Homozygous KO Not separated from Nrg1.I 
ErbB4 Overexpression Generation and characterization of GAD67-ErbB4 
transgenic mice. (Work in progress Lin) 
 Heterozygous KO Behavioural phenotype linked to SZ phenotype 
(Stefansson et al., 2002)  
 Homozygous KO Lethal at embryonic day (E) 10,5-11, failure in heart 
development  (Tidcombe et al., 2003). 
 Homozygous KO heart 
rescue phenotype 
Defects in cranial neural crest cell migration, aberrant 
cranial nerve architecture, increased number of large 
interneurons, lactation deficits. Lack of STAT5A 
phosphorylation (Liu et al., 1997, Fried et al., 2002). 
Altered populations of hippocampal interneurons 
(Neddens and Buonanno, 2010). 
Table 2. Shown are the effects of alterations in the Nrg1-ErbB4 signalling system in mouse 
animal models.  
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Several studies combined genetic modified animal models of SZ with 
environmental factors like e.g. stress (isolation stress in single caging, 
psychosocial stress by social defeat or maternal separation etc.). This is 
thought to mimic the “Two Hit” hypothesis of SZ in the respective animal model. 
SZ is a human specific disorder diagnosed by a psychiatrist and obviously 
cannot be exactly matched in any animal model. Nonetheless, several mouse 
models display behavioural alterations resembling certain (endo)phenotypes of 
SZ (Tab. 3). The construct validity underlying these phenotypes, especially 
regarding modelling of positive symptoms of SZ, is often under debate. 
 
Domain  Schizophrenia in humans Rodent phenotype 
Positive 
symptoms 
Psychomotor agitation Hyperlocomotion in open field 
Catatonia Catatonia like state in bar test 
Hallucination, delusion, thought 
disorders 
Lack of readouts 
Negative 
symptoms 
Social withdrawal Decrease in social interaction 
Decrease in nest building ability 
Restricted interest, stereotypic 
behaviour 
Repetitive behaviour  
Affect flattening Lack of reliable readouts 
Anhedonia Decrease in sucrose preference 
Cognitive 
symptoms 
Working memory deficits Impaired performance in T-maze 
Impaired performance in 8-arm maze 
Decreased spontaneous alternation 
in Y-maze 
Deficit of attention Decrease sustained attention in 
5CSRTT 
Decreased set shifting ability 
Decreased spatial reversal or 
reversal of discriminant operant 
learning 
Disturbance of sensorimotor gating Diminished pre-pulse inhibition  




2.15  NRG1-ERBB4: from proteins to network analysis 
2.15.1 Why addressing the NRG1-ERBB4 signalling system? 
As described above, gene defects play the major part in the development of the 
vulnerability to SZ. Nonetheless, available studies fail to link the disease to a 
single gene or to a precise subset of genes. Therefore, the assumption that SZ 
is a generic term or a superordinate concept of different diseases ending up in a 
similar set of similar or slightly different phenotypes is presumable. If there is 
not “one schizophrenia” existing with one causative SZ gene, I assume that 
newly developed drugs, for a determined subset of patients are the auspicious 
novelties. The NRG1-ERBB4 signalling network seems to be one of the most 
promising and best accessible SZ key players to address in the development of 
new drugs. In detail the following subsets of information on NRG1-ERBB4 are 
available.   
2.15.2 Protein-protein-interactions and NRG1-ERBB4 signalling 
Specific protein-protein-interactions (PPI) in cells are the basic units of 
signalling cascades.  Most cellular processes are regulated through signalling 
cascades or more complex structures of interlinked cascades named signalling 
networks or pathways (Neddens and Buonanno, 2010). Signal processing 
needs different regulation of information. This leads to diversification, 
amplification, diminution or alteration of the signal and interexchange between 
different cascades. The endpoints of signalling cascades are changes in 
expression levels of the cellular proteins thereby inducing apoptosis, 
proliferation, growth or other changes in cellular behaviour. 
Of crucial importance for an inter-cellular communication is the reception of 
signals from other cells. Signals are transferred from the outside to the inside 
through a ligand representing the stimulus activating specific transmembrane 
receptors. Once activated, receptors recruit adaptor molecules and activate 
signalling cascades forwarding information through the cytosol to the nucleus. 
In the cytosol further processing takes place and different signal cascades are 
interlinked. In the nucleus gene activity is modulated according to the processed 
information, causing on and off switching of genes or modulating the gene 
expression (Taniguchi et al., 2006). A plurality of subsequent processes for 
example protein turnover and stress reactions to low oxygen levels are 
important parts of signal processing (Fishman and Porter, 2005). 
The overall architecture of the NRG1-ERBB signalling system is organised in a 
bowtie or hourglass like structure (Fig. 4). A multitude of ligands binds to 
corresponding subtypes of ERBB receptors, thereby activating a handful of 
adapters and then initialising various cascades to deliver signals to the nucleus 
(Yarden and Sliwkowski, 2001; Oda et al., 2005). Drugs and pharmacological 
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substances can act through binding of receptors outside the cells, or by 
inhibiting the functionality of enzymes, or alter the structure of proteins and 
protein complexes (Oda et al., 2005; Yarden and Pines, 2012). 
 
Figure 4: Bowtie structure of the ERBB signalling network (Yarden and Sliwkowski 
2001) 
2.15.3 Neuregulin1 
Neuregulins (NRGs) are signalling molecules or ligands that bind to specific 
receptor tyrosine kinases (RTKs) i.e. ERBB3 and ERBB4. The Neuregulin 
family consist of four genes named Nrg1-Nrg4. The best characterised ligand is 
Neuregulin1 (NRG1). More than 31 isoforms of this ligand are described (Falls, 
2003). The effect of the NRG1 ligand depends on the cell type, tissue context 
and activated receptors. NRG1 acts e.g. as differentiation factor in the 
peripheral nervous system (PNS) (Adlkofer and Lai, 2000) and regulates myelin 
sheet thickness in axon-Schwann cell interactions (Michailov et al., 2004). In the 
central nervous system (CNS) NRG1 promotes synaptogenesis (Kwon et al., 
2008; Ozaki et al., 1997). 
Historically, NRG1 was associated with various biological functions. First, it was 
named Heregulin/neu differentiation factor (HRG/NDF) that activates HER/neu-
oncogenes or glial growth factors that promote proliferation of Schwann cells 
(Grossmann et al., 2009; Brockes et al., 1980). Furthermore, NRG1 was found 





Figure 5: Splice variants of Nrg1 (modified Mei XIong 2008) 
The three most abundant splice isoforms of NRG1 in mice are Nrg1-typeI-1a, 
Nrg1-typeII-1a and Nrg1-typeIII-1a (Fig. 5). All isoforms harbour a C-terminal 
transmembrane domain, but differ in the N-terminus. Type I and type II harbour 
an extracellularly localised immunoglobulin like (Ig-like) domain. In contrast, 
type III contains a cysteine-rich domain (CRD) with an additional 
transmembrane domain.  The transmembrane isoforms of NRG1 are cell type 
dependently processed by a set of metalloproteases, e.g. TNFalpha-converting 
enzyme (TACE) or beta-site APP cleaving enzymes (BACE). When cleaved, the 
NRG1 intracellular domain can back signal to the nucleus and the extracellular 
domain acts as a paracrine (type I-II) or as juxtacrine signal (type III) (Mei and 
Xiong, 2008). 
NRG1 binding activates ERBB3 and ERBB4 receptors by inducing homo- and 
hetero-dimerisation of ERBB1-4 receptors, in particular NRG1 can activate 
ERBB1-3, 1-4, 2-3, 2-4, 3-3, 3-4, 4-4 receptor pairs (Mei and Xiong, 2008). It is 
postulated that a single ligand is sufficient to activate the dimers (Liu et al., 
2012). 
The most prominent bioactive part of all Nrg1 isoforms is the EGF like domain.  
The EGF like domain is 55 amino acids (AA) long (Fig. 6). A 62 AA stretch, 
resembling NRG1 AA Thr176–Lys238, including the EGF like domain, is 
commercially available via different manufactores. Thiss domain is 
overexpressed in bacteria and afterwards purified. It is highly active and 





Figure 6: Amino acid sequence of NRG1. Complete precursor chain of NRG1-beta, the 
EGF like domain is highlighted in red. Modified from Reprokin. 
 
2.15.4 ERBB receptor tyrosine kinase family 
In humans there are four different ERBB receptors described, named EGFR, 
ERBB2, ERBB3, and ERBB4. Some of them have different splice variants.  
ERBB receptors recognise specific signalling molecules e.g. NRGs or EGF and 
react by forming homo or hetero dimers. The receptor-complexes promote the 
signal by cross-phosporylation by tyrosine kinase activities and subsequent 
recruitment of phosphor-adaptor molecules, that than lead to the activation of 
further signalling cascades. 
ERBB1 EGFR HER1 mErbB1 
ERBB2 Neu HER2 mErbB2 
ERBB3  HER3 mErbB3 
ERBB4  HER4 mErbB4 
Table 4. Names and synonyms for ERBB receptors. HER: human epidermal growth factor 
receptor. 
 m: murine, (Citri and Yarden, 2006; Yarden and Sliwkowski, 2001) 
All ERBB receptors are glycosylated type I trans-membrane proteins 
characterised by four extracellular domains (I-IV) and one intracellular tyrosine 
kinase domain (Fig. 7 and 8). NRG ligands bind to the extracellular domains I 
(L1) and III (L2).   The cysteine rich domains II and IV take part in the receptor 
dimerization (Burgess et al., 2003). After dimerization, the receptors 
phosphorylate each other, shift to the trans state and activate signalling 
cascades via adaptor recruitment. All ERBB receptors are capable of forming 
homo- or heterodimers with each other (Yarden and Pines, 2012). 
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ERBB2 lacks the ability to bind to ligands (Marmor et al., 2004, Yarden and 
Sliwkowski, 2001). Furthermore, the receptor shows high auto-phosphorylation 
levels (Lonardo et al., 1990) which leads to its constitutive activity (Di Fiore et 
al., 1990). ERBB2 is a classical breast cancer candidate being the first receptor 
ever targeted utilising an antibody (Trastuzumab, trade name Herceptin 1998)  
in an anti-cancer therapy (Hudis, 2007). The preferred binding partners for  
ERBB2 are ERBB3 and ERBB4 (Tzahar et al., 1996). 
ERBB3 has no active tyrosine kinase domain. The receptor can bind to adapter 
molecules but its hetero-dimerisation is necessary for promoting signals 
(Carraway et al., 1994).  
ERBB4 is the most similar receptor compared to EGFR (Plowman et al., 1993). 
At least 4 different isoforms of the receptor are known: ERBB4-JM-a-CYT-1, 
ERBB4-JM-a-CYT-2, ERBB4-JM-b-CYT-1, ERBB4-JM-b-CYT-2 (Tzahar et al., 
1996). 
The splice variant JM-a, has an extracellular cleavage site in the stalk-region 
next to the transmembrane region. The cleavage site can be processed by 
TACE (tumour necrosis factor- converting enzyme) and -secretase (Rio et al., 
2000; Ni et al., 2001). The processing cleaves the receptor into two fragments: 
an extracellular and an intracellular one being able to shuttle to the nucleus and 
acting as transcriptional activator (Williams et al., 2004; Vidal et al., 2005). 
The second splice variant defined by the inclusion (Cyt1) or the exclusion (Cyt2) 
of exon 26. Importantly, exon 26 harbours the binding site for the regulatory 
domain PIK3R1, promoting PI3K signalling (Elenius et al., 1999; Carpenter, 
2003). 
The activation of receptor pairs is ligand-dependend and specific. NRG1 and 
NRG2 bind to ERBB3 and ERBB4, whereas NRG3 and NRG4 seem to bind 
only to ERBB4. EGF and TGFactivate EGFR only (Marmor et al., 
2004,Yarden and Sliwkowski, 2001). 
The expression patterns of the receptors in the brain are cell type-dependent. 
The receptor pair ERBB2/ERBB3 is expressed in glial cells, and the pair 
ERBB2-ERBB4 in neurons (Buonanno and Fischbach, 2001). ERBB4 is 





Figure 7: Functional and structural features of ERBB receptors that are unique to each 
receptor  
The black arrows indicate the ligand-binding clefts. The dashed circles indicate the 
dimerisation loops. The white arrows marks the ATP binding cleft. The sizes of the coloured 
rectangles below the protein structures represents the fractions of docking site specifity 
meaning the number of binding sites for each indicated protein normalised to the total 
number of phosphotyrosine docking sites of each receptors. AR, amphiregulin; BTC, b-
cellulin; EGF, epidermal growth factor; EGFR, EGF receptor; EPGN, epigen: EPR epiregulin; 
GBM, glioblastoma; GI, gastrointestinal tract; GRB2, growth factor receptor-bound protein 2; 
HBEGF, heparin-binding EGF-like growth factor; NRG, neuregulin; NSCLC, non-small-cell 
lung cancer; SHC, SRC-homology domain-containing; STAT5, signal transducer and 






Figure 8: Schematic illustration of ERBB4 domain structure, its variants and binding 
sites for adapter molecules. 
ECD, extra cellular ligand binding domain; ICD, intra cellular domain; SS, signal sequence; 
TK, tyrosine kinase domain; L1,L2, ligand interacting domains; CR1, CR2, cysteine-rich 
domains; modified from (Zeng et al., 2007b) 
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2.15.5 NRG1-ERBB4 signalling in the nervous system 
The three best characterised signalling pathways initiated through ERBB 
receptors are the Ras-Mitogen Activated Protein Kinase Ras-MAPK pathway, 
the PI3K-Akt/PBK pathway and the Phospholipase C/Protein Kinase C pathway. 
The STATs (Signal Transducer and Activator of Transcription) can be activated 
via direct binding to ERBB receptor pairs (Jones et al., 2006; Marmor et al., 2004; 
Schulze et al., 2005). 
 
Figure 9: Schematic representation of signalling pathways initialised by ERBB4 
receptors.  
Modified from: Schizophrenia: Emerging targets and Therapeutic Strategieies (Karam et al., 
2010). 
2.15.6 Adapters of ERBB receptors  











The phosphoinositide 3-kinase (PI3K) is a nodal point of different pathways in 
the cell. Its function involves cell growth, proliferation, differentiation, motility, 
survival and intracellular trafficking. The PI3Ks were first described by Lewis 
Cantley (Auger et al., 1989). A very recent study confirmed explicitly the role of 
ERBB4 promoted PI3K signalling in SZ (Law et al., 2012a). PI3Ks are involved 
in learning and memory and in long-term potentiation (Man et al., 2003). They 
bind to phospho-tyrosine 1056 of the ERBB4-JMA-CYT1 variant. The 
recruitment of PI3K to the receptors is promoted by NRG1 i.e. the EGF-like 
domain (Williams et al., 2009). The PI3 kinases are the central elements of the 
PI3K/Akt signalling pathway. 
The PI3K are subdivided in 3 classes named class I, II, III (Leevers et al., 1999) 
(Tab. 5). 
Class I PI3Ks are activated via G-protein coupled receptors (GPCRs) and 
receptor tyrosine kinases (RTKs). They form heterodimers and phosphorylate 
Phosphatidylinositol 3-phosphate (PI(3)P), Phosphatidylinositol (3,4)-
bisphosphatePI(3,4)P2) and Phosphatidylinositol (3,4,5) trisphosphate 
((PI3,4,5)P3). 
The Class I PI3Ks consists of two subunits: catalytical subunit p110 with three 
variants (p110a, p110b and p110c) and the regulatory subunit p85. The 
regulatory subunit has five variants: the highest expressed are p85a and p55a, 
followed by p50a, p85b, p55y. 
 
 group gene protein aliases 
class I 
catalytic 
PIK3CA PI3K, catalytic, alpha polypeptide p110-a 
PIK3CB PI3K, catalytic, beta polypeptide p110-b 
PIK3CG PI3K, catalytic, gamma polypeptide p110-g 




 PIK3R1 PI3K, regulatory subunit 1 (alpha) p85-a 
PIK3R2 PI3K, regulatory subunit 2 (beta) p85-b 
PIK3R3 PI3K, regulatory subunit 3 (gamma) p85-g 
PIK3R4 PI3K, regulatory subunit 4 p150 
PIK3R5 PI3K, regulatory subunit 5 p101 
PIK3R6 PI3K, regulatory subunit 6 p87 
class II PIK3C2A PI3K, class 2 alpha polypeptide PI3K-C2a 
 PIK3C2B PI3K, class 2 beta polypeptide PI3K-C2b 
PIK3C2G PI3K, class 2 gamma polypeptide PI3K-C2g 
class III PIK3C23 PI3K, class 3 Vps34 






The signal transducer and activator of transcription 5 (STAT5A) is a member 
of the family of seven structurally and functionally related transcription factors 
(STAT1, STAT2, STAT3, STAT4, STAT5A, STATB, STAT6). Normally STATs 
are activated by Janus Kinases (JAKs), respond to cytokines (JAK/STAT 
pathway) and can be phosphorylated by RTKs e.g. EGFR. After 
phosphorylation STATs homo- or hetero-dimerise and translocate to the 
nucleus to act subsequently as transcription factors. STAT signalling cascades 
are associated with cellular transformation (Kisseleva et al., 2002). Disturbed 
phosphorylation of STATs was found in ErbB4 homozygous KO mice 
(Tidcombe et al., 2003). STAT5A binds to pY984 ERBB4-JM-a-CYT1 and its 
increased binding to mErbB4 after Nrg1 stimulation was shown (Wehr, 
unpublished). 
2.15.9 SHC1 
The SH2 domains containing transforming protein 1 (SHC1) is the 46kDa 
variant expressed by the ShcA mRNA. It is an ubiquitously expressed adapter 
protein that signals through the mitogen activated protein kinases (MAPK) 
pathway and takes part in the regulation of apoptosis and drug resistance. The 
SHC1 protein contains a SH2 domain, a PTB domain and a central region 
bearing various phosphorylation sites. Null mutant mice homozygous for Shc 
dye at E11.5 because of heart defects (Ravichandran, 2001; Pelicci et al., 1992). 
SHC1 binds to phosphorylated Tyr1284 of the ERBB4-JM-a-CYT1 and its 
increased binding to ErbB4 after Nrg1 stimulation was showen (Wehr, 
unpublished). 
2.15.10 GRB2 
The growth factor receptor bound protein 2 (GRB2) is an phospo-adaptor 
protein. It is involved in signal transduction, transformation, cell communication 
and proliferation. The protein contains one SH2 two SH3 domains. It links the 
EGFR RTKs to the activation of Ras and the MAPKs ERK1 and 2 (Schulze et 
al., 2005). 
2.15.11 SRC 
The proto-oncogene SRC is a tyrosine kinase. C-Src phosphorylates SHC and 
STAT5a. For the discovery of this kinase as the first oncogene kinase J. 
Michael Bishop and Harold E. Varmus were awarded with the Nobel Prize in 
1989 (Olayioye et al., 1999; Keely et al., 2000; Sato et al., 2000). 
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2.16  Downstream pathways 
2.16.1 PI3K/ AKT pathway  
The phosphatidylinositide 3-kinase (PI3K)-AKT-mammalian target of 
Rapamycin (mTOR) pathway is a key regulator for proliferation, growth, survival, 
protein synthesis, and glucose metabolism. 
PI3Ks convert PIP2 to PIP3. This activates AKT (acute transforming retrovirus 
(AKT-8) also known as protein kinase B or RAC-PK) a central serine/threonine 
kinase. AKT is upstream to both mTOR and of GSK3(Yap et al., 2008) (Fig. 
10). 
 
Figure 10: The PI3K, AKT, mTOR pathway 
 
2.16.2 MAPK /ERK pathway 
The mitogen-activated protein kinase (MAPK) pathway (Fig. 11) is an important 
central pathway linked to growth, proliferation, differentiation, and survival of 
various cell types. In general the “MAPK pathway” is a cassette of three kinases, 
which are sequentially activated. Starting point of the cascade might be e.g. a 
growth factor. 
The very downstream kinase MAPK is activated via phosphorylation through 
MAPKK (MAPK kinase), which is activated through MAPKKK (MAPKK kinase). 
The MAPKs are deactivated via MAPK phosphatases (MKPs). In eukaryotic 
cells at least twelve different MAPKKKs, seven MAPKKs and eight MAPKs 
active in at least four different modules are described. For example one module 
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is the RAF/MEK/ERK cassette. The most upstream kinase is activated by 
membrane recruitment, usually mediated by adapter molecules, such as Grb2 
Sos1 and Shc1. These are recruited to the membrane by an activated RTK. 
MAPKK is named MEK and the MAPK “extracellular signal-regulated kinase” is 
called ERK for historical reasons. 
 
Figure 11 MAPK pathway 
Introduction 
40 
2.17  Localisation of NRG1-ERBB4 signalling in the neuronal 
architecture 
2.17.1 Glutamate hypothesis of SZ 
Glutamate is the most common neurotransmitter in the mammalian brain. 
Glutamate receptors have excitatory properties and are important for neural 
development, neuronal survival and synaptic plasticity. 
The glutamate receptors in the mammalian CNS are subdivided in: 
Ionotropic recptors NMDA ligand gated ion channels  
 AMPA  
 Kainate  
Metabotropic mGluRs G-protein coupled 
Table 6. Overview of the different Glutamate receptors 
2.17.2 NMDA 
Increasing evidence suggests that NMDA hypo-function is involved in the 
pathophysiology of SZ (Homayoun and Moghaddam, 2007). Low doses of 
NMDA antagonists like PCP, MK801 or Ketamine can induce SZ-like psychotic 
symptoms (Bian et al., 2009). PCP and Ketamine lead to decrease parvalbumin 
(PV) stained interneurons. Reduction of parvalbumin or somatostatin stained 
interneurons  and decrease of mRNA expression of somatostatin, parvalbumin 
and glutamate acid decarboxylase (GAD 67) are key findings for SZ (Konradi et 
al., 2011). PCP and Ketamine lead to increased cortical glutamate level. 
Elevated levels of glutamate are observed in some brain regions of SZ patients. 
 “At the Network level, psychomimetic doses of NMDA antagonist may favour 
the balance of excitation over inhibition by blocking NMDA-dependent excitatory 
inputs to GABAergic interneurons” (Christoph Ott, 2012 personal 
communication). 
“Subcortical NMDA receptor dysfunction, leading to elevated cortical glutamate 
levels and potentially to excitotoxic processes, may be important, particularly in 
the early stages of the disease” (Christoph Ott, 2012 personal communication). 
mGLu2/3  
Recent findings suggest that the compound LY404039 and its oral prodrug 
LY2140023 targets the metabotropic glutamate system. The effective treatment 
of SZ patients is still under debate (Mezler et al., 2010).  
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2.17.3 Hyper- and hypo-frontality in SZ 
The gamma frequency oscillations of SZ patients performing working-memory 
tasks are disturbed. Responsible for this is most likely loss of inhibition of 
parvalbumin positive (PV+) interneurons (Uhlhaas and Singer, 2010; Haenschel 
et al., 2009; Barr et al., 2010). 
 
 
Figure 12: Prefrontal cortex, Thalamus and Hippocampus, connections in mice and 
man, modified by (Pratt et al., 2012). 
Dysfunctional connectivity in schizophrenia. Aberrant activity in both rodent models of the 
disease (left panel) and in patients (right panel) is centred on prefrontal – hippocampal – 
thalamic networks. 
 
2.17.4 From neuronal circuits to single synapses 
A small functional substructure of the brain is a simple neuronal circuit. A 
neuronal circuit is defined as a hierarchical network of inhibitory and excitatory 
neurons. In the cerebral cortex excitatory glutamatergic pyramidal cells and 
inhibitory GABAergic neurons form a micro-network (Fig. 13). The pyramidal 
cells are specialised in the transfer of information between cortical areas and to 
other parts of the brain. The interneurons function as breaks and oscillation fine 
tuners to the pyramidal cells. Disturbance of the balance lead to circuit miss-
function. In SZ a certain class of interneurons seem to be affected. The PV+ 
interneurons, including Basket cells and Chandelier cells, localised in the 
dorsolateral prefrontal cortex show a decrease in Glutamate decarboxylase 
isoform 67 kDa (GAD67) expression in SZ (Akbarian et al., 1995; Hashimoto et 
al., 2003; Marín, 2012). Expression of ERBB4 protein in humans and monkeys 
is restricted to the somatodendritic compartments of interneurons and is absent 
from pyramidal cells (Neddens et al., 2011; Neddens and Buonanno, 2011; 
Buonanno, 2010). The precise localisation of ERBB4 in CNS has not been 
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described systematically yet and has to be further analysed. For further 
information see: (Neddens and Buonanno, 2011). 
 
Figure 13: Cortical interneuron network 
Different classes of cortical interneurons are distinguished by morphology, neurochemical 
content, intrinsic electrophysiological properties and pattern of connectivity. Interneurons i.e. 
Basket cells target the soma and basal dendrites of pyramidal cells, Chandelier cells contact 
the axon initial segment and Martinotti cells and neurogliaform cells primarily contact the 
dendrites of pyramidal cells. The cells form a complex network of inhibition and excitation 
synchronised to a distinct oscillation. Modified from (Marín, 2012). 
 
2.17.5 Alterations found in the neuronal circuit 
Two different reasons are hypothesised to be responsible for the reduced 
activity of the PV+ interneurons in SZ. 
A loss of function of interneurons might be caused by (I) a reduction of inhibitory 
synapses number (Woo et al., 1998), or (II) by a failure in the recruitment of the 
interneurons to their correct final localisation, thereby preventing functional 
excitation of these inhibitory interneurons (Grunze et al., 1996; Gunduz-Bruce, 
2009).  
NMDA receptor antagonists or the conditional deletion of NR1 subunit of 
NMDAR lead to the dis-inhibition of excitatory pyramidal cells and a loss of 
synchrony, showing SZ like symptoms (Belforte et al., 2010; Carlén et al., 2012).   
Introduction 
43 
2.17.6 NRG1-ERBB4 in the development of PV+ interneurons 
ERBB4 directs the migration of PV+ interneurons in response to NRG1 (Flames 
et al., 2004). NRG1-ERBB4 signalling controls the integration and synapse 
formation of PV+ interneurons with pyramidal cells in neuronal circuits (Fazzari 
et al., 2010). Moreover, PV+ interneurons deficient in ERBB4, receive less input 
by pyramidal cells than normal ones (Ting et al., 2011). Interestingly, mice 
lacking ERBB4 specific in PV+ Interneurons have an impaired working memory 
phenotype (Wen et al., 2010) resembling cognitive deficits observed in SZ. 
An overview of the location and implication of the findings is given in (Fig. 14) 
for neuronal circuits and in (Fig. 15) for synapse. 
 
Figure 14: Alterations found in cortical circuits SZ patients and animal models  
Spines and 67kDa glutamate decarboxylase (Gad67) are reduced. Loss of ERBB4 alters 
presynaptic functions of the Chandelier cells and post synaptic the functions of the Basket cells, 
resulting in a loss of inhibitory function and synchrony. The Pyramidal cell responds with 




Figure 15 Synapse, modified (Pratt et al., 2012) 
The picture shows the most prominent genes implicated in the aetiology of schizophrenia. 
NRG1-ERBB4 signalling regulates the function and morphology of the synapse. DISC1 
coordinates signalling pathways that regulate synaptic structure (DISC1 with 
phosphodiesterase 4B (PDE4B) and TRAF2 and NCK–interacting kinase (TNIK)) a7 subunit 
containing nicotinic acetylcholine receptors (nAChRs) are strongly implicated in disease risk 
via gene copy number variations. Major histocompatibility complex (MHC) molecules have 
some role in the maintenance and plasticity of synaptic connections. AMPA: (a-amino-
3hydroxy-5methyl-4-isoxazole propionic acid receptor (AMPAR); mGluR: metabotropic 
glutamate receptor; NMDAR: N-methyl-D-aspartate receptor; PRSS16: serine protease 16; 
VGLUT1: vesicular glutamate transporter 1. 
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2.18  Targeting NRG1-ERBB4 with protein-protein interaction 
assays 
2.18.1.1 First generation drugs 
The first class of drugs also named ‘typical’ drugs used in the treatment of SZ is 
termed neuroleptics and act as antipsychotic drugs. Neuroleptics were found in 
MDMA (3,4-methylenedioxy-N-methylamphetamine) and PCP (Phencyclidine) 
induced psychotic mice models. All of these drugs target the dopamine system. 
They bind to the dopamine D2 receptor subtype and block them in the 
mesolimbic dopaminergic system.  
Prominent first generation drugs are Chlorpromazine (first synthetised in 1950) 
and Haloperidol (1958). 
These drugs display severe side effects. The dopamine blockade in the 
nigostratial and hypothalamic-pituitary systems lead to extrapyramidal side 
effects mimicking Parkinson’s disease, hyperprolactinaemia, sedation 
metabolic-syndrome and hypotension. The patients have to take the drugs for 
their whole life. Moreover, the first generation drugs are used only for 
symptomatic treatment and they do not affect the cause of the disease 
(Hudepohl and Nasrallah, 2012). 
2.18.1.2 Second generation drugs  
Second generation drugs, also named ‘atypical’ drugs, are multi-affinity receptor 
target agents targeting specific D2 receptor subtypes or compounds with a 
balanced activity against serotonin (5-hydroxytryptamine) versus dopamine.  
Atypical drugs, even if failing to treat all symptoms of SZ, treat a broader set of 
symptoms than first generation drugs and display a diminished side effect 
profile due to reduced extrapyramidal side effects. They also target specifically 
dopamine receptors in various degrees to perform the therapeutic action. 
Prominent representatives of atypical drugs are Clozapine (Barros 2011), which 
reverses altered spine formation in NRG ERBB2-4 mice, Olanzapine and 
Risperidone (Penzes et al., 2011).  
Typical and atypical drugs that target dopamine receptors support the dopamine 
hypothesis of SZ. Nevertheless, they fail in curing SZ and treat only some 
symptoms with occasionally tremendous side effects. Principally, no 
accelerated progress in SZ-drug development in the past 50 years has been 
observed. As the construct validity of SZ in animal models cannot be fully 
accomplished, the complexity of an animal model obscure smaller effects, costs 
for animal experiments and maintenance are high and usability of animals in 
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HTP screenings are limited, animal models seem not to be the right system for 
large compound screening.  
At least, knowledge of the genetic risk factors of SZ should be tried to be 
translated into artificial systems, resembling partially valid models to perform 
HTP screens identifying chemical lead compounds to develop new classes of 
substances which subsequently need to be active in the corresponding 
translational/genetic mouse model. 
2.18.2 Classic hit to lead discovery  
Most screens have been performed with in vitro assays. Substance libraries 
were tested against “naked” proteins. A hit generated in this kind of assay has 
to be evaluated extensively afterwards and may i.e. often not enter cells or 
tissues. 
Hit confirmation means first retesting of the hits in the same assay system with 
the same assay conditions. Than, dose-response curves are generated to 
determine key pharmacological hallmarks (sensitivity, efficacy etc.). Orthogonal 
testing follows. The hits are tested in different assays or with different 
technologies. In a secondary screening the hits are tested in a cellular 
environment to ensure membrane permeability. Chemical amenability 
/accessibility has also to be ensured. Intellectual property is the next ever-
present issue for commercial screens. 
Biophysical testing is used to access if the compound binds to the target, i.e. 
nuclear magnetic resonance or isothermal titration calorimetry.  
After hit confirmation, hit expansion follows. Compound clusters from the screen 
are chosen and expanded. The clusters contain compounds with high target 
affinity (below 1uM), low molecular weight and moderate lipophilicity. The 
compounds should not interfere with the P450 enzymes or bind to the human 
serum albumin. The compounds should also be stable, soluble in water, and 
should be cell permeable, they should further not exhibit cytotoxicity and should 
not be rapidly metabolised.   
The compounds have to show significant biological activity in cellular assays 
and selectivity versus other related targets. 
Lead optimization is the later process of chemical modification of lead (hit) 
compounds to get more potent leads with less off-target active structures 
(Bleicher 2003, Astle2010). 
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2.18.2.1 Compound screens 
Compound screens give the opportunity to test large numbers of drugs, 
compounds or lead structures for primary effects on proven therapeutically 
relevant targets. For subsequent structural modifications (medicinal chemistry), 
it is important to identify the exact mechanism or mode of action. For HTP-
compound screens an assay should be reliable, robust, scalable, fast in 
response, easy to readout, and mimicking the mechanism observed as close as 
possible.  
Proximal outputs of the NRG1-ERBB4 signalling system can be monitored with 
PPI assays i.e. at the level of receptor dimerization or the phospho-adapter 
recruitment. For these types of analyses the following assay-systems should be 
discussed. 
2.19  Cell based assays 
PPIs can be analysed with genetic or biochemical methods. Genetic methods 
contain e.g. FRET (Fluorescence Resonance Energy Transfer), BRET 
Bioluminescence Resonance Energy Transfer) or complementation systems 
like yeast to hybrid. Biochemical methods include e.g. protein complex 
immunoprecipitation (Co-IP) (Boute et al., 2002; Uetz and Hughes, 2000). The 
accurate method depends on the questions asked and the usability e.g. in high 
throughput or fully automated systems. 
2.19.1 Biochemical methods e.g. Co-IP  
The Co-IP is based on a classical immunoprecipitation. A protein of interest is 
pulled down from a lysate via a specific antibody. If the protein is interacting 
with a second protein this protein is bound to the first protein. A second 
antibody is then used to probe against the second protein and so to detect the 
PPI. Unfortunately, the interaction can take place in vitro in the lysate which 
might lead to artefacts in the detection. A quantification of the PPI can be done 
via ImageJ or other image programs. The method is cost and labour intensive 
and difficult to automate in bigger scales. 
2.19.2 Affinity columns  
A peptide is bound to an affinity column. If a cell lysate is loaded on the column 
and proteins interacting with the peptide sequence bind to the peptide and can 
be purified afterwards. The putative interaction partners can be further analysed 
via MALDITOF etc.  
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2.20  Protein fragment complementation assays  
2.20.1 Yeast two hybrid 
The Yeast two-hybrid (Y2H) assay is a protein fragment complementation assay 
to measure PPI or protein-DNA interactions. In the classical version, the LacZ 
reporter gene is under the control of the upstream activating sequence UAS. 
The UAS transcription factor Gal4 is fragmented in an UAS binding domain and 
a transcriptional activator domain. Both domains can be fused to two putative 
interacting proteins of interest (pray and bait), and if these proteins come to 
close proximity, modify the Gal4 transcription factor and activate the reporter 
gene. The Y2H is a fast and scalable low-tech assay. 
On the other site yeast is not the ideal organism to express mammalian proteins 
due to lack of specific chaperons and localisation mechanisms: Furthermore, 
interactions that take place beside the nucleus cannot be detected and this 
method produces a high false positive failure rate. In conclusion, Y2H is not 
suitable to detect interactions of huge mammalian membrane proteins (Stagljar 
et al., 1998). 
 
2.21  Split TEV 
The split TEV method is a protein fragment complementation assay, based on 
the NiA inclusion protease from the tobacco etch virus (TEV). The protease is 
split into an N- and a C-terminal part (NTEV + CTEV), thereby setting apart the 
catalytic residues. When NTEV and CTEV are fused to proteins of interest, 
which are capable of interacting with each other, the TEV protease activity is 
reconstituted as the fragments come into close proximity. In turn, the protease 
activates an artificial reporter by cleaving at a highly specific site encoded by 
ENLYFQ’G/S. Artificial reporters can be of transcriptional nature or reporter 
protein-based(Wehr et al., 2006).  
A direct reporter protein is i.e. an inactive luciferase enclosed by two mutated 
Estrogen receptor domains (ERT2) domains bound via TEV cleavage sites 
(tevS). The two large ERT2 domains prevent luciferase from proper folding to 
functional form. TEV protease activity releases the luciferase from the ERT2 
domains, it folds to a functional confirmation and the activity of luciferase as a 
readout can be measured(Wehr et al., 2006). 
Transcription based system use i.e. the artificial transcription factor galactose 4-
viral protein 16 (GV). The GV is bound with the tevS to one of the to interacting 
proteins with split TEV protease halves. Reconstitution of TEV-protease activity 
cleaves the tevS and releases the GV to shuttle to the nucleus and activate a 
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reporter protein under the control of the upstream activator site of five GAL4 
responsive elements (UAS) site. A reporter protein can be i.e. a fluorescent 
protein like enhanced green fluorescent protein (EGFP) or an enzyme like the 
Firefly luciferase. Using a transcription factor and an enzyme as read out 
allowes also a high magnification of the signal. 
The assay is robust, scalable, and was shown to be highly specific for ERBB 
receptors. It constitutes an optimal assay to access the intercellular NRG1-
ERBB4 signalling cascade potentially adaptable to a HTP-screen (Wehr et al., 
2006; Wehr et al., 2008a; Djannatian et al., 2011). 
 
2.22  z’-Factor 
For HTP screening, the z’-factor is a statistical determinant of the robustness 
and reliability of the assay. It links a large number of single measurements of 
unknown effects and effect sizes to a set of positive and negative controls. The 
z’-factor is calculated for small (or pilot) screens to predict if the assay is 
qualified for HTS.  Four parameter are used, the means (µ) and the standard 




2.22.1 The interpretation of the z’-factor: 
 1 is the ideal z’-factor. It can never exceed and is impossible to matched.   
 1-0.5 is an excellent assay. 0.5 is the value when p n, p and n 
show a separation of twelve standard deviations.
 0.5-0 is a marginal assay. The assay is not automatically qualified for 
HTP screening. For complicated but stable assays lower z’-factors of e.g. 
0.4 can be defined as limit. 
 0 is a yes/no assay with no separation window, overall not suitable for 
HTP screening. 
 Less than 0, the assay is not qualified for HTP screening, as positive and 
negative controls do not have any separation window and overlap 




2.23  Aim of the thesis 
SZ is a severe disease. To date there are no drugs available, which mediate or 
attenuate the negative symptoms and cognitive deficits. Genetic studies 
showed that the NRG1-ERBB4 signalling system is altered at least in a 
subgroup of SZ patients. Moreover, the NRG1-ERBB4 signalling system most 
likely influences biological processes that are central to the diseases (i.e. 
interneuron migration and function with an impact on the excitatory-inhibitory 
balance and associated working memory and cognitive deficits). Therefore, 
addressing NRG1-ERBB4 signalling is one of the most promising targets for the 
development of new drugs for SZ.  
The first main aim of the thesis is the design, development and characterisation 
of a split TEV-based co-culture assay to monitor the most proximal steps of the 
NRG1-ERBB4 signalling cascade. The assay must be sensitive, robust and 
adaptable to high-throughput approaches for future screenings of huge 
compound libraries. The second main aim is the engineering and validation of 
the secondary assays useable to analyse putative hits from larger screens. 
As a pilot study, the developed assay will be used to screen 727 FDA approved 
drugs obtained from the NIH collection. The recovered hits will be further 
validated by an extensive set of secondary assays containing different Nrgs, 
ERBB receptors and adapter proteins, to get a fast and clear insights into the 
specificity of drug function, and to discard false positive hits. The aims of the 
screening project are (1) the detection of unknown therapeutic potentials in 
drugs available already on the market, and (2) the identification of new lead 
structures from tested substances for further lead optimisation processes. 
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3 Chemicals and Reagents 
Chemicals were received from Amersham Biosciences, BD Falcon, BioRad, 
Carl Roth, Eppendorf, Invitrogen, Merck, Riedel de Haen, Roche, Serva, 
Sigma and VWR. 
3.1 Laboratory suplies 
Consumable supplies, which are not mentioned separately were purchased 
from commercial sources as BD Falcon, Eppendorf, Gilson, Greiner-Nunc and 
Menzel-Gläser. 







Cryo tubes      Nunc 
ECL hyperfilms     Amersham Bioscience 
Electroporation cuvettes (1,2,4 mm)  Biorad 
NuPAGE 4-12%Bis-Tris Gels   Invitrogen 
PVDF Membrane Hybond P   Amersham Biosciences 
Reaction tubes     Eppendorf 
3.2 Laboratory equipment 
Hardware 
Atroum 611 Water Putification System  Sartorius 
Gene Pulser Xcell     Biorad 
Hood       Heraeus 
Microplate reader Mithras LB 940  Berthold Technologies 
Microscopes      Leica 
Leica DM IRBE (invers) 
Leica DM RXA 
Leica TCS SP5 X (confocal) 
Nucleofector      Amaxa 
SDS PAGE gel electrophoresis system  Invitrogen 
Xcell SureLock NuPAGE system   Invitrogen 
Sonicator Bandelin Sonoplus   Bandelin 
X-ray film developer KODAK XOMAT  Kodak 
CellStarRoboter     Hamilton 
 
EDV Hardware 
Canon iRC3580     Canon 
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HP Color Laserjet 4550    Hewlet Packard 
Laptop Lenovo T61 
iMac 11,2      Apple 
 
EDV Software 
Adobe package     Adobe 
DNASTAR Lasergene    DNAStar 
Firefox      Mozilla Foundation 
Microsoft Office 2003    Microsoft 
Microsoft Office X     Microsoft 
Zotero      www.zotero.org 
Chemsketch      ACD Labs   
 
Kits 
Calf intestine phosphatase (CIP)   Roche 
Nucleobond PC 20      Machery-Nagel  
NucleoBond Xtra Midi EF    Machery-Nagel   
Nucleobond PC 500 EF     Machery-Nagel  
Nucleobond PC 10.000 EF    Machery-Nagel  
3.2.1 Antibodies 
Name Anti Supplier 
Phospho-Akt (Ser473) Rabbit Cell Signaling Technology 
Akt Rabbit Cell Signaling Technology 
FLAG M2 Mouse Sigma Aldrich 
HA Rat Roche 
c-Myc Mouse Santa Cruz Biotechnology 
V5 Mouse Invitrogen 
Phospho-p70 S6 Kinase (Thr389) (108D2) Rabbit Cell Signaling Technology 
p70 S6 Kinase Rabbit Cell Signaling Technology 
Phospho-HER4/ErbB4 (Tyr984) Rabbit Cell Signaling Technology 
p-ErbB4 (Tyr 1056) Rabbit Santa Cruz Biotechnology 
Phospho-p44/42 MAPK (Erk1/2) (Thr202/ Tyr204) 
(D13.14.4E) XP Rabbit Cell Signaling Technology 
p44/42 MAPK (Erk1/2) (137F5) Rabbit Cell Signaling Technology 
ErbB-4 (C-7) Mouse Santa Cruz Biotechnology 
Phospho-HER4/ErbB4 (Tyr1284) (21A9) Rabbit Cell Signaling Technology 
GSK-3? (27C10) Rabbit Cell Signaling Technology 
Phospho-GSK-3?/? (Ser21/9) Rabbit Cell Signaling Technology 
 
Table 8. Antibodies used 
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3.2.2 Oligonucleotides 
Were synthezised in house by MPI-EM core facility  
Primers 
Delivery concentration  50 pmol/ul 





HS306 PIK3R1-CTEV-2HA    KanR 
HS309 SRC-CTEV-2HA    KanR 
HS310 GRB2-CTEV-2HA    KanR 
HS311 STAT5A-CTEV-2HA    KanR 
HS316 SHC1v2-CTEV-2HA    KanR 
 
RTKs 
HS275 ERBB4-Glink-NTEV-tevS-GV-2HA  AmpR 
HS276 ERBB4-Glink-CTEV-2HA   KanR 
HS322 EGFR-Glink-NTEV-tevS-GV-2HA   AmpR 
HS323 EGFR-Glink-CTEV-2HA   KanR 
HS324 ERBB2-Glink-NTEV-tevS-GV-2HA  AmpR 
HS325 ERBB2-Glink-CTEV-“HA   KanR 
HS326 ERBB3-Glink-NTEV-tevS-GV-2HA  AmpR 
HS327 ERBB3-Glink-CTEV-2HA   KanR 
 
Split TEV 
TC118 TM-TEV     KanR 
TC97  TM-tevS-GV    KanR 
TC84  pCMV-GV    KanR 
 
NRGs 
V368  Neuregulin1.I-beta1a 
V369  Neuregulin1.II-beta1a 
V370  Neuregulin1.III-beta1a 
 
Other 
  TM-FRB_IRES_FKBP 
  HTR5A-NTEV-tevS-GV-2HA 
  -Arrestin2-CTEV-2HA 
 







3.2.4 Bacterial strains 
E. coli DH5a     Invitrogen 
E. coli DH10B     Invitrogen 
E. coli XL1-blue    Statagene 
E. coli One shot Mach 1-T1   Invitrogen 
E. coli DB3.1 ccdb survival 
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3.2.5 Mammalian cell lines 
HEK293  Human Embryonic Kidney immortalised cell line 
   (ATTC) (DuBridge et al., 1987) 
HEK293FT  Human Embryonic Kidney immortalised cell line 
   (ATTC) (Javanbakht et al. , 2003) 
PC12   Rat adrenal pheochromocytoma cell line  
   (ATTC) (Grene and Tischler. 1976) 
PC12TO  expresses TetR-VP16 transactivator (Clontech) 
PC12  
Neuroscreen-1 optimised for screening PC12 cells (Thermo Fisher Scientific. 
Oli-neu  Murine oligodendroglial precursor immortalised cell line 
   (Jung et al.,1995) 
NIH3T3   mouse embryonic fibroblasts 
   (Todaro and Green, 1962) 
SHSYY5  Neuroblastoma cells) 
 
3.2.6 Solutions and buffers 
 
PBS (Phosphate buffered saline) 10x 
NaCL     100g 
KCl     2,5g 
NA2HPO4 x 2H2O   7,2g 
KH2PO4    2,5g 
Disolve, adjust pH to 7,2 with NaOH, add H2O to 1000ml 
 
TBS (TRis buffered saline),  10x 
Tris-Base (1M; pH 8)   50ml   (f.c. 50mM) 
NaCL (5 M)     30ml   (f.c. 150mM) 
 
3.2.7 Buffers for molecular biology 
 
DNA sample buffer, 10x 
Bromphenolblue   0,25% 
Xylencyanol    0,25% 
Ficoll (Type400)   15% 
In ddH2O 
 
TAE (Tris /Acetat/EDTA) buffer, 50x 
Tris-Base pH 8    242g (2M) 
EDTA (0,5 M; pH 8)   100ml (1mM) 
Add ddH2O to 1000ml 
 
TE (Tris - EDTA) buffer,  
Tris-Base pH 7,4   10mM 
EDTA (0,5 M; pH 8)   1mM 
 
Ethidiumbromid 
EtBr 1% in ddH2O   10mg/ml 
Final concentration in the gel      1ug/ml 
 
dNTP mix 50x 
dATP, dCATP, dGTP, dTTP  10mM (2,5 mM each) 
f.c. in the PCR    200uM (50uM each) 
 
LB-medium (Luria and Bertani medium / Luria brooth) (BERTANI, 1951) 
Bacto Yeast extract   0,5% 
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Bacto Peptone    1% 
NaCl     1% 
Optional Agar    1% for plates  
 
SOC - medium  
Bacto Yeast extract   0,5% 
Bacto Peptone    2% 
NaCl     10mM 
Glucose    20mM 
KCl     2,5mM 
MgSO4     10mM 
 
Antibiotics    f.c. in agar plates 
Kanamycin    50ug/ml  
Ampicilin    100ug/ml 
Chloramphenicol 
Gentamycin 
Zeocyn ( low salt agar) 
3.2.8 Luciferase assay buffers 
Lysis-buffer 
Passive lysis buffer (5x)  Promega (Cat# E1941) 
Dilute 30ml of 5x Buffer in 120 ml ddH2O 
 
Firefly-luciferase-assay buffer (Gaunitz and Papke, 1998)  
       500 ml   1500 ml 
Tricine      20 mM  1792 mg  5376 mg 
(MgCO3)4*Mg(OH)2*5H2O   1,07 mM  260 mg   780 mg 
(Magnesiumcarbonat-Hydroxid-Pentahydrat)           
MgSO4     2,67 mM 161 mg    483 mg 
EDTA       0,1 mM  100 µl (0,5 M)  300 µl 
DTT     33,3 mM 2570 mg  7710 mg 
Coenzym A    270 µM 1 05 mg   315 mg 
D-Luciferin, free base   470 µM  66 mg   198 mg 
ATP     530 µM          146 mg   438 mg 
 
For dissolving of (MgCO3)4*Mg(OH)2*5H2O titrate the pH with HCL until the solution is clear. 
Afterwards adjust the pH with 5M NaOH to7.8 
Ad Luciferin and ATP at last. Control pH 
Storage of the Buffer ad -20°C without light, thaw at room temperature 
 
Renilla-luciferase-assay buffer 
500 ml   1500 ml 
 
NaCl     1,1 M  32,15 g  96,45 g 
Na2-EDTA    2,2 mM  2,2 ml (0,5 M)   6,6 ml 
(Disodium ethylenediamine tetraacetate) 
KxPO4 (pH 5,1)    0,22 M  110 ml 1 M KH2PO4 330ml  
BSA      0,44 mg/ml 220 mg   660 mg 
NaN3      1,3 mM  42,25 mg  126,75 mg 
Coelenterazin (in 100% EtOH)  1,43 mM 300 µl  Stock  900 µl 
 
KxPO4 (pH 5,1): 1M KH2PO4, Adjust the pH with KOH to 5.1 
add Coelenterazin as last ingredience 
Coelenterazin stock is 1mg in 1ml EtOH, Storage at -20°C 
Adjust the pH of the Buffer to 5.0  
Storage of the Buffer ad -20°C without light, thaw at room temperature 
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All substrates are from PJK (http://www.pjk-gmbh.de). 
D-Luciferin, free acid:    No. 260150 
Co-Enzyme A:     No. 260809 
ATP:      No. 260920 
DTT:     No. 260710 
Coelenterazin:    No. 260350 
 
3.2.9 Solutions for cell culture 
 
2x freezing medium for eukaryotic cells 
DMEM     55% 
DMSO     20% 
FBS     45% 
 
PLL 250x 
Poly-L-Lysine in ddH2O  5mg/ml 
f.c. for coating PC12 plates  0,02mg/ml 
 
Penicillin-Streptomycin 100x 
Potassium Penicillin   10,000 U / ml 
Streptomycin Sulfate   10,000 ug / ml 
 
Trypsin-EDTA 10x 
Trypsin     5g 
EDTA     6,85 mM 
 




DMEM  1g Glucose/l Lonza   phenol red 
DMEM  4,5 g Glucose/l Lonza  phenol red 
DMEM  1g Glucose/l Lonza   
DMEM  4,5 g Glucose/l Lonza   
 
Horse Serum HS, heat inactivated for 45’’ at 56°C 
Fetales Bovines Serum FBS, heat inactivated for 45’’ at 56°C 
PenStrep 
GlutaMAX-I (stable L alanine-L-glutamine-dipeptide) 
 
Cell line Glucose  Percent FCS  Percent HS    PSG 
HEK  4,5%  10%   ----   1% 
PC12  1%  10%   5%   1% 
 
Standard IP buffer (1% NP40) 
For 250ml     Final concentration [] 
12.5ml 1M Tris pH7.5    50 mM 
7.5ml 5M NaCl     150 mM 
2.5ml NP40 (or 25 ml 10% NP40)  1 % 
0.5ml 0.5M EGTA    1 mM 
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Add freshly:  
 Complete tablet (Roche)(mini for 10 ml) 
 Phosphatase inhibitor II and III (Sigma): 10 µl/ml each 
 NaF (0.5M):  200 µl/ml (f.c. 100 mM) 
Optional: 
Na3VO4 (0.2M); 5µl/ml (f.c. 1mM) 
PMSF (100 mM): 10 µl/ml 
 DTT (1M): 10 µl/ml 
 
IP buffer for anti-Flag IP (with 1% Triton-X100): 
For 250ml      Final concentration  
12.5ml 1M Tris pH7.5     50 mM 
7.5ml 5M NaCl      150 mM 
2.5ml Triton-X100 (or 25 ml 10% Triton-X)  1 % 
0.5ml 0.5M EGTA     1 mM 
0.5M EGTA: 50 ml titrate with 5M NaOH (ca. 8 ml), or with 10M NaOH ca. 4 ml). 
 
1X Running buffer: 
3.03 g Tris 
14.4 g Glycine 
1 g SDS 
add water to 1 l 
 
1X Transfer buffer: 
3.03 g Tris 
14.4 g Glycine 
200 ml Methanol 
add water to 1 l 
 
Sucrose buffer for brain lysates 
 
sucrose 80%  4°C  320mM   1,37ml 
1M Tris    10mM   100µl 
2M NaHCO3  4°C  1mM   5µl 
2M MgCl2   1mM   5µl 
H2O       8,134ml 
protease inhibitor     1 tablet 
Phosphatase inhib.  Na4P2O7  225µl 
(-20°C freezer)   NaF   200µl 
    Na3VO4  50µl  
ZnCl2   10µl 
total volume      10ml 
 
4x LDS sample buffer (NUPAGE) 
40% glycerol               4.6ml 87% glycerol 
564 mM Tris-Base     0.682g 
424 mM Tris-HCl     0.666g 
LDS (lithium dodecyl =lauryl sulphate)   0.8g 
2.5% (v/v) phenol red (1%solution)   250ul 
7.5% (v/v) Serva Blue G250 (1%solution)  750ul 
2mM EDTA      40ul 0.5M EDTA or 0.006g 
1x buffer should be pH 8.5. Do not adjust the pH. 
 
2x Freezing medium for mammalian cells 
10 ml  15 ml 
DMSO (20%)  2 ml  3 ml 
FCS (25%)  2,5 ml  3,75 ml 
DMEM (55%)  5,5 ml  8,25 ml 
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3.3 The Clinical Collection 
The NIH Clinical Collection (NCC) is a plated array of 281 (NCC201) and 446 
(NCC003) small molecules with a history of human clinical trials. The 
substances are distributed by Molecular Libraries Small Molecule Repository 
(MLSMR) Evotec San Francisco. The collection was assembled by the 
American National Institutes of Health (NIH). Similar collections of Food and 
Drug Administration (FDA) approved drugs have been used to detect 
undiscovered bioactivity and therapeutic potentials. The aim of the collection 
is to do likewise, to provide excellent starting points for chemical lead 
optimisation or even to discover treatment effects in new diseases areas.
 
Figure 16: NIH Clinical colection 
Image by Evotec 
 http://www.nihclinicalcollection.com/NCCAnnotatedChartVP.JPG 
For the screen all chemicals are solved in DMSO and used in a final 
concentration of 10µM if possible. All substances were purity checked at 
16.11.2007 aliquoted at 10.12.2010 or 29.09.2011. For a detailed list of drugs 
see apendix. 
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3.3.1   
3.4 Drugs for validation 
Name  Manufacturer Amount Order number 
Lapatinib Axon 10mg 1395 
CI-1033 Axon  5mg 1433 
Staurosporin Cayman  100µg 81590 
SB-431542 hydrate Sigma 5mg S4317 
        
EGF-like domain Reprokine 50µg RKQ02297 
mEGF Reprokine 50µg RKP01132 
Rapamycin Calbiochem 100µg 533210 
MK-801 (Dizocilpine) Sigma 25mg M107 
        
Spironolactone Sigma 1G S3378 
Eplerenone Sigma 10mg E6657 
Canrenone Santa Cruz 1g 205616 
        
Topotecan  Selleckchem 50mg S11231 
SN38 Tocris 10mg 2684 
        
Vincristine Tocris 10mg 1257 
Mevastatin Sigma 5mg M2537 
Albendazole Sigma 10g A4673 
CCPA Tocris 10mg 1705 
        
K252a LC Laboratories 1mg K-2151 





4.1 General lab routine  
Methods not described in detail were performed according to “Molecular 
cloning: A Laboratory Manual” (Maniatis,1982). Molecular biology standard 
methods were performed according to Sambrook and Russel (Sambrook and 
Russell, 2001) and to the manufacturer  s instructions if not indicated 
otherwise. 
4.2 Transformation of chemically competent bacteria 
Aliquots of transformation-competent bacteria (E.coli, strain XL1 blue, DH5α, 
Mach1) were thawed on ice or on the way. 2.5-30μl of a ligation or 
recombination reaction was added to 50-100μl cells (for retransformation of 
existing plasmids 1ul DNA and 10ul bacteria is sufficient), followed by an 
incubation step on ice for 5-30 min. The bacteria were heat-shocked at 42°C 
for 30 sec, and then cooled on ice for 2 min. 600μl cold LB medium or SOC 
medium without antibiotics was added, and the mix was incubated at 37°C for 
45 min without or with moderate shaking. During this incubation the cells start 
expressing the appropriate antibiotic resistance. Then, 100-800μl were plated 
on pre-warmed LB-agar plates containing the appropriate antibiotics. Sterile 
glass beads were used to equally distribute the bacteria. The plates were 
incubated overnight at 30-37°C depending on the encoded genes. (Note 
ERBB constructs should be expressed on not more than 32°C). 
4.3 Electroporation of bacteria 
The commercially available electro-competent E.coli strain DH10B was diluted 
1:4 with sterile 10% glycerol, and 20μl aliquots were made. For 
electroporation, the bacteria were thawed on ice, 2-2.5μl of a recombination 
or ligation reaction was added, and the mix was transferred into a 1mm 
electroporation cuvette (BioRad). 
Be aware of to high concentrations of salt in the DNA. In case of producing an 
electric arc dilute the DNA further with the 10% glycerol. The electroporation 
was performed using the ‘GenePulserII’ (BioRad) with the following settings: 
1.75kV, 25μF capacitance and resistance of 200Ω. The cells were 
resuspended in 600μl cooled LB, or alternatively in SOC medium, without 
antibiotics and incubated at 37°C for 45 min with moderate shaking. The 
bacteria were plated as described above in the section ‘Transformation of 
chemically competent bacteria’. 
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4.4 Plasmid purification 
Plasmid DNA preparations are based on a modified protocol of Birnboim and 
Doly (Birnboim and Doly, 1979), depending on the alkaline cell lysis followed 
by SDS precipitation of proteins and genomic DNA. The plasmid DNA was 
bound to a silica membrane under appropriate high-salt conditions, washed 
and finally eluted with buffer TE or H2O. Plasmid DNA was isolated from fresh 
overnight bacterial LB cultures grown to an OD of 2 to 3 using the Plasmid 
DNA Purification Kits (Mini, Midi, Maxi, Maxi EF and Giga scale) provided by 
Macherey-Nagel. Detailed description of the procedures can be found in the 
manuals provided by the manufacturers. 
4.5 Plasmid DNA mini preparations 
In brief, the pelleted bacteria (2-4 ml of the overnight culture) were 
resuspended in 250μl buffer A1 with RNAse. Cell lysis was performed by 
adding 250μl lysis buffer A2. After 5 min incubation the reaction was stopped 
by adding 300μl neutralization buffer A3. The mix was centrifuged for 10min 
to pellet genomic DNA as well as proteins, and the clear supernatant was 
then loaded onto the column. The resin membrane was washed with 600μl 
buffer AQ, dried by centrifugation for 2 min, and finally, the plasmid DNA was 
eluted in 100μl H2O or TE buffer.  
4.6 Plasmid DNA midi preparations 
In brief, pelleted bacteria (200ml of the overnight culture) were resuspended 
in 4 ml buffer S1 with RNAse. 4ml buffer A2 was added to lyse the cells and 
after 5 min incubation at RT cell lysis was stopped by adding 4ml buffer S3 
pre-chilled to 4°C. The suspension was incubated on ice for 5-15min. In the 
meantime, the column was equilibrated with 2.5ml buffer N2. The cleared and 
filtered lysate was loaded on the column. The column was washed twice with 
10 ml buffer N3, and the DNA was eluted in 5ml buffer N5. Finally, the DNA 
was precipitated using 35% f.c. isopropanol, and it was re-suspended in 100 
μl TE buffer. The expected amount of plasmids is 200-500µg. The f.c. in stock 
is adjusted to 1µg/µl. 
4.7 Photometric concentration determination of nuclear acids 
Concentration and purity of a nucleic acids solution can be analysed by 
spectrophotometry. According to the Lambert-Beer law, the concentration of a 
solution is directly proportional to its extinction or absorption, that is 
A=ε*c*l 
with ε representing the molar extinction coefficient (unit M-1cm-1), c being the 
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concentration (unit M) and l being the optic path length (cuvette thickness) 
that the light passes through the sample (unit cm). The extinction coefficients 
for nuclear acids at  λ = 260nm are: 
guanine:  ε =  12010  M-1cm-1  
cytosine:  ε =  7050  M-1cm-1  
adenine:  ε =  15200  M-1cm-1  
thymine:  ε =  8400  M-1cm-1  
(uracile:  ε =  8111  M-1cm-1) 
Using a spectrophotometer, the absorption at 260nm (maximum of absorption 
of nucleic acids) and 280nm (maximum of absorption of aromatic amino acids 
in proteins) of the nucleic acid solution was determined. For a reliable 
measurement, it is of importance that the value for the absorption at 260nm is 
set between 0.1 and 1 to fit the linear range of the photometer. Therefore, a 
proper dilution of the sample was necessary. To determine the concentration 
the following relation was applied: 
1 OD260 (optical density at 260nm) = 50mg/ml for double stranded (ds) DNA 
1 OD260 = 40mg/ml for single stranded (ss) RNA  
1 OD260 = 33mg/ml for ss oligonucleotides 
The equation to determine the concentration of dsDNA was 
c (μg/μl) = OD260 * 50 * dilution factor/1000 
The purity of a given sample was assessed by the relative absorption values 
of 260 nm over 280nm. Clean preparations of DNA and RNA would return 
values between 1.8 and 2.0 whereas significantly lower values indicated a 
protein contamination. 
4.8 Agarose gel electrophoresis 
Agarose gels of 0.8%-4% were used to separate DNA fragments between 
0.1kb and 15kb of size. The proper amount of agarose was added to 1x TAE 
buffer, and the suspension was heated, in the microwave, for appr. 5min, or 
longer, until the agarose was completely dissolved. In case of ethidium 
bromide gels the solution was allowed to cool to 60°C to minimise evaporation 
of gases, and ethidium bromide was added to a final concentration of 1μg/μl. 
Be aware of ethidium bromide evaporating in to hot agarose. Don´t breath the 
fumes!  
In case of acrydin orange nothing is added to the agarose 
The fluid agarose was poured into a gel-casting form, and combs were 
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inserted to define the pockets for sample loading. The agarose needed 20-
120min to solidify depending on the room temperature. Solid agaros gel is 
storable for 4 weeks at 4°C. The gel was placed in a chamber containing 1x 
TAE buffer. The DNA samples were prepared by adding the proper volume of 
10x loading dye (ethidium bromide gel) or 10x OrangeG and GelRed 
containing loading dye (ethidium bromide free gels) and loaded into the 
pockets of the gel. The voltage applied was 30-180V (5-10 V/cm), depending 
on the size of the gel chamber and the agarose concentration used. For 1.5% 
agarose gel to analyse restriction digests the following settings were used: 
small 120V 
medium  150V 
large  180V 
DNA molecules migrate to the positive electrode as the phosphates in the 
DNA backbones are negatively charged. The speed of the migration is 
lowered by the size of the DNA molecule and the obstruction by the fishnet 
like structure of the agarose gel, resulting in their size-dependent separation. 
The DNA could be visualised by the fluorescence of the incorporated ethidium 
bromide when exposed to UV light source emitting 260nm.  
OrangeG could be visualized via a BioDoc Analyzer 
The 100bp marker or 1kb marker (Fermentas, St. Leon-Rot) were used as 
molecular size standards. Gel chamber, casting form and combs were 
produced by the workshop of the Max-Planck-Institute. 
4.9 Isolation of DNA from agarose gels 
To isolate DNA from agarose gels the Gel and PCR clean up kit provided by 
Macherey-Nagel was used. The area of the gel containing the desired DNA 
was excised under UV light (356nm, Intas UV systems, Heidelberg) with a 
scalpel. The step should be as fast as possible, cause UV light will crosslink 
DNA and therefore cause mutations. The excised Gel was weighted and 
transferred to an Eppendorf reaction tube. The DNA was purified according to 
the manufacturer’s instructions. In brief, for each 100mg of agarose gel, 200μl 
of buffer NTI was added. The mix was incubated for 5-20min at 50°C until the 
agarose was dissolved completely. The sample was loaded onto a silica 
membrane, washed with 600μl buffer NT3, dried, and finally eluted in 30-50μl 
buffer NE prewarmed to 60°C. Concentration and size of the DNA was then 
checked via agarose gel electrophoresis. 
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4.10  DNA digest with restriction endonucleases 
DNA restriction digests were performed using type II restriction 
endonucleases in reaction volumes of 20-200μl. Type II restriction 
endonucleases induce cleavage mostly within their palindromic recognition 
sequences of 4-8 nucleotides, and yield in 5  - or 3  -DNA overhangs or blunt 
ends depending on the enzyme. Most enzymes were supplied with one of four 
standard 10x reaction buffers (NEB, New England Biolabs). 0.5 to 1μg of DNA 
were used for analytical digests, 5-25µg of DNA were used for preparative 
digests, respectively. The restriction enzyme unit ‘U’ defines the amount of 
enzyme that is required to cut 1μg DNA in 1 hour at 37°C. Usually, 2- to 3-fold 
the amount of enzyme was used in digests and the digests were incubated for 
two hours. To save enzymes larger digests were incubated for longer than 
two hours e.g. overnight.  
4.11 DNA sequencing 
DNA sequencing was performed at the Institute’s DNA Core Facility 
(Department of Neurobiology, MPI of Experimental Medicine, Göttingen) lead 
by Dr. Fritz Benseler. DNA sequencing is based on a modified dideoxy chain 
reaction termination method according to Sanger (Sanger et al., 1977). The 
approach is based on a linear DNA amplification in the presence of a 
sequencing primer, a DNA-polymerase, normal deoxynucleoside 
triphosphates (dNTPs), and modified nucleotides (dideoxyNTPs) that 
terminate DNA strand elongation. DideoxyNTPs stochastically incorporate into 
the newly synthesized DNA by replacing the normal dNTPs thereby 
terminating the synthesis. The products of different length are separated by 
capillary electrophoresis. As each of the four dideoxyNTPs is coupled to a 
different fluorescent dye the DNA fragments can be characterised by size, 
and the terminal nucleotide is identified. Through a repetitive procedure, the 
DNA sequence is determined.  
4.12  Sequence analysis of DNA 
Sequencing data was analysed using the DNAstar software, version 8, 
provided by Lasergene. The obtained sequences were also aligned to 
databases of the ‘National Center for Biotechnology Information’ (NCBI, 
http://www.ncbi.nlm.nih.gov) and ENSEMBL (http://www.ensembl.org). 
4.13  Modification of DNA 
Ligation of DNA The enzyme DNA ligase derived from the bacteriophage T4 
catalises the formation of covalent phosphodiester bonds between free 3’-
hydroxy and 5’-phosphate overhangs of double stranded DNA. Cofactors 
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needed for this reaction are Mg2+ ions and ATP. The cloning of DNA 
fragments, that is the ligation of insert and vector, was performed for 2h at 
room temperature or overnight at 4°C. The 10-20μl of a ligation reaction 
contained 50-100ng vector DNA, 150-300ng insert DNA (molar ratio 1:3), 
1.5U T4 DNA-ligase, and the ATP-containing 10x buffer provided by the 
manufacturer. (Note: ATP decays over time. If the Ligation is not working ATP 
is probably gone). The reaction was stopped by incubation at 65°C for 10min. 
Standard ligation reaction:  
x μl   vector  (50-100ng DNA)  
x μl   insert  (150-300ng DNA)  
1μl   10x buffer  
0.5μl  T4 ligase  (1.5U)  
Add up to 10μl ddH2O  
4.14  Dephosphorylation of 5’-DNA fragment overhangs, 
vectors only 
The terminal 5’-phosphate groups of dsDNA can be removed by phosphatase 
treatment using the enzyme calf intestinal alkaline phosphatase (CIP). This 
helps to reduce the likelihood of unwanted vector re-ligations. As CIP is 
compatible with NEB-, Roche- and Promega-buffers 1-2μl of the enzyme was 
added to a completed DNA digest and incubated at 37°C for maximal 20 min. 
To stop the reaction the digested DNA fragment was heat inactivated and/or 
purified by agarose electrophoresis. 
4.15  Cloning of PCR products 
PCR products were purified by agarose electrophoresis and using the Gel and 
PCR clean up kit (Macherey-Nagel). The PCR products were, if they 
contained terminal restrictions sites, first cut with the appropriate restriction 
enzyme(s), purified, and then used for ligation into the designated vector. 
PCR products amplified with Taq-polymerase were also directly sub- cloned 
into the pGemT or pGemTeasy vector (Promega) through so-called TA 
cloning. The technique is based on the property of the Taq-polymerase to 
attach an additional nucleotide (preferentially adenosine) to the 3’-end of the 
completed PCR product. The pGemT vectors can be purchased in a 
linearised form with complementary 5’-thymine overhangs which bind to the 
PCR fragment. If a proofreading polymerase with 3’-exonuclease activity (e.g. 
Pfu-polymerase, Stratagene) was used in the PCR, the adenosine overhangs 
had to be added in a second reaction using the Taq-polymerase. To do this, 
25μl of the purified PCR product were incubated with 5μl 10x buffer, dATP (f.c. 
0.2mM), and 5U Red Taq-polymerase in a final reaction volume of 50μl 
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incubated for 10min at 37°C. The reaction was purified with the help of the 
Gel and PCR clean up kit (Macherey-Nagel). Therefore, 200μl buffer NTI was 
added per 100μl PCR reaction volume, the mix was applied onto the column, 
washed with buffer NT3 dried, and finally eluted in 30-50μl buffer NE. 5-7μl 
was used for ligation. 
4.16  Amplification of DNA by polymerase chain reaction 
The polymerase chain reaction (PCR) was developed by Kary Banks Mullis 
(Mullis et al., 1992; Mullis and Faloona, 1987), and is now a commonly used 
method for selective in vitro amplification of defined DNA fragments. The DNA 
synthesis begins with the annealing of two DNA oligonucleotides (primers), 
which flank the DNA stretch that is supposed to be amplified. One primer 
anneals as a sense primer to the plus strand of the DNA, the other primer 
binds as an anti-sense primer to the minus strand. The polymerase 
recognises the dsDNA (primer and template) and exponentially amplifies the 
DNA region flanked by the primers. The synthesis is catalysed by 
thermostable Taq-polymerases (derived from the thermophilic bacterium 
Thermus aquaticus) or proofreading polymerases (e.g. Pfu-polymerase, 
Stratagene, derived from the thermophilic archaea bacterium Pyrococcus 
furiosus). The latter one helps to reduce the mutation rate by its 5’-3’-
exonuclease activity by one power to about one mutation in 106 nucleotides. 
Standard PCR reaction (20μl):  
x μl template (10-100ng)  
1μl sense (forward) primer (10pmol/μl)  
1μl anti-sense (reverse) primer (10pmol/μl)  
2μl 10x reaction buffer (including MgCl2)  
1-5μl dNTP mix (dATP, dCTP, dGTP, dTTP; f.c. 0.2mM each)  
0.8μl Taq polymerase (5 U/μl) Add ddH2O to 20μl 
A PCR reaction consists of three main steps:  
1. denaturation,  
2. primer annealing 
3. elongation.  
The PCR steps are run at different temperatures, and they are repeated 
multiple times in cycles. At the beginning of the PCR, an initial denaturation at 
95°C was used to remove any DNA secondary structures followed by a primer 
annealing step between 50-60°C where the primers are supposed to bind to 
their complementary DNA sequence. The annealing temperature was 2-4°C 
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lower than the computed melting temperature of the primers. At 72°C the 
elongation was performed, which is the optimum temperature for the Taq-
polymerase. The extension time was calculated depending on the template 
length and the polymerase used. Non proofreading polymerases require up to 
30sec per 1kb template, whereas proofreading enzymes need about 1min per 
1kb. The PCR ended in a final elongation step at 72°C to ensure complete 
synthesis. Depending on the DNA template and the purpose (cDNA, plasmid 
DNA, genomic DNA) 15-36 cycles were run. The volume of the PCR reaction 
was 20μl (genotyping) or 50μl (preparative PCR). 
Standard PCR protocol 
3 min →  95°C, initial denaturation  
30 sec →  56°C, annealing  
60 sec →  72°C, elongation  
30 sec →  95°C, denaturation 
60 sec →  55°C, final annealing  
10 min →  72°C, final elongation cycle 
Designing primer sequences 
Primers were designed with melting temperatures (Tm) of 60°C. Primer 
melting temperature can be roughly calculated with the help of the following 
formula: Tm = (A+T)2+(G+C)4, with A, T, G and C indicating the numbers of 
the corresponding nucleotides in the primer sequence. For a more precise Tm 
determination, an online algorithm developed by Warren A. Kibbe (Kibbe, 
2007) was used (http://www.basic.northwestern.edu/biotools/oligocalc.html). 
Site-directed mutagenesis 
This method of PCR-based in vitro mutagenesis presents a fast approach to 
exchange and manipulate one or more nucleotides, also simultaneously, in a 
DNA molecule. Following aspects for the design of the mutagenesis 
oligonucleotides have to be considered: The length of the oligonucleotide is 
supposed to be in the range between 24bp and 45bp. 
The Tm of the oligonucleotide should be higher than 78°C and is calculated by 
using the following formula: Tm = 81.5+0.41 (% GC)-675/N-% mismatch (with 
N being the length of the oligonucleotide in bp and % GC reflecting the GC 
content in per cent). 
The mutation, deletion or insertion should preferentially lie in the middle the 
oligonucleotide and flanked by each side with 10-15bp which exhibit 100% 
complementarity to the target sequence The GC content of the 
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oligonucleotide should not be below 40%. 
The oligonucleotide should start and end with at minimum one G or C. 
The mutagenesis PCRs are exclusively performed using proofreading 
polymerases. The PCR product was digested with DpnI, a restriction 
endonuclease, which specifically recognises the methylated sequence 
5’Gm6ATC 3’, and therefore cuts only the parental template DNA generated 
in E.coli. The mutated sample was gel purified and transformed into bacteria 
for amplification. 
4.17  One-way gateway 
The gateway recombination system is based on site-directed recombination 
and uses enzymes derived from the bacteriophage lambda that are able to 
transfer DNA fragments between vectors (Hartley et al., 2000) This cloning 
strategy works with much higher efficiency than the conventional cloning 
technique that is based on type II endonucleases and T4 DNA- ligase. For 
detailed information on gateway cloning see Invitrogen’s web page 
(http://de.invitrogen.com/site/de/de/home/ProductsandServices/Applications/C
loning/Gateway- Cloning.html). To clone an ORF or other DNA fragments of 
interest specific recombination sites (attB1 and attB2) have to be added to 
both ends via PCR. The PCR product was recombined in a ‘BP reaction’ with 
a ‘donor’ plasmid, termed pDONR, containing attP1 and attP2 recognition 
sites. The BP reaction is catalised by the Gateway BP clonase II enzyme mix. 
Each BP reaction contained:  
3μl  attB-PCR product  (10-100ng/μl) 
1μl  pDONR    (100ng/μl)  
1μl  BP clonase II 
BP reactions were incubated overnight at RT. To optimize conditions for 
transformation, 1μl of proteinase K was added and incubated at 37°C for 10 
min, followed by a heat-inactivation step at 95°C for 10 min. 1μl of the 
inactivated BP reactions was taken for electroporation in DH10b bacteria or 
for chemical transformation in XL1blue bacteria. Clones were selected by the 
appropriate antibiotic, and the insert was sequenced.  
One major feature of the gateway system is that bacteria harbouring a not 
recombined donor vector after a recombination reaction are not supposed to 
survive as the pDONR vector contains the toxic gyrase inhibitor encoded by 
the ccdB gene flanked by the recombination sites. The ccdB gene is only 
replaced by an insert when the recombination event was successful, ensuring 
that only properly recombined clones survive and produce colonies. 
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Constructs containing the pDONR backbone and the DNA insert represent 
‘entry clones’ (pENTR). These constructs carry attL sites (the product of 
recombination of attB and attP sites). To generate the final ‘expression clones’, 
abbreviated pEXPR, the attL sites of the Entry clones are recombined with 
attR sites of a ‘destination vector’, or pDEST, in an ‘LR’ reaction, catalysed by 
the Gateway LR Clonase II enzyme mix. 
Each LR reaction included:  
1 μl pENTR (25-100ng/μl)  
1μl pDEST (100ng/μl)  
1μl LR clonase 
2μl H2O 
The reaction was incubated at RT overnight followed by a proteinase K digest. 
1μl of the reaction was transformed into DH10b electro-competent or 
DH5chemical competent bacteria. The resulting pEXPR clones were then 
analysed by restriction digest and sequencing and functionally tested by 
transient transfection in cell culture followed by luciferase assays, 
fluorescence assays or western blotting. 
4.18  Subculturing of eukaryotic cells 
Eukaryotic cells (HEK293, HEK293FT, PC12, etc) were cultivated on 15 cm 
dishes or cell culture flasks at 37°C in a humidified incubator containing 5% 
CO2. After reaching 70-90% confluence, cells were subcultured by washing 
with PBS and mild treatment with 2.5 ml trypsin/EDTA for 1-5 min at 37°C 
until they detached from the culture dish. The reaction was stopped by adding 
5ml serum-containing culture medium, the cells were resuspended and the 
cells were pelleted by centrifugation for 3 min at 800g. The supernatant was 
discarded, the pellet resuspended in fresh medium, and an appropriate 
inoculum (typically, a dilution of 1/10 to 1/5) was plated onto new dishes. 
4.19  Thawing and cryopreservation of cell lines 
Frozen stocks of cell lines were kept at -196°C submerged in liquid nitrogen in 
2ml cryovials. Aliquots were quickly thawed in a water bath at 37°C, 
suspended with 3 ml pre-warmed growth medium, and centrifuged for 3 min at 
800g to remove the DMSO with the supernatant. The pellet was resuspended 
in fresh medium and plated onto a 15 cm culture dish. 
For cryopreservation cells were grown on 15 cm dishes until reaching 90% 
confluency. The medium was removed, and the cells were detached using 
trypsin as described above. The cells were counted using a Neubauer 
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counting chamber, and, after centrifugation, resuspended in an appropriate 
volume of ice-cold growth medium to obtain a concentration of about 4 million 
cells per 1 ml. 500 μl of the cell suspension was transferred into a cryovial 
already containing an equal volume of the ice-cold 2x freezing medium. 
The samples were mixed gently by inverting the tubes three times and quickly 
frozen at -20°C. After two hours the cells were transferred to –80°C for one 
day and finally to liquid nitrogen for long term storage. 
4.20  Coating with poly-L-lysin 
For PC12 cells, it is important to coat the dishes with poly-L-lysin (PLL). The 
negatively charged polysaccharid structures on the cell surface bind to the 
positively charged PLL allowing better adherence of the cells. For coating, 
dishes were incubated with 0.02 mg/ml PLL in ddH2O for 20 min at RT, then 
washed twice with sterile water, air-dried, and stored at 4°C until further use. 
96 well plates were coated using the Hamilton Lab Star robot. 30µl of PLL 
solution were pipetted in each well. The PLL solution incubated for 20’’. 
Afterwards the wells were washed twice with ddH2O. The coated plates were 
sterilized via UV light for 1h 
4.21 Transfection of mammalian cells 
DNA-transfer in eukaryotic cells with lipofectamine2000 
The transient transfection of plasmid DNA in eukaryotic cells was done using 
lipofectamine2000 (Invitrogen). The approach is based on the formation DNA-
containing liposomes that are endocytosed by the cell. Cells were typically 
transfected in 96-well plates for reporter gene assays. Depending on the cell 
line different numbers of cells were plated: 
Cell line   96well  6well   15cm 
PC12TO   40.000  1.000.000   5M 
PC12WT   40.000  1.000.000 
PC12 Neuroscreen 50.000 
HEK293    20.000  500.000   5M 
HEK293FT          5M 
The protocol provided by the manufacturer was modified to obtain optimal 
results. For a single well of a 96-well plate, both the 10-200ng (mini or midi 
prep) of DNA and 0.2μl of lipofactamine2000 were diluted in 15μl OptiMEM 
each. The solutions were mixed separately, incubated for 5min, and then 
Methods 
 71 
combined, resulting in 30μl. The mix was vortexed for 20sec. and incubated 
for 20 min at RT. The growth medium was completely removed from the cells, 
and 30μl of the OptiMEM containing DNA/lipofectamine complexes were 
applied onto the cells. After two hours, 30μl of regular growth medium was 
added to each well. The cells were allowed to express the plasmids for 24-
48h, and subjected to a given procedure, i.e. western blots or reporter gene 
assays. 
4.22  DNA transfer in eukaryotic cells with electroporation 
During electroporation a brief current pulse induces a transmembrane electric 
field in the cells, which leads to local instabilities of the cell membrane 
(electro-pores). In this short period macromolecules such as DNA are able to 
enter the cell. With optimal setting of the parameters, cells recover and can be 
subcultured. For the generation of stably transfected Hek293 cells, 5M cells 
were mixed with 20μg linearised plasmid and transferred into an 
electroporation cuvette (4 mm). 
Parameters for electroporation were the following: 950μF, 220 V. After 
electroporation, cells were incubated under standard conditions. 
4.23  Generation of stable cell lines 
Cells were transfected and selected with the indicated drug selection 
concentrations corresponding to the repsective resitance encoded on the 
expression plasmid. 
Hek293   
Puromycin  200ng/ml  
Hygromycin  100µg/ml selection  50µg/ml maintaining 
G418   400µg/ml selection  200µg/ml maintaining 
Hygromycin Co integration  
Vector MSCV Hygro Hygromycin 50µg/ml   1-5;000,000 cells 
2 µg pMSCV Hygro  10 µg Plasmid of interest linearised  
Electroporate the cells and plate the cells on a PLL coated cell culture Plate  
Start the selection 24h after transfection. After 5 days nearly all cells are dead 
After 2 weeks positive survival clones should be visible by eyesight  
Alternatively, transfection via Lipofectamin 2000 (Invitrogen cat.-no.: 11668-




Transfection scheme for a 10 cm dish: 
 O-MEM LF2000 DNA 
DNA tube: 1,5 ml 20 µl - 1,2µg  
 
Add the OptiMEM to both tubes; mix well through pipetting and incubate 5 min 
at room-temperature (RT). Mix the LF/OptiMEM mixture and the 
DNA/OptiMEM, incubate 20min at RT. Change the medium with 3ml of 
LF/DNA-mix per dish, incubate for 1-2 h at 37°C, then add 3 ml of fresh 2x 
growth medium. Start selection 24h after transfection 
PC12TO 
Hygromycin Co integration  
Vector MSCV-hygro  Hygromycin  200µg/ml  1-5,000,000 cells 
2 µg pMSCV Hygro 10  µg Plasmid of interest linearised  
50µg /ml Hygro is not enough!  
Important for freezing and thawing of stable cells:  
When you freeze the cells change 3h before freezing the growth-media to 
media without selection antibiotics. For freezing use a freezing medium with 
the double amount of serum at least. Don’t forget the DMSO. When thawing 
let the cells grow for 24h in a growth medium without selection antibiotics. 
After 24h you can add the selection antibiotics. 
4.24  Luciferase reporter gene assays 
4.24.1 Single assay 16x6 measurement points 
Luciferases are enzymes which catalytic activity leads to the emission of 
visible light upon substrate conversion. The most commonly used luciferase is 
the firefly luciferase that catalyses the following reaction:  
luciferin + ATP    → luciferyl adenylate + PPi 
luciferyl adenylate + O2  → oxyluciferin + AMP + light 
Transcriptional activity of a given promoter can be investigated by transfecting 
the cells with a reporter construct carrying a luciferase ORF under the control 
of this particular promoter. Expression level, of the luciferase reporter gene, is 
then quantified by adding luciferase substrate and ATP to the cellular lysates 
and measuring the intensity of the emitted light. Luciferase reporter gene 
assays were performed in HEK293 cells and PC12 cells in 96-well plates. 12-
48 h after transfection the medium was removed and 30-40 μl of 1x passive 
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lysis buffer (Promega) was added to each well. The plates were incubated for 
20 min at RT under moderate or fast shaking (200-1400 rpm) and assayed 
immediately, stored at 4°C up to 6h or frozen at -20°C. Prior to analysis the 
samples were transferred to black, white or black and white plastic microtiter 
plates. White wells increase the signal. Black plates decrease the noise. Black 
and white plates combine both features. 
 
Figure 17: Reaction of D-Luciferine with the firefly luciferase (modified from 
sigmaaldrich.com) 
 
4.24.2 Normalisation and transfection control 
Measurements of the firefly luciferase (Photinus pyralis) activity are commonly 
normalized to the activity of a different reporter, e.g. Renilla luciferase (Renilla 
reniformis) that is expressed under a constitutively active promoter. This is 
done to rule out differences in cell number, transfection efficiency, and RNA 




Figure 18: Reaction of Coelenterazine with the Renilla luciferase (modified from 
Komabiotech.co.kr). 
A mix of three different plasmids encoding Renilla luciferas under control of 
different promoters was used. To visually control transfection efficiency an 
equal amount of pEYFPnuc, a construct for CMV promoter-driven expression 
of the nuclear localized enhanced yellow fluorescent protein was used. 
TC34  SV40 -Rluc 
TC35   TK   -Rluc 
TC33  CMV  -Rluc 
TC48  CMV  -EYFPnuc 
The plasmids were mixed at the following ratio: SV40:TK:CMV = 10:2:1 to 
compensate for the different potency of the promoters.  
The Renilla mix is prepared with the following recipe  
pSV40_Renilla   100µg 
pTK_Renilla    20µg 
pCMV_Renilla   10µg 
pEYFPnuc     13µg  in 1300µl 
Final concentration of all 110ng/µl  
(100ng Renilla plasmids and 10ng EYFPnuc). 
Dependent on the assay the Renilla mix has to be modified to meet the 
requirements or to prevent usage of promoters which react to the assay. The 
TK-promoter seems to be promoter of choice for NRG1-ERBB4 assays.The 
fluorescent protein can be exchanged with other colours e.g. 
pEYFP, pEYFPnuc, pECFP CI, DSRed, pCherry  
20ng of the Renilla mix was cotransfected per well along with any firefly 
reporter gene assay, if not indicated otherwise. For standard luciferase 
reporter gene assays six technical replicates were analysed to enhance 
statistical reliability. Transfection efficiency was checked via fluorescent 
protein expression. Bioluminescence measurement was performed with the 
help of the Microplate reader Mitras LB940 or Microlumat Plus 96V (Berthold 




1) Injection of 40-75 μl firefly luciferase substrate, 2-60 sec reaction time, 1-
10sec measurement of light signals  
2) Injection of 40-75 μl Renilla luciferase substrate, 2-60 sec reaction time, 1-
10 sec measurement of light signals 
The firefly and the Renilla luciferases display high substrate specificity and do 
not cross-react. Moreover, firefly luciferase activity is blocked by the pH 
conditions of the Renilla substrate. 
4.24.3 Statistical analysis  
Data were exported from MicroWin 2000 and analyzed with Excel or 
GraphPadPrism. For normalisation, the firefly-value was divided by the 
corresponding Renilla-value to get the relative luciferase unit (RLU). Mean, 
standard deviation (SD) and standard error of the mean (SEM) of the six 
technical replicates were calculated.  
4.25  Screening of high throughput assays 96 well formats 
4.25.1 Automated PLL coating 
The Hamilton Labstar robot was programed to coat 96 well plates. The plates 
were opened than 30ul of PLL/H2O were pipetted. The plates were incubated 
for 20 min., than washed with 2 times 50ul H2O. The dried plates were 
sterilised by one hour UV-light exposition. 
4.25.2 In solution transfection of PC12 cells 
To transfect huge amounts of equal cells with equal plasmids we used the 
following protocol per one 96well plate. 4,000,000 cells were harvested and 
diluted in 5ml phenol red free DMEM. The following plasmids were diluted in 
2,5ml Optimem and mixed. 
2µg   ERBB4-NTEV-tevS-GV_2HA  
2µg   PIK3R1-CTEV_2HA 
2µg   UAS firefly luciferase 
2µg   TK-Renilla luciferase 
0,5µg  pECFP CI 
20ul of Lipofectamin2000 were diluted in 2.5ml Optimem and mixed. 
Both Optimem aliquots were mixed and incubated for 20min. Afterward the 
5ml Optimem and the cells in DMEM were carefully mixed, and incubated at 
37°C at 5% CO2 for 2h.  
4.25.3 Plating of cells 
10ml solution, containing 4,000,000 in solution transfected cells, per 96well 
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plate, were stored in the bubble paddle reservoir of the Hamilton Cellstar 
robot. 100ul per well were pipetted using the 96er pipet head. The 
homogeneity of the solution over time is sustained by mild paddeling of the 
reservoir. Keep in mind that the reservoir has a “death volume” of 50ml/5 
plates. The finished plates were stored in the cytomat automated cell culture 
(34 plates maximum). 
4.25.4 Handling of stable Nrg1-type-I expressing cells 
1,000,000 Nrg1-type-I expressing PC12 cells per plate were harvested and 
diluted in 10ml phenol red free DMEM. The cells were placed in the Cellstar 
robot in the bubble paddle reservoir (see above). 10,000 cells/well were 
plated in each well. Note, stable cell lines grow slower than normal PC12 cells, 
probably due to Hygromycin. Start in time with growing the cells.  
4.25.5 Dispension of drugs 
The drugs of the NCC library were diluted in DMSO to an f.c. of 1mM. 80 
drugs were used per 96well-plate using the collums 2-11 (blue). 1A-D is 
further stimulated with 10mg/ml EGFld (yellow). 12A-D is inhibited with 100nM 
CI-1033 (red) and 12E-H with 10µM Lapatinib (lilac). 
24h after in solution transfection the plates were processed with the Cellstar 
robot. They were driven out of the incubator, opened, and stimulated with 2ul 
of Drug/DMSO. 30min. after the drug stimulation, the cells were stimulated 
with 100ul DMEM with 10,000 Nrg1-typeI expressing cells per well, 
automatically pipetted with the 96well head from the bubble paddle reservoir. 
Afterwards the cells were automatically incubated for another 24h. 
 
Figure 19:  Layout of a 96 well-plate for HTP screen  
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4.25.6 Automated dual luciferase assay 
Plates were emptied of medium. The cells were lysed by application of 35ul of 
passive lysis buffer and high speed shaked for 10 min. The plates were 
measured in the LB plate reader. 30ul of firefly substrate were pipetted in 
each well, the plate was shaken for ten sec. and than firefly luciferase activity 
was measured. Than 30µl Renilla substrate were pipeted in each well, the 
plate was shaken for ten sec. and than Renilla luciferase activity was 
measured. The data was automaticly exported as text file and analysed using 
the following TinR script. 
4.25.7 Analysis of results with TinR 
The data was analysed with TinR using the following script: 
library("cellHTS2") 
 
 # Script to analyse Luci Screens with cellHTS2 
 # part 1 creates all folders and fiules wich are neccesary to run the cellHTS2 package 
 # part2 runs cellHTS2 
 # part1 
 
   # Please specify Replicate number and number of substance plates 
    subPlates=as.numeric(winDialogString("How many Substance Plates were used", "4")) 
    reps=as.numeric(winDialogString("How many replicates", "3")) 
    experimentName <- studyName <- winDialogString("Name of the study?", "screen1") 
    #create new folder with studyName 
    datadir<-paste("Z:/User/Systasy project NEW/Operative Business/ERBB4 PI3Kp85a split TEV 
Compound screen/Analysis with R/",studyName,sep="") 
    dir.create(datadir)     
    dir(datadir) 
    setwd(datadir) 
    #create SUBFOLDERS 
    dir.create(paste(datadir,"/logRatio",sep="")) 
    dir.create(paste(datadir,"/rawdata",sep="")) 
    # choose all rawdatafiles and copy them to Study folder 
    csa<-choose.files(default = "Z:/User/Systasy project NEW/Operative Business/ERBB4 PI3Kp85a split 
TEV Compound screen/Analysis with R", caption = "Select the LUCI rawdata files",multi = TRUE) 
    file.copy(csa,paste(datadir,"/rawdata",sep="")) 
    allfiles <- dir(paste(datadir,"\\rawdata\\",sep=""))    # place all raw data files into a RawData subfolder 
    f2r<- allfiles[grep("TXT",allfiles)] 
  
  # go through all rawdata files and extract relevant data and create new files  
  for(fi in f2r){ 
  te<-read.table(paste("rawdata/",fi,sep=""),skip=9) 
  ff<-te[1:96,] 
  ffname=paste(strsplit(fi,".TXT")[[1]],"_FF",sep="") 
  ff<-cbind(rep(ffname,times=96),ff) 
  rn<-te[101:196,] 
  rnname=paste(strsplit(fi,".TXT")[[1]],"_RN",sep="") 
  rn<-cbind(rep(rnname,times=96),rn) 
  write.table(ff,paste(ffname,".TXT",sep=""),quote=F,row.names=F,col.names=F,sep="\t") 
  write.table(rn,paste(rnname,".TXT",sep=""),quote=F,row.names=F,col.names=F,sep="\t") 
  } 
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  # generate platelist.txt file 
  allfiles <- dir(datadir)    # place all raw data files into a RawData subfolder 
  f2r<- allfiles[grep("TXT",allfiles)] 
  ma<-matrix("NA",nrow=length(f2r),ncol=4) 
  Filename=NULL 
  for(i in 1:subPlates ) { 
  print(i) 
      FileNamesRNTemp = f2r[seq(reps*(i-1)*2+2,reps*i*2,by=2)] 
      FileNamesFFTemp = f2r[seq(reps*(i-1)*2+1,reps*i*2,by=2)] 
      Filename = c(Filename,FileNamesRNTemp,FileNamesFFTemp) 
  } 
   
  Plate = rep(1:subPlates,each=reps*2) 
  Replicate = rep(1:reps,subPlates*2)  
  Channel =   rep(rep(1:2,each=reps),subPlates)  
  ma<-cbind(Filename,Plate,Replicate,Channel) 
  write.table(ma,"Platelist.txt",row.names=F,quote=F,sep="\t") 
 
  # part2 
 
  if(subPlates == 4) { 
     file.copy("Z:/User/Systasy project NEW/Operative Business/ERBB4 PI3Kp85a split TEV Compound 
screen/Analysis with R/ScreeningLibraries/Ncc-201/Plateconf.txt",datadir) 
     file.copy("Z:/User/Systasy project NEW/Operative Business/ERBB4 PI3Kp85a split TEV Compound 
screen/Analysis with R/ScreeningLibraries/Ncc-201/Description.txt",datadir) 
     file.copy("Z:/User/Systasy project NEW/Operative Business/ERBB4 PI3Kp85a split TEV Compound 
screen/Analysis with R/ScreeningLibraries/Ncc-201/drug list.txt",datadir) 
  } 
  if(subPlates == 6) { 
     file.copy("Z:/User/Systasy project NEW/Operative Business/ERBB4 PI3Kp85a split TEV Compound 
screen/Analysis with R/ScreeningLibraries/Ncc-003/Plateconf.txt",datadir) 
     file.copy("Z:/User/Systasy project NEW/Operative Business/ERBB4 PI3Kp85a split TEV Compound 
screen/Analysis with R/ScreeningLibraries/Ncc-201/Description.txt",datadir) 
     file.copy("Z:/User/Systasy project NEW/Operative Business/ERBB4 PI3Kp85a split TEV Compound 
screen/Analysis with R/ScreeningLibraries/Ncc-003/drug list.txt",datadir) 
  } 
   
x <- readPlateList("Platelist.txt", name=experimentName, path=datadir) 
 
x <- configure(x,  
    descripFile="Description.txt",  
    confFile="Plateconf.txt", 




xn <- normalizePlates(x, scale="multiplicative", method="median",  
varianceAdjust="none") 
 
ctoff <- quantile(Data(xn)[, , 1], probs = 0.05, na.rm = TRUE) 
 
xn1 <- summarizeChannels(xn, fun = function(r1, r2, thresh = quantile(r1, 
  probs = 0.05, na.rm = TRUE)) ifelse(r1 > thresh, 
  r2/r1, as.numeric(NA))) 
 
xn1 <- normalizePlates(xn1, scale = "multiplicative", 




xsc <- scoreReplicates(xn1, sign = "-", method = "zscore") 
xsc <- summarizeReplicates(xsc, summary = "median") 
xsc <- annotate(xsc, geneIDFile="drug list.txt",      # enter annotation file name 
path=datadir) 
 
par(mfrow = c(1, 2)) 
ylim <- quantile(Data(xsc), c(0.001, 0.999), na.rm = TRUE) 
boxplot(Data(xsc) ~ wellAnno(xsc), col = "lightblue", 
outline = FALSE, ylim = ylim)             
imageScreen(xsc, zrange = c(-2, 4)) 
 
 negControls <- vector("character", length = dim(Data(x))[3]) 
  negControls[1] <- "(?i)^PC12 Nrg1-typeI$"                ## neg controls for channel 1, Renilla, PC12 
Nrg1.typeI cells are baseline 
  negControls[2] <- "(?i)^Lapatinib$|^CI-1033$"      ## neg controls for channel 2, Firefly 
  posControls <- vector("character", length = dim(Data(x))[3]) 
  posControls[2] <- "(?i)^EGF-like domain$"           ## pos controls for channel 2 
 
setSettings(list(platelist = list(intensities = list(include = TRUE)), 
screenSummary = list(scores = list(range = c(-4, 4))))) 
 
negControls <- "(?i)^Lapatinib$|^CI-1033$" 
posControls <- "(?i)^EGF-like domain$" 
 
out <- writeReport(raw = x, normalized = xn1, scored = xsc, 
outdir = "logRatio", map = TRUE, posControls = posControls, 








4.25.8 Preparation of dose response dilutions for 96well format. 
To prepare a master plate start by solving the drug in DMSO. Prepare 150ul 
of 10mM stock solution. Prepare 2 stripes of a 96 well plastic plate with 
following DMSO amounts. 
Pipette 100ul stock solution in 1a, pipette 34ul stock solution in 1b, mix by 
pipetting 10times up and down. Transfer 10ul from 1a.2a., mix, transfer 10ul 
from 2b.2c., repeat top down pipetting for all wells except 7b. that remains 
pure DMSO.  8a. and b. remains empty for assay stimulation controls.  
Dose response curves from f.c. 100µM to 0.0001µM can now be generated by 
pipetting 2ul to wells containing final 200ul co-culture or cell culture buffer.  
Note pipetting of small amounts (2ul) with 8 channel pipets is inaccurate 12ul 
are needed for 6 wells. Plan with 150-200% as master mix. 90µl will only be 
secure enough for 5*96 well plates. 
4.26  Biochemical methods 
4.26.1 Western Blot 
Western blotting is a classical method for immunological detection of proteins 
in biological samples (Towbin et al., 1992). 
4.26.2 Sodium dodecyl sulphate polyacrylamid gel 
electrophoresis (SDS-PAGE) 
Unlike DNA, proteins may be positively or negatively charged or neutral and 
do not have a linear relationship between weight and charge due to 
differences in amino acid composition. To enable directed migration of 
proteins in the electric field SDS is used to produce a negative charge. After 
heat denaturation at 70°C the polypeptide chains unfolds to expose the 
hydrophobic regions which can non-covalently bind SDS hydrophobic tails at 
the stochiometry of 1 SDS molecule per 2 amino acids. Additional treatment 
with dithiotreitol (DTT) reduces all intra- and intermolecular disulfide bonds. 
Protein lysates were mixed with 4x LDS sample buffer and 10% DTT (f.c. 
0.1M) and incubated at 70°C for 10 min. 2- 5μg were used for western blotting. 
For SDS-PAGE NuPAGE Novex Bis- Tris Gels (Invirtogen) were used with 
Xcell SureLock NuPAGE buffer chambers (Invitrogen) according to the 




4.26.3 Transfer of proteins on membranes 
The transfer of proteins from the gel to a PVDF membrane was performed 
with the Xcell SureLock  estern Blot System (Invitrogen) according to the 
manufacturer  s instructions. Prior to transfer PVDF membranes were 
activated for 3min in 100% methanol and afterwards rinsed in transfer buffer. 
The transfer was done at 30V for 2h while the chamber was placed in ice 
water. 
4.26.4 Detection 
When the transfer was completed the membrane was incubated in blocking 
buffer (5% non fat milk powder in TBS-T for normal antibodies or 5% BSA in 
TBS-T for -phospho antibodies) for at least 30min at RT. The primary 
antibody was applied in the appropriate dilution in blocking buffer at 4°C 
overnight. The membrane was rinsed twice with TBST and than washed with 
TBST three times for 10min and was subsequently incubated with the 
appropriate horse-radish peroxidase (HRP)-conjugated secondary antibody 
for 1h at RT. After two times rinsing and three wash steps for 10 min in TBS-T 
the membrane was treated with enhanced chemiluminescence (ECL) 
detection solution for 1 min according to the manufacturer  s recommendations 
and enclosed in plastic foil. In a dark chamber an ECL-hyperfilm was exposed 
to the membrane and developed with KODAK-O-MAT. For reprobing the 
membrane was incubated with 0,5M NaOH for 3min at RT or Restore WB 
stripping buffer according to the manual. The membrane was then washed in 
TBS-T and blocked again as described above. All incubation steps were 
performed under constant moderate shaking or rolling. 
4.27  The MK801 mouse model 
NMDA antagonists are tools to produce SZ-like symptoms in animal models 
and human subjects (Eyjolfsson et al., 2006). This is based on the first 
findings (Luby et al., 1959) that Phencyclidine induces a psychotic state with 
positive and negative symptoms in healthy humans (Snyder, 1980). The 
underlying mechanism of glutamate receptor blockage was discovered in 
1982 (Lodge and Anis, 1982).  The dysfunction of the combined dopaminergic 
and glutamatergic transmitter system in the pathogenesis of SZ has been 
broadly discussed (Javitt and Zukin, 1991; Olney and Farber, 1995; Flores 
and Coyle, 2003; Carlsson et al., 1999). The disturbance of glutamatergic 
neurotransmission, has been reported in patients with distinct negative 
symptoms and cognitive deficits (Harrison and Weinberger, 2005; Goff and 
Coyle, 2001; Tsai and Coyle, 2002). All known SZ susceptibility genes act on 
glutamatergic synaptic transmission (Harrison and Weinberger, 2005), and 
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reduced GABA synthesis has also been described in SZ patients (Lewis et al., 
2005). 
Therefore, MK801, the most potent non-competitive NMDA receptor complex 
antagonist, is used to model SZ symptoms in animal models. MK801 binds to 
a site in the ion channel and blocks cat ion flow. Therefore, the receptor 
acquires the open confirmation that is dependent on the agonist MK801.  
The drug produces locomotor hyperactivity in rodents that may correspond to 
positive symptoms of SZ (Nilsson et al., 2004), social withdrawal that is a core 
phenotype of negative symptoms (Sams-Dodd et al., 1997), pre-pulse 
inhibition deficits, and maybe cognitive deficits (Arnt, 1998). 
MK801 is reported to trigger auditory hallucinations (Allen and Young, 1978). 
In addition, MK801-elicited effects were studied on hippocampal and 
prefrontal GABAergic interneurons in rodent animal models (Braun et al., 
2007). 
 
Figure 20: Model of the local neuronal circuit dis-inhibition in response to MK801 in 
the cortex.  
A) An inhibitory GABAergic interneuron (IN, i.e. Chandelier cell or Basket cell) receives input 
from the excitatory pyramidal cell (PC) thereby exerting an inhibitory control by recurrent 
projections to the pyramidal cell. B) In presence of the NMDA receptor antagonist MK801, this 
local feedback inhibition becomes disrupted, whereas the excitatory input is sustained via 
non-NMDA (AMPA/kainate) receptors, which do not respond to MK801. Due to this imbalance 
the total excitatory output is predicted to be enhanced. Image taken from (Braun et al., 2007). 
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4.28  Drug tests in mice 
4.28.1 Drugs and treatments 
Spironolactone (Sigma-Aldrich) was dissolved in 0.9% NaCl with 1% DMSO 
and 0.002% Tween®20. MK801 (Sigma-Aldrich) was dissolved in 0.9% NaCl 
with 1% DMSO. Drugs were stored in DMSO at -20°C and diluted freshly 
before experiments. Spironolactone (20mg/kg), MK801 (0.5mg/kg), and 
vehicle (0.9% NaCl with 1% DMSO) were injected i.p. in volumes of 10ml/kg. 
4.28.2 Mice 
C57Bl6/N male mice were purchased from Charles River (Sulzfeld, Germany) 
at the age of three weeks. After arrival, animals were housed in standard 
plastic cages with food and water ad libitum in the colony room, with a 12 
hours light-dark cycle (lights switched on at 8:00 a.m.). One week prior 
experiments, mice were placed in single cages and habituated to 
experimental rooms. Experiments were conducted with nine weeks old 
animals. Treatment groups were analysed at balanced time points during the 
light phase to exclude an interference of circadian rhythm on drug actions.  
4.28.3 Behavioral studies 
To assess the effects of Spironolactone on MK801-induced hyperactivity mice 
were injected with corresponding drugs according to the protocol depicted in 
(Fig. Figure 55 A) Animals were divided randomly in one of the following four 
treatment groups: Group 1 was injected twice with vehicle ([veh+veh], n=13), 
group 2 was administered with Spironolactone and vehicle ([Spiro+veh], 
n=14), group 3 treated with vehicle and MK801 ([veh + MK801], n=12), and 
group 4 injected with Spironolactone and MK801 ([Spiro+MK801], n=14). 
100min after the first injection (vehicle or Spironolactone) each animal 
underwent the open field test. The open field test was conducted in a 
Plexiglas arena (45 x 45 x 55 cm high). Each mouse was placed individually 
in an open field box and was allowed to explore freely the test arena for 20 
min to determine baseline activity. After 20min, the experiment was stopped 
for 4min to administer the second injection (vehicle or MK801 according to the 
protocol in (Figure 55 A) Subsequently, animals were placed back to the open 
field box and left undisturbed for 120min. The distance travelled, the time 
which each mouse spent active, and the time spent in the centre of the arena 
(defined as 70% of central area) were analysed as an indicator of anxiety. The 
numbers of rearings were taken as a sign of exploratory drive. All movements 
were monitored by infrared sensors and analysed by the ActiMot software 




5.1 Design of a screening platform for Nrg1-ERBB4 signalling 
A cell-based assay that can be used for HTP screening approaches has to 
meet specific criteria, such as scalabilty and, robustness. Moreover, it has to 
provide a simple but quantifiable readout.  
The screening assay described here is mimicking proximal aspects of the 
Nrg1-ERBB4 signalling using a co-culture assay of two different cell 
populations (Figure 25). The first population represents PC12 cells expressing 
constitutively active mouse-derived Nrg1-typeI-1a (Figure 26, Figure 27). 
The second population represents also PC12 cells but expressing human 
ERBB4 fused to the N-terminal part of the TEV protease (NTEV) that is linked 
via a TEV protease cleavage site (tevS, sequence: ENLYFQ’G) to the artificial 
transcription factor Gal4-VP16 (GV). As ERBB4 is a type I transmembrane 
receptor, GV is anchored to the membrane as long as no functional TEV 
protease is present. Activated ERBB4, i.e. Nrg1 ligand-bound and dimerised 
ERBB4, is auto-phosphorylated at several specific Tyr residues in the C-
terminal region that act as binding sites for phospho-adapter molecules, such 
as the regulatory subunit of the PIK3, PIK3R1, that binds to phosphorylated 
Tyr residues within YXXM motifs. Therefore, PIK3R1 fused to the C-terminal 
part of the TEV protease (CTEV), is also expressed in the second cell 
population. In this assay, activated ERBB4 binds to PIK3R1initiating the 
formation of TEV protease activity as both TEV protease fragments get into 
close proximity, which allows the refolding of the inactive fragments into a 
functional TEV protease. The protease can cleave at the tevS to release the 
artificial transcription factor GV that in turn translocates to the nucleus. Here, 
GV induces the transcription of a firefly luciferase reporter gene that is under 
the control of upstream activating sequences (UAS-Fluc). UAS-Fluc is the 
third component that has to be introduced into the second cell population to 
complete the assay. Using a firefly luciferase as readout allows for a linear 
amplification of an occurred ERBB4/PIK3R1 interaction event. In addition, the 
luciferase assay is an easy-to-use readout, stable, and very sensitive assay 
(Figure 22, Figure 28). 
5.1.1 Normalisation 
For normalisation purposes, the assay system is co-transfected with a Renilla 
luciferase vector. The Renilla luciferase is constitutively expressed under the 
control of the Thymidine kinase (TK) promoter. It is assumed that the 
transfection efficiency can be compared across all wells using the enzymatic 
activity of the Renilla luciferase. Choosing the correct promoter for the Renilla 
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luciferase is vital, as some promoters like the CMV or SV40 promoter seem to 
respond to growth factors, such as the EGFld and other introduced effects like 
shRNAs (C. Hammer personal communication). In addition, the normalisation 
vector in the screen is used to detect toxic substances by means of absolute 
Renilla values. 
5.1.2 Concentrations of plasmids 
All plasmids in the assay are regularly used in the concentration of 20ng/well. 
Titration assays have shown that this concentration is sufficient to yield 
optimal induction ratios for the Nrg1-induced ERBB4/PIK3R1 assay, which is 
also in agreement with a previous report using the split TEV technique for 
ERBB4 assays (Wehr et al, 2008). 
5.1.3 Cell numbers per well 
Two different cell concentrations have to be considered. First, cell numbers of 
population 1 have to be high enough to provide a detectable and stable signal, 
but adjusted to reasonable levels to prevent overcrowding as cells still divide 
within the 48h duration of the assay. 40,000 PC12 cells/96-well were 
determined to be optimal. Second, the Nrg1-typeI-expressing cells have to be 
adjusted. A number of 5,000-10,000 cells/96-well resulted in a stable 
activation of the assay that allowed both further activation or inhibition.  
5.1.4 Cell types tested for the assay 
We tested PC12, HEK293, and CHO cells for usability in the screen. PC12 
cells performed best in transient assays. HEK293 cells gave unstable results 
in transient assays and, unfortunately, a triple transgenic HEK293-derived cell 
line stopped working reliably. CHO cells gave no stable results at all. 
5.1.5 Transfection methods 
We tested FuGeneHD, Lipofectamine LTX, and Lipofectamine 2000. For 
PC12 cells, Lipofectamine 2000 was best suitable, as it could well be used for 
both adherent and in-solution transfections. For screening purposes, in-
solution transfection was used to increase homogeneity of transfected cells in 
the wells. A special steering device named “bubble paddle reservoir” available 
within the Hamilton Microlabstar Plus robot was used to further increase 
homogeneity of the cells. 
5.1.6 Workflow of the NRG1-ERBB4 assay 
Critical to HTP-screening are the time points applied in a workflow of a given 
assay. When using in-solution transfection, two time points are critical. First, 
the components of the assay have to be expressed and correctly localised to 
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the membrane, a process that occurs during the expression phase of the 
transiently transfected cells after plating. Second, a good time window has to 
be chosen for the application of the drugs and concomitant addition of the 
Nrg1-type1-expressing cells. We tested various setups with six hours 
differences between each time point and found a reasonable measurement 
window between 12h expression/12h stimulation and 24h expression/36h 
stimulation. After a total assay duration of 72h, the plates were overgrown and 
the cells started to die. For screening purposes, working hours also have to 
be considered. Therefore, a 24h expression/24 stimulation workflow was 
chosen. 
5.1.7 Stability of the luciferase signals 
To provide a robust readout the luciferase signal has to be stable over the 
time needed for the measurement. For HTP screening, the processing of the 
assay plates should be as fast as possible. Therefore, cells are lysed using an 
8-well dispenser head, allowing to dispense the buffer in minimal time. In 
addition, the buffer used, the Promega passive lysis buffer, is formulated to 
provide optimal stability for luciferase enzymes. When the substrates are 
added to the cell lysates, the luciferase reaction starts immediately. The firefly 
luciferase signals are relatively stable, with 80% stability over the first 5 
minutes. The Renilla luciferase signals decrease fast, with a reduction of 50% 
within two minutes. To start the measurement, luciferase substrates are 
dispensed across the plate, followed by orbital mixing and the measurement 
itself for which the detector head moves again across the plate. The minimum 
time required for a measurement of one plate in one run in our luciferase 
reader is 100 seconds for dispensing, 10 seconds for mixing, and 100 
seconds for reading. Thus, firefly and Renilla luciferase activity is measured in 
each well 110 seconds after addition of the substrate. As the timing for each 
well regarding substrate addition and reading is the same the initial dramatic 
decrease in Renilla luciferase activity should not have an effect on the 




Figure 21: Kinetics of firefly and Renilla luciferase 
Decay of firefly luciferase (Fluc, blue) and Renilla luciferase (Rluc, red) signal over 20 min. 
The Fluc signal drops regularly over 20 min, then remaining with about 50% of activity. 
The Rluc signal initially drops fast, losing about 50% of its activity within the first 2 min, but 




5.1.8 Protocol at a glance one 96 well plate 
The experiments lead to the following protocol used in the screening assay: 
Transfection Protocol 
1. Pipet DNA 
2. Mix DNA with 1/2 volume Optimem 
3. Vortex 
4. Incubate 2-5 minutes 
5. add LF2000 to other 1/2 volume Optimem 
6. Vortex 
7. Incubate 2-5 minutes 
8. Combine LF2000/Optimem and DNA/Optimem mix 
9. Vortex 
10. Incubate 30 minutes at RT 
11. Add cells (in medium, with same volume as total volume of Optimem)  
12. Incubate 2h at 37°C, but no shaking/rocking 
13. Plate cells on 96 well plates, 100µl/96-well. No centrifugation 
necessary 
14. Incubate 24h for protein expression. Check expression using a GFP-
transfected control plate. 
15. Add drugs (2 µl in DMSO, f.c. 10µM). Controls: 10 µM Lapatinib, 0.1 
µM CI-1033. 
16. Add EGF-like domain (f.c.10 ng/ml; 20 ng/ml added in 100µl) or PC12 
Nrg1-typeI cells (in 100µl) 
17. Incubate further 24h  
18. lyse cells for assay (35 µl PLB/96-well) 
5.2 Component controls 
5.2.1 CMV-GV 
The PC12 cells are transfected with UAS-Fluc and GV. The UAS-Fluc can be 
activated by constitutively active expression of the GV that is under the control 
of the CMV promoter. In HTP screens, all substances that interfere with Fluc 
activity have to be eliminated to reduce false positive signals (Figure 23).  
5.2.2 TM-TEV/TM-GV 
The PC12 cells are transfected with TM-TEV, TM-GV, and UAS-Fluc. TEV 
protease and GV are bound to a membrane anchor termed TM, a 
transmembrane domain present in the plasmid pHOOK. Both the protease 
and the GV are localised to the membrane. Any substance that interferes with 




Lapatinib is an ERBB-specific receptor tyrosine kinase inhibitor. In the screen, 
it is used as control acting as an inhibitor. 10 µM of Lapatinib leads to highly 
decreased luciferase activity in the screen (Figure 29). 
5.2.4 CI-1033 
CI-1033 is a non-specific receptor tyrosine kinase inhibitor. It is used in the 
screen as further control also acting as a highly potent ERBB4 inhibitor. 
100nM. CI-1033 results in even more decreased luciferase activity compared 
to 10µM Lapatinib (Figure 29). 
5.2.5 EGFld 
The NRG1 EGF-like domain (EGFld) is a potent activator of ERBB3 and 
ERBB4 activity. In the screen, it is used to further activate the assay, with 
levels that are above the ones induced by Nrg1-typeI-expressing cells. 
10ng/ml EGFld (ca1.5nM, MW ca. 7.2 kD) are sufficient to activate the assay 
nearly to maximum levels. EGFld domain represents the functional domain of 
human NRG1 for ERBB3/4 activation. Therefore, EGFld represents the most 
effective way to activate ERBB3/4. Substances that are found in the screen 
and modulate Nrg1-ERBB4 signalling, but fail to modulate EGFld-ERBB4 






Figure 22: Schematic representation of the shape and function of the constructs 
used in the screen 
A) Distal of the signalling cascade is a PC12 cell line stable expressing Nrg1-typeI1a. 
Nrg1 is localised in the membrane, processed, and then released into the medium. B) The 
ERBB4 receptor is fused to the N-terminal moiety of the TEV protease. In addition, it is 
fused to the GalV-VP16 transcription factor via the TEV protease-specific cleavage site 
ENLYFQ`G. The alpha regulatory subunit of the PI3-kinase, PIK3R1, is fused to the C-
terminal moiety of the TEV protease. C) The ERBB4 receptor homodimerises after binding 
to Nrg1-typeI. D) After forming homodimers, ERBB4 receptor pairs auto-phosphorylate 
each other. E) The ERBB4 homodimer recruits the PIK3R1 to the PI3-kinase binding site 
at Tyr 1056.F) The recruitment of PIK3R1 to the ERBB4 homodimer brings the N- and C- 
terminal fragments of the TEV protease in close proximity. G) Both fragments of the TEV 
protease fold into the active protease and regain protease activity. The TEV protease 
targets the TEV-specific cleavage site and releases the Gal4-VP16 transcription factor. 
The transcription factor shuttles to the nucleus and activates the UAS-Fluc reporter gene. 
H) Activation of the UAS-Fluc reporter gene results in a higher firefly luciferase activity, 




Figure 23: Controls of the screen 
A) Renilla luciferase. Effect of a toxic substance. B) Constitutively active GV-UAS-firefly 
assay. The Cytomegalovirus promoter (CMV) was placed in front of the Gal4-VP16 (GV) 
artificial transcription factor. C) TM-TEV/TM-GV.A transmembrane anchor (HOOK) was 





Figure 24: Background of the assay 
ERBB4/PIK3R1split TEV assay in PC12 cells. ERBB4 was fused to NTEV-tevS-GV-2HA. 
PIK3R1 was fused to CTEV-2HA. ERBB4 dimerises after stimulation with 10ng/ml EGF-
like domain and recruits PIK3R1. Further controls (inset) show the background of the 
assay. The background of non-stimulated ERBB4/PIK3R1 is about ten times higher than 




Figure 25: Design of the co-culture assay for the screen 
A) Schematic representation of the differences between Nrg1-typeI- and Nrg1-typeIII-
mediated signalling in co-culture assays. B) Schematic representation of the co-culture 
assay. Cell population one expresses Nrg1-typeI. The receiving cell, i.e. cell population 
two, expresses ERBB4-NTEV-tevS-GV-2HA and PIK3R1-CTEV-2HA. After binding to 
NRG1-typeI, ERBB4 homodimerises and recruits PIK3R1. TEV protease activity is 
reconstituted, cleaving at the tevS to release GV. GV translocation to the nucleus results 
in increasing Fluc activity.C) Microscopic images of the co-culture assay. 40,000 PC12 
-C1; 10,000 Nrg1-typeI cells were 
transfected with EYFPnuc. D) Dose response of the Nrg1-ERBB4 assay using increasing 
numbers of Nrg1-typeI-expressing cells. E) Dose response of the Nrg1-ERBB4 assay 




Figure 26: Difference between stimulation with Nrg1-typeI and NRG1-type III stable 
cell lines 
ERBB4/PIK3R1split TEV assay in PC12 cells. ERBB4 was fused to NTEV-tevS-GV-2HA. 
PIK3R1 was fused to CTEV-2HA. ERBB4 dimerises after stimulation with 
indicatednumbers of Nrg1-typeI- or Nrg1-typeIII-expressing PC12 cells, then recruiting 
PIK3R1.  
 
Figure 27: Western blot analysis showing stable expression of, Nrg1-typeI and Nrg1-
typeIII in PC12 cells 
Stable PC12 cell lines were generated using plasmids V368 (Nrg1-typeI-1a) and V370 
(Nrg1-typeIII-1a). Plasmids were not linearised before transfection. Co-selection was 
performed using the Hygromycin-containing plasmid pMSCV-hyg, with a dilution of 1:10 (1 
part pMCV-hyg, 9 parts Nrg plasmids) and 100µg/ml hygromycin. Maintenance of stable 
cells was done with 50µg/ml hygromycin in regular PC12 medium. Western blots were 




Figure 28: Robustness of the assay 
Dose response of the ERBB4/PIK3R1 co-culture assay using increasing amounts of EGF-
like domain. Comparison of three plate. ERBB4/PIK3R1split TEV assay in PC12 cells. 






Figure 29: ERBB4 kinase inhibitor controls, Lapatinib and CI-1033 
A) Lapatinib is described as an ERBB-specific kinase inhibitor. The image shows the 
specificity of Lapatinib against the kinases within the human kinome tree (Karaman et al., 
2008). The in-vitro kD of Lapatinib on ERBB4 is 54nM. Chemical structure of Lapatinib 
(Karaman et al., 2008 supplements; Medina and Goodin, 2008). B) CI-1033 is described 
as a kinase inhibitor not specific to ERBBs. The image shows the specificity of CI-1033 
against the kinases within the human kinome tree (Karaman et al., 2008). The in-vitro kD 
of CI-1033 on ERBB4 is 29nM. Chemical structure of CI-1033 (Karaman et al., 2008 
supplements; Slichenmyer and Fry). C) Comparison of the effects of Lapatinib and CI-
1033 on the ERBB4/PIK3R1split TEV assay in PC12 cells. ERBB4 was fused to NTEV-








5.3 The NCC201 screen  
The NCC201 library was screened according to the described parameters. 
5,000 (Figure 30) and 10,000 (Figure 31) PC12 Nrg1-typeI cells were used for 
the stimulation. A z’-factor of >0.5 was obtained when full activation was 
triggered using EGF-like domain and inhibition using Lapatinib and CI-1033. 
Both screens resulted in one putative activator and one putative inhibitor. The 
inhibitor was identified to be Spironolactone. It causes a highly significant 
decrease of the luciferase activity in the screen (p< 0.0001). The activator 
was identified to be Albendazole. It causes a highly significant increase in 
luciferase activity (p< 0.0001). Both hits were recovered from both types of 
screens, either run with 5,000 or 10,000 Nrg1-typeI-expressing PC12 cells. In 
addition, both hits showed no toxic effect in the GV-UAS-Fluc technical control 
screen.  
The inhibitor Spironolactone is also found in a screen stimulated to maximum 
levels using the EGF-like domain, indicating a strong effect of the drug 
towards ERBB4 receptor activation, but not Nrg1-typeI processing as the 
EGF-like domain already represents a form that is most possibly reduced in 




Figure 30 Screen of the NCC201 library 
A) ERBB4/PIK3R1 split TEV based screening assay in PC12 cells. ERBB4 was fused to 
NTEV-tevS-GV-2xHA; PIK3R1was fused to CTEV-2HA. ERBB4 dimerises after 
stimulation with 5.000 Nrg1-typeI cells and recruit PIK3RI. Cells were further stimulated 
with EGFld (10ng/ml), Lapatinib (10µM), CI-1033 (0.1µM), or 80 different compounds (see 
plate design). Luciferase data was analysed using tinR (see script in the methods). B) 
Extracted data from the screen showing the significance of the effect of the top inhibitor 
Spironolactone. C) Extracted data from the screen showing the significance of the effect of 




Figure 31: Screen of the NCC201 library 10k Nrg1-typeI cells 
A) ERBB4/PIK3R1 split TEV based screening assay in PC12 cells. ERBB4 was fused to 
NTEV-tevS-GV-2xHA; PIK3R1was fused to CTEV-2HA. ERBB4 dimerises after 
stimulation with 10.000 Nrg1-typeI cells and recruit PIK3RI. Cells were further stimulated 
with EGFld (10ng/ml), Lapatinib (10µM), CI-1033 (0.1µM), or 80 different compounds (see 
plate design). Luciferase data was analysed using tinR (see script in the methods). B) 
Extracted data from the screen showing the significance of the effect of the top inhibitor 
Spironolactone. C) Extracted data from the screen showing the significance of the effect of 




Figure 32: Detailed analysis of the functionality of the screen 




Figure 33: Counter-screen of the NCC201 library with EGF-like domain 
A) ERBB4/PIK3R1 split TEV based screening assay in PC12 cells. ERBB4 was fused to 
NTEV-tevS-GV-2xHA; PIK3R1was fused to CTEV-2HA. ERBB4 dimerises after 
stimulation with 10ng/ml EGFld and recruit PIK3RI. Cells were further stimulated with 
Lapatinib (10µM), CI-1033 (0.1µM), or 80 different compounds (see plate design). 
Luciferase data was analysed using tinR (see script in the methods). B) Extracted data 




Figure 34: Counterscreen of the NCC201 library with GV 
PC12 cells were transfected with GV and stimulated with Lapatinib (10µM), CI-1033 
(0,1µM), or 80 different compounds (see plate design). The red circles show that now 





5.4 The NCC003 Screen 
The NCC003 library was screened according to the described parameters. 
10,000 PC12 Nrg1-typeI cells were used for the stimulation. A z’-factor of > 
0.5 was obtained when using EGFld for activation and the Lapatinib and CI-
1033 for inhibition. From this part of the library, Topotecan showed the 
strongest inhibiting effect. 
 
 
Figure 35: NCC003 screen 
Split TEV-based screening assay in PC12 cells. ERBB4 was fused to NTEV-tevS-GV-
2HA. PIK3R1 was fused to CTEV-2HA. The complete assay was stimulated with 10ng/ml 
EGFld. Lapatinib and CI-1033 are used as negative controls and inhibit kinase activity with 
a concentration of 10µM for Lapatinib and 0.1µM for CI-1033 (12A-H). Topotecan is 





5.5 Hit validation  
From the NCC201 screen, two hits were recovered, the putative activator 
Albendazole and the putative inhibitor Spironolactone. From the NCC003 
screen, one hit was recovered, the putative inhibitor Topotecan. During the 
development of the co-culture screen a couple of interesting substances 
showed alterations in the firefly activity, with minor statistical significance. 
These substances were chosen to test the validity of the validation concepts 
. 
Name Location  Putative function 
Spironolactone NCC201 P1 D7 Inhibitor 
Albendazole NCC201P3 A3 Activator 
Topotecan NCC003 P3 A4 Inhibitor 
Vincristine NCC003 P6 B02 Inhibitor 
Mevastatin NCC003 P6 H4 Inhibitor 
CCPA NCC003 P6 B6 Activator 
K252a test substance Paper (Kuai et al. 2010) Activator 
Table 12: overview of candidate hits recovered from the screen (italics) and additionally 
validated substances  
The hit validation is separated into three parts, named (I) vertical, (II) 
horizontal and (III) orthogonal validation.  
(I) The vertical validation addresses at what level of the signalling cascade a 
candidate might be acting. In the co-culture assay, I tested whether the 
substance interfered with the localisation and processing of Nrg1, the binding 
of Nrg1 to the ERBB receptors, the homodimerisation of the receptors, the 
auto-phosphorylation of the receptors, the adaptor recruitment to the receptor, 
and all artificial components of the assay.  
(II) The horizontal validation examines the specificity of the substances on 
Nrg1-ERBB4 signalling. Different forms of NRG1-typeI, different homo and 
heterodimers of ERBB receptors, and different adapters of the ERBB system 
can be tested, resulting in more than 200 potential combinations to test.  
(III) The orthogonal validation can be sub-divided further. First, the hit 
substances’ effects on the downstream signalling cascades were addressed 
using other methods, such as phospho-specific antibodies.  Second, the 
candidates were tested in split TEV assays using related (i.e. other receptors, 
such as the GPCR HTR5A) and unrelated interaction partners (i.e. the model 
Results 
 107 
interaction of FRB and FKBP. Third, hit compounds were searched for 
structurally closely related substances, and their effects on the 
ERBB4/PIK3R1 co-culture assay were then analysed. Finally, first attempt 
towards the in vivo validation of the primary hit Spironolactone in a mouse 




Spironolactone is a synthetic, steroid like drug, which targets primarily the 
mineralocorticoid receptor (MCR), but it has also anti-androgen and 
progesterone properties. It acts as a competitive MCR antagonist (e.g. 
Aldosterone receptor).  
The MCR is a cytosolic receptor bound to 
HSP90 proteins. After Aldosterone binding 
HSP90 proteins are released, causing the 
MCR to homodimerise and to translocate to 
the nucleus, where the MCR binds hormone 
response elements (Fuller et al., 2012; Pippal 
and Fuller, 2008). It has been shown that a 
Spironolactone-bound MCR does not 
translocate to the nucleus, as this inhibits the 
dimerisation of the receptor (Grossmann et al., 
2012). A BRET study showed that a 
Spironolactone-bound MCR does not 
homodimerise, in contrast to a Aldosterone-
bound MCR (Grossmann et al., 2012). 
Spironolactone is used as diuretic, antihypertensive, and anti-androgen 
(Ogden et al., 1961). The known target profile of Spironolactone has been 
reported to include a much broader spectrum than the MCR only. To date, the 
following pharmacological inhibition or activation of the following receptors 
have been described (Fagart et al., 2010): 
 
Receptor IC50 
Mineralocorticoid receptor 24nM 
Androgen receptor    77nM 
Glucocorticoid receptor 2.42µM   
Progesterone receptor 0.74µM 
Table 13. IC50 values of various targets of Spironolactone (Fagart 2010) 
The half-life of Spironolactone is difficult to determine (Brittain, Analytical 
Profiles of Drug Substances and Excipients). It is rapidly metabolised in the 
liver, and more than 17 metabolites were isolated from humans. It is unclear 
whether one or more of these metabolites are responsible for the effects 
observed in pharmacological studies. Spironolactone also was reported to 
  
Figure 36: Spironolactone  
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mildly deteriorate depressive behaviour when combined with the anti-
depressant drug amitriptyline (Holsboer, 1999). 
 
Figure 37: Map Spironolactone metabolites 
Spironolactone is processed in the liver and metabolised into 17 metabolites. It is 
speculated that these metabolites also have an effect on the MCR, and may have other 
unknown functions as well. It is not known whether the structural integrity of 
Spironolactone is kept in a co-culture assay without liver processing (Analytical Profiles of 




In the screens performed, Spironolactone was found to decrease Nrg1-
ERBB4 signalling with varying but consistent levels (5,000 and 10,000 PC12 
Nrg1-typeI cells). Spironolactone was further validated in the secondary 
screening process where 10ng/ml EGF-like domain was used to stimulate 
ERBB4 signalling. The GV control screen showed that Spironolactone is not 
toxic for the cells at screening concentrations. 
Next, possible modes of actions for Spironolactone were analysed. To do this, 
a vertical validation approach was used that addressed the pathway from 
upstream to downstream components including technical controls. In addition, 
a horizontal validation approach was initiated to investigate potential functions 
for other NRG isoforms, ERBB receptors, and adapter molecules, such as 
GRB2 and SHC1.  
5.6.1 Vertical validation for Spironolactone 
An inhibitory dose response assay was established for Spironolactone. The 
dose response to increasing concentrations of Spironolactone in the Nrg1-
typeI-ERBB4/PIK3R1 co-culture assay showed an IC50 of 0.9 µM ( 
Figure 38). 
5.6.2 Technical controls for Spironolactone validation 
5.6.2.1 Renilla luciferase 
TK-Rluc reported the toxicity of Spironolactone. Spironolactone is toxic for the 
cells in this assay at concentrations at an IC50 of 56.4µM. Figure 39 
5.6.2.2 The Gal4-VP16 control assay 
In a first technical control assay, UAS-Fluc was co-transfected with GV only. 
This setup showed the effect of Spironolactone on the GV/UAS reporter 
system and the firefly luciferase. The IC50 of Spironolactone in this assay is at 
a concentration of 10.7µM (Figure 39). 
5.6.2.3 TEV protease control assay 
To correct for any effects elicited by the TEV protease and its activity at TEV 
protease cleavage sites, a transmembrane version of the TEV protease (TM-
TEV) was co-transfected with a transmembrane-bound GV carrying an 
internal TEV cleavage site (TM-GV), along with UAS-Fluc and Rluc reporters. 
The IC50 for Spironolactone in this constitutively activated TEV protease 
assay was determined to be at a concentration of 24.3µM. When comparing 
this IC50 value with the one obtained from the GV control assay (IC50, 10.7µM), 
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I can conclude that Spironolactone most likely has no effect on TEV protease 
activity (Figure 39). 
5.6.2.4 1-cell assay with soluble Nrg1-EGF-like domain 
To test whether the Spironolactone effect is targeted against Nrg1-typeI 
expression or processing, the Nrg1-typeI-expressing PC12 cells were 
exchanged for the soluble EGF-like domain. The EGF-like domain was used 
as a surrogate for any processed Nrg1 isoforms. The replacement of Nrg1-
typeI with EGF-like domain showed no functional differences in the 
performance of the assay, suggesting that Spironolactone does not target full 
length Neuregulin processing and activity (Figure 39). 
The adapter proteins PIK3R1 and SRC are primarily targeted by 
Spironolactone 
The effect of Spironolactone on the recruitment of various other adapter 
proteins was analysed. In the split TEV-based assay, SHC1, STAT5A and 
GRB2 showed an IC50 of roughly 5µM, SRC and PIK3R1 displayed an IC50 of 
about 0.7µM Spironolactone. These data suggest that in particular the binding 
of the adapter molecules PIK3R1 and SRC to the ERBB4 receptor is inhibited 




5.6.3 Horizontal validation  
Dimerisations of the ERBB receptor family 
5.6.3.1 ERBB4 receptor dimerisations 
A prerequisite for ERBB4 receptor activation is the dimerisation with itself or 
ERBB2, which is the preferred partner for all ERBB receptors. Therefore, split 
TEV assays were setup consisting of an ERBB4-NTEV-tevS-GV co-
transfected with either ERBB2-CTEV or ERBB4-CTEV. Efficient activation 
was tested using EGF-like domain (Figure 42,Figure 43), followed by dose-
response analyses for Spironolactone on the ERBB2/4 heterodimerisation 
and ERBB4 homodimerisation. The ERBB2/4 dimerisation yielded an IC50 
2.2µM, and the ERBB4 homodimerisation showed an IC50 of 2.4µM 
Spironolactone.  
5.6.3.2 ERBBx/ERBBy 
In addition, a complete panel of ten different ERBB receptor homo- and 
heterodimers stimulated with 10ng/ml EGF-like domain was measured. All 
combinations tested showed an IC50 of 2.2µM to 9.2µM Spironolactone (see 
table 14 below). A comparison to the ERBB4/PIK3R1 assay clearly showed a 
bias towards a selective inhibition for the adapter assay involving PIK3R1 
(Figure 42). 
5.6.3.3 ERBB2/ERBB4 dimerisation and adapters  
To get further insight of Spironolactone’s specificity towards the potential 
inhibition of ERBB2 and ERBB4, the adapter recruitment for ERBB2/4 
heterodimers was analysed. The adapter recruitment of ERBB2/ERBB4 
showed IC50 values between 0.6µM and 1.7µM (Figure 46). 
5.6.3.4 ERBB2/ERBB3 dimerisation and adapters 
Likewise, the adapter recruitment for ERBB2/3 heterodimers was measured. 
The analysis showed IC50 values between 0.5µM and 0.9µM. The comparison 
of the datasets obtained with ERBB2/3 and ERBB2/4 indicates that the effect 
of Spironolactone is not ERBB4-specific, but also inhibits ERBB3-mediated 
adaptor recruitment assays Figure 45. 
5.6.3.5 ERBB4/PIK3R1 assay and effects caused by other Aldosterone 
derivatives  
To get further insight into Spironolactone’s specificity, the data from the 
NCC201 and the NCC003 screens were analysed for Aldosterone derivatives 
and structures related to Spironolactone. 25 structural related drugs were 
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identified. None of these drugs showed a similarly efficient inhibitory effect on 
the ERBB4/PIK3R1 co-culture assay (Figure 49) 
 
5.6.3.6 ERBB4/PIK3R1 assay and effects caused by Eplerenone and 
Canrenone 
Eplerenone, the second generation substance of Spironolactone used in the 
clinics, was also tested in the ERBB4/PIK3R1 assay stimulated with EGF-like 
domain. Eplerenone is structural and functional closely related to 
Spironolactone but did not show any effect in the ERBB4/PIK3R1 assay 
(Figure 48). 
Canrenone, a metabolite of Spironolactone lacking the thioketone group was 
also tested in a similar ERBB4/PIK3R1 assay and showed also no specific 
inhibiting effect (Figure 48). 
The analysis of Eplerenone and the Aldosterone derivatives suggests that the 
measured effect is Spironolactone-specific and not a general side effect 
caused by other MCR antagonists or Aldosterone derivatives (Figure 49).  
5.6.4 Orthogonal validation  
5.6.4.1 ERBB1/ERBB1/EGF 
Spironolactone showed an effect on EGF-stimulated ERBB1/ERBB1 
homodimerisation, with an IC50 of 1.1µM Spironolactone (Figure 50).  
To address whether Spironolactone is specific to the inhibition of ERBB 
receptor-mediated signalling, I tested Spironolactone’s effect in various other 
split TEV assays that also included the regulated activation of a G-protein-
coupled receptor (GPCR). 
5.6.4.2 GPCR Serotonin receptor 5A (HTR5A) activation  
Spironolactone showed no effect on the Serotonin-stimulated HTR5A--
arrestin (ARRB2) split TEV assay (Figure 51). 
5.6.4.3 FRB/FKBP model interaction induced by Rapamycin 
Spironolactone showed a minor effect on the Rapamycin-induced FRB/FKBP 




5.6.5 Summary IC50 validation Spironolacone 
      IC50 in µM  
  Rluc   56.4 
  GV   10.7 
TM-TEV TM-GV   24.3 
NTEV-tevS-GV CTEV    IC50 in µM  
ERBB4 ERBB4   2.4 
ERBB3 ERBB4   4.4 
  ERBB3   3.1 
ERBB2 ERBB4   2.2 
  ERBB3   3.2 
  ERBB2   9.2 
ERBB1 ERBB4   4.3 
  ERBB3   2.9 
  ERBB2   5.8 
  ERBB1   6.0 
 V5 tag NTEV-tevS-GV CTEV   IC50 in µM 
 ERBB4 SHC1 4.9 
   GRB2 4.8 
   SRC 0.7 
   PIK3R1 0.7 
   STAT5A 4.6 
        
ERBB2 ERBB3 SHC1 0.9 
   GRB2 0.6 
   SRC 0.9 
   PIK3R1 0.5 
   STAT5A 0.7 
        
ERBB2 ERBB4 SHC1 0.8 
   GRB2 0.8 
   SRC 1.8 
   PIK3R1 0.8 
   STAT5A 0.7 
NTEV-tevS-GV CTEV   Drug   
ERBB1 ERBB1 EGF 1.1 
ERBB4 PIK3R1  co-culture assay 0.9 
ERBB4 PIK3R1  Eplerenone n.c. 
ERBB4 PIK3R1  Canrenone n.c. 
FRB FKBP Rapamycin 18.8 
Table 14. Summary of IC50 values  
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These data suggest that Spironolactone affects the complete family of ERBB 
receptors, with a biased activity profile towards more efficient inhibition of 
adapter recruitment, particularly PIK3R1 and SRC. 
5.6.6 Biochemistry  
The biochemical, or orthogonal, validation of Spironolactone compared to 
Lapatinib showed the following effects: 
Antibody Lapatinib Lapatinib / 
EGFld 




    
ERBB4 (Santa 
Cruz) 
 activated  partial degradation 
pERBB4 Y1284 
(SHC) 
 inhibited   
pERBB4 
Y1056(PIK3) 
 inhibited  partially inhibited  
pERBB4 Y984 
(STAT5) 
 inhibited   
S6K     
pS6K  inhibited   
ERK1     
pERK1 
T202/Y204 
inhibited inhibited   
Table 15. Results of the biochemical validation using phospho-specific antibodies  
The validation shows a clear difference between Lapatinib and Spironolactone 
effects. Lapatinib inhibits the phosphorylation at the three adapter docking 
sites Y1284 (SHC1), Y1056 (PIK3R1), and Y984 (STAT5A). Spironolactone 
has only a mild effect on the phosphorylation at the PIK3R1 docking site 
Y1056.  
Lapatinib inhibits phosphorylation of ERK1 independent of EGF-like domain 
stimulation. Spironolactone, however, has no effect on the phosphorylation 
levels of ERK1.  
The data suggests a difference in the mode of action of Spironolactone and 
the Lapatinib (Figure 54). 
5.6.7 Validation in HEK293 cells 
Western blot analysis on HEK293 cell lysates using phospho-specfic 
antibodies showed a similar effect of Lapatinib and Spironolactone on the 
phosphorylation levels of ERBB4 at Y1284 (Figure 53). 
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5.6.8 Validation in a MK801 mouse model of psychosis 
MK801 is an antagonist of the NMDA-type Glutamate receptor and has been 
shown to induce psychosis/schizophrenia-related behaviours including 
hyperactivity in rodents when applied experimentally (Eyjolfsson et al., 2006). 
The mode-of-action of MK801 is unclear but it has been suggested to act 
mainly on NMDA receptors located on interneurons thereby altering the 
balance of excitation and inhibition (Figure 20).Thus, MK801 and the Nrg1-
ERBB4 signalling may modulate similar cellular circuits affected in psychiatric 
diseases. To assess the potential impact of the novel Nrg1-ERBB4 inhibitor 
spironolactone on mouse behaviour, we applied the MK801 model of drug-
induced psychosis. 
Mice were administered with drugs following the protocol depicted in (Figure 
55 A). Their locomotor behavior in the open field, i.e. distance travelled, time 
which mice spent active, time spent in the centre of the test arena, and the 
number of rearings were analysed (Figure 55 B-F). For the analysis shown, 
only the time between the second injection until 60 min post injection has 
been taken into account, as effects are strongly attenuated later on. 
MK801-treated animals showed a hyperactivity phenotype compared to 
controls. Mice treated with Spironolactone displayed a tendency towards less 
distance travelled (Figure 55 B). Interestingly, mice treated both with MK801 
and Spironolactone showed a non-significant tendency towards less distance 
travelled compared to mice injected with MK801 only.  
When the total locomotor behaviour was analysed, the non-significant 
tendency observed in doubly-injected mice was not visible (Figure 55 C). 
Of interest, mice injected with Spironolactone only spent less time being 
active (Figure 55.D), and also spent less time in the centre of the open field 
arena compared to a control group (Figure 55 E). As reported before, MK801-
injected mice displayed readily a higher activity than controls, and spent only 
a little amount of time in the centre. Double-treated mice, however, showed 
only a non-significant tendency towards less activity, and also spent only a 
very low percentage of the time in the centre of the test arena (Figure 55 E).  
Last, I looked at rearings to assess curiosity. However, the analysis showed 
no significant measure compared to controls (Figure 55 F).  
Taken together, our results suggest that Spironolactone reduces spontaneous 
locomotor activity in the open field test as adding Spironolactone on top of a 





Figure 38: Dose Response of SpironolactoneSplit TEV assay in PC12 cells. 
 ERBB4 was fused to NTEV-tevS-GV-2xHA; PIK3R1 was fused to CTEV-2HA. ERBB4 
dimerises after stimulation with 10.000 NRG1-Type I PC12 cells and recruits PIK3R1. 
Cells were treated with indicated concentrations of Spironolactone. Cells were harvested 




Figure 39: Technical controls 
A) Merge of the results of the technical controls versus ERBB4/PIK3R1 (red).  
Datasets shown from (B) to (E) were merged. B) ERBB4/PIK3R1. ERBB4 was fused to 
NTEV-tevS-GV-2xHA; PIK3R1 was fused to CTEV-2HA. Cells were stimulated with 
10ng/nl EGFld. C) Renilla Luciferase assay Cells were transfected with 20ng/well TK-Rluc. 
D) GV assay in PC12 cells. Cells were transfected with 20ng/well CMV-GV, UAS-Fluc, 
and TK-Rluc. E) TM-TEV/TM-GV assay in PC12 cells. Cells were transfected with 




Figure 40: Vertical validation Spironolactone, overview  
A) Schematic depiction of the ERBB4/adapter recruitment. B) Schematic drawings of the 
adapters used. C) Schematic drawings of experimental time course. Cells were 
transfected and after 24h incubation time stimulated with 10ng/ml EGFld. Cells were lysed 
and analysed 24h after stimulation. D) Z’-factors obtained from the assays. 
E) ERBB4/adapter recruitment. ERBB4 was fused to NTEV-tevS-GV-2xHA; adapters were 




Figure 41: Vertical validation Spironolactone ERBB4/adapter recruitment 
A) Comparison of ERBB4/adapter recruitment assays with ERBB4-PIK3R1 recruitment 
(red). ERBB/adapter recruitment for SHC1, GRB2, and STAT5a are less efficiently 
inhibited as compared to ERBB4/PIK3R1 recruitment. ERBB4/SHC1 is intermediate. B-E) 
ERBB4/adapter recruitment. ERBB4 was fused to NTEV-tevS-GV-2xHA; adapters were 




Figure 42: Homo and heterodimerisations of ERBB receptors 
A) Schematic drawings of all possible ERBB homo and heterodimer combinations. Note, 
that ERBB1 (EGFR) is activated by EGF, and not by NRG1-typeI, and that ERBB2 lacks a 
NRG1-binding site whereas ERBB3 lacks intrinsic kinase activity. ERBB4 binds to NRG1 
as homodimer and is able to cross-phosphorylate itself. B) Schematic drawings of 
experimental time course. Cells were transfected and after 24h incubation time stimulated 
with 10ng/ml EGFld. Cells were lysed and analysed 24h after stimulation. C) ERBB homo- 
and hetero-dimerisation. ERBBx/ERBBy split TEV assay in PC12 cells. ERBBx was fused 





Figure 43: ERBB4 homodimerisation 
A) Schematic depiction of ERBB4 homodimerisation. B) Comparison of ERBB4 
homodomerisation with ERBB4/PIK3R1 interaction. C) ERBB4/PIK3R1. D) 
ERBB4/ERBB4. ERBB4 was fused to NTEV-tevS-GV-2xHA; PIK3R1 and ERBB4 were 






Figure 44: ERBB homo and heterodimerisation 
A) Comparison of ERBB homo and heterodimerisation assays with ERBB4-PIK3R1 
recruitment. ERBB homo/heterodimerisations are less efficiently inhibited as compared to 
ERBB4-PIK3R1 recruitment. B-K) ERBB homo and heterodimerisations. ERBBx was 
fused to NTEV-tevS-GV-2xHA; ERBBy was fused to CTEV-2HA. PC12 cells were 




Figure 45: Horizontal validation ERBB2/3 and adapters 
A) Schematic representation ERBB2/ERBB3 heterodimerisation. B) Assay performance. 
ERBB2/ERBB3 heterodimerise after stimulation with 10ng/ml EGFld and recruit adapters 
as indicated. C) Comparison of the z’-factors obtained from the assays. D-H) 
ERBB2/ERBB3/various adapters. ERBB2 was fused to a V5 tag, ERBB3 was fused to 
NTEV-tevS-GV-2xHA; adapters were fused to CTEV-2HA. PC12 cells were stimulated 




Figure 46: Horizontal validation ERBB2/ERBB4 and adapters 
A) Schematic representation ERBB2/ERBB4 heterodimerisation. B) Assay performance. 
ERBB2/ERBB4 heterodimerise after stimulation with 10ng/ml EGFld and recruit adapters 
as indicated. C) Comparison of the z’-factors obtained from the assays.D-H) 
ERBB2/ERBB4/various adapters. ERBB2 was fused to a V5 tag, ERBB4 was fused to 
NTEV-tevS-GV-2xHA; adapters were fused to CTEV-2HA. PC12 cells were stimulated 





Figure 47: Data compilation of horizontal and vertical validation assays with 
Spironolactone 
A) Detailed comparison of the datasets of the technical, vertical and horizontal validation. 




Figure 48: Comparison Spironolactone, Canrenone, Eplerenone 
A) Spironolactone, exerts a strong dose-response dependent inhibitory effect on the 
recruitment of PIK3R1 to ERBB4 (Fluc and Rluc signal). A’) Molecular structure (skeletal 
formula) of Spironolactone. B) Canrenone (metabolite of Spironolactone) exerts no dose-
response dependent effect on the recruitment of PIK3R1 to ERBB4. B’) Molecular 
structure (skeletal formula) of Canrenone. C) Eplerenone (2
nd
 generation substance of 
Spironolactone) exerts no dose-response dependent effect on the recruitment of PIK3R1 
to ERBB4. C’) Molecular structure (skeletal formula) of Eplerenone. All assays are 




Figure 49: Analysis of substances structurally related to Spironolactone 
A) Selected results from the NCC201/NCC003 screen with sterol-related substances. The 
25 compounds that show the closest structural relationship to Spironolacton were 
analysed for inhibition of an ERBB4/PIK3R1 co-culture assay (Compounds were 
suggested by pupchem.org.as related compounds) The red line indicates the mean of the 
combined effects (RLU 46.4; 100%). Spironolactone was the most efficient substance in 
inhibiting the assay (RLU 9.3; 20%). B) Molecular structures of Spironolactone, 
Aldosterone, Flunisolide and Betamethasone. Flunisolide and Betamethasone show an 




Figure 50: Effect of Spironolactone on ERBB1/1 dimerisation induced by EGF 
ERBB1 was fused to NTEV-tevS-GV-2xHA; ERBB1 was fused to CTEV-2HA. PC12 cells 
were stimulated with 1ng/ml EGF.  
 
Figure 51: Effect of Spironolactone on stimulated HTR5a/-arrestin2 
HTR5A was fused to NTEV-tevS-GV-2xHA; /-arrestin(amino acids 1-382 of ARRB2) 
was fused to CTEV-2HA. PC12 cells were stimulated with 1µM Serotonin.  
 
Figure 52: Effect of Spironolactone on the FRB/FKBP interaction induced by 
Rapamycin 
TM-FRB was fused to NTEV-tevS-GV, FKBP was fused to CTEV. PC12 cells were 




Figure 53: ERBB4 phosphorylation levels are inhibited by Lapatinib and 
Spironolactone  
HEK293 cells were transiently transfected with ERBB4-NTEV-tevS-GV as indicated. Cells 
were allowed to express the vectors for 24h, and then stimulated with 10µM Lapatinib, 
10µM Spironolactone (Spiro), and 10ng/ml EGF-like domain (EGFld). Cells were then 
incubated for additional 24h. Protein lysates were blotted and probed against antibodies 
as indicated. Calculated protein sizes (in kDa): ERBB4, 146.8; ERBB4-Glink-NTEV-tevS-




Figure 54: Analysis of phosphorylation levels of ERBB4 and major downstream 
signalling kinases 
ERBB4 phosphorylation is inhibited by Lapatinib and Spironolactone. PC12 cells were 
transiently transfected with plasmids as indicated. Cells were allowed to express the 
vectors for 24h, and then stimulated with 10µM Lapatinib, 10µM Spironolactone (Spiro), 
and 10ng/ml EGF-like domain (EGFld). Cells were then incubated for additional 24h.  
Protein lysates were blotted and probed against antibodies as indicated. Calculated 







Figure 55: Effects of Spironolactone on MK801-induced hyperactivity in mice tested 
in an open field setup 
Effects of Spironolactone on MK801-induced hyperactivity in mice tested in open field.  
A) Experimental protocol. 9 weeks old C57Bl/6N male mice were divided randomly in one 
of 4 treatment groups: group 1 injected twice with (v) vehicle ([veh+veh], n=13), group 2 
administered with Spironolactone (S) and vehicle ([Spiro+veh], n=14), group 3 treated with 
vehicle and (M) MK801 ([veh+MK801], n=12), and group 4 injected with Spironolactone 
and MK801 ([Spiro+MK801], n=14). 100 min after the first injection, mice were placed in 
the open field arena for 20 min to score baseline activity. Thereafter, animals were taken 
out of the test boxes for 4 min, administered with a second injection, and returned to the 
open field arena for the next 120 min where activity was monitored. 
B) Distance travelled in open field arena depicted as a percentage of mean distance 
travelled during baseline activity. A 2-way ANOVA was performed pairwise between 
different treatments during the time window between intervals 1 to 15. [Veh+MK801] 
animals showed hyperactivity when compared with [veh+veh] controls (interaction time × 
treatment F(14,322)=5.73; p<0.0001; effect of treatment F(1,23)=17.92; p=0.0003; 2-way 
ANOVA). [Spiro+veh] mice showed a non-significant tendency to travelled less distance 
then [veh+veh] (F(1,25)=3.39 p=0.0774, 2-way ANOVA). Animals treated with 
[Spiro+MK801] displayed a slight tendency to travel shorter distance than mice with 
induced hyperactivity [veh+MK801] (effect of treatment F(1,24)=2.89; p=0.1018; 2-way 
ANOVA). 
C) Distance travelled in open field. Mice treated with spironolactone [Spiro+veh] travelled 
less distance than [veh+veh] controls (49.79 m ±27.93 vs 77.76 m ±36.39; p=0.0369). 
[veh+MK801] animals covered longer distance than [veh+veh] (138.4 m ±56.65 vs 77.76 
m ±36.39; p=0.0036). [Spiro+MK801] animals showed a non-significant tendency to cover 
a shorter distance than [veh+MK801] mice (113.4 m ±63.49 vs 138.4 m ±56.65; p=0.0849). 
D) Time which mice spent active during open field test. [Spiro+veh] animals spent less 
time active than control [veh+veh] group (19.79% ±9.761 vs 30.47% ±12.71; p=0.0273). 
[veh+MK801] displayed more activity than [veh+veh] (43.33% ±11.47 vs 30.47% ± 12.71; 
p=0.0240). [Spiro+MK801] treated group showed non-significant tendency towards less 
activity when compared with [veh+MK801] mice (36.57% ±13.92 vs 43.33% ±11.47; 
p=0.1166).  
E) Percentage of time which mice spent in the center of the open field arena. 
Spironolactone administered with vehicle significantly reduced the percentage of time in 
which mice were scored in the centre of the open field arena compared to controls 
([Spiro+veh] 1.643% ±1.706 vs. [veh+veh] 8.046% ± 9.518; p=0.0387). Similarly, groups 
injected with [veh+MK801] and [Spiro+MK801] spent very low percentage of time in the 
center of test arena (2.442% ±2.009 and 1.371% ±1.410, respectively). 
F) Number of rearings performed during open field test. Mice treated with spironolactone 
[Spiro+veh] displayed a non-significant tendency towards less rearings when compared to 
[veh+veh] controls (70.36 ±46.80 vs 167.6 ±129.4; p=0.0765). The [veh+MK801] group 
displayed similar number of rearings to controls (117.3 ±83.32 vs 167.6 ±129.4; p=0.6053). 
Spironolactone did not have a significant impact on rearings in the [Spiro+MK801] treated 
group when compared with the [veh+MK801] group (89.93 ±74.79 vs 117.3 ±83.32; 
p=0.2367). 
Veh, vehicle; Spiro, Spironolactone; black dots, veh+veh (n=13); light blue dots, Spiro+veh 
(n=14); red dots, veh+MK801 (n=12); dark blue dots, Spiro+MK801 (n=14). Data 




5.7 Validation Albendazole 
The activator hit found in the screen of the NCC201 library is Albendazole. 
Albendazole is a Benzimidazole compound normally used as anthelmintic in 
the treatment of worm infections (van Schalkwyk et al., 1979). It binds to 
tubulin and inhibits the polymerization of microtubules (Nayak et al., 2011). 
There is a highly significant activation of luciferase activity in the Nrg1-typeI-
ERBB4/PIK3R1co-culture assay when applying 10µM Albendazole 
(p<0,0001)(Figure 57 A). 
 
Figure 56: Chemical structure of Albendazole 
5.7.1 Technical controls for Albendazole 
5.7.1.1 Renilla Luciferase  
To test for potential Albendazole-mediated toxicity, PC12 cells were 
transfected with the Renilla luciferase. The test revealed a toxic effect against 
the co-culture assay at concentrations between 33µM to 100µM (Figure 57 B). 
5.7.1.2 The Gal4-VP16 control assay   
The technical control GV/UAS-Fluc showed a 3-fold increase of 300% of the 
Fluc activity. The EC50 of Albendazole is at 0.3µM (Figure 57 G). 
5.7.1.3 TEV protease control assay 
To test for any stimulating effects elicited by the TEV protease and its activity 
at TEV protease cleavage sites, a transmembrane version of the TEV 
protease (TM-TEV) was co-transfected with a transmembrane-bound GV 
carrying an internal TEV cleavage site (TM-GV), along with UAS-Fluc and 
Rluc reporters. Like the GV control assay, the TM-TEV/TM-GV assay showed 
a comparable 2.5-foldincrease of the firefly activity, with an EC50 of 1.0µM 
Albendazole (Figure 57. F) 
5.7.1.4 Co-culture assay using increasing numbers of Nrg1-typeI-
expressing cells 
To test Albendazole’s activating effect at different pre-activated conditions, the 
co-culture assay ERBB4/PIK3R1 was stimulated with 1,000, 5,000, and 
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10,000 Nrg1-typeI-expressing PC12 cells. All three assays roughly showed a 
2-fold activation of the firefly luciferase activity, with an EC50 of 0.3µM 
Albendazole (Figure 57 C).  
5.7.1.5 Single cell assay with soluble Nrg1-derived EGF-like domain 
The single cell ERBB4/PIK3R1 assay was stimulated with 1 or 5ng/ml EGF-
like domain to get two different pre-activated conditions. Both assays showed 
a 1.5-fold activation of the firefly luciferase activity, with an EC50 of 0.6µM 
Albendazole at a concentration of 1ng/ml EGF-like domain, and an EC50 of 
0.4µM Albendazole and 5ng/ml EGF-like domain (Figure 57 D,E).  
The comparison of the data revealed that firefly luciferase activity was highly 
increased in the technical control assays when Albendazole was applied at 
high concentrations. For example, the GV technical control assay displayed 
strongly increased readings for firefly luciferase at Albendazole concentrations 
that were not toxic for the cells as measured by Renilla luciferase activity 
(Figure 57 D, D’, D’’). Therefore, Albendazole seems not to be a specific 
activator of Nrg1-ERBB4 signalling, but rather an unspecific activator of either 
GV, the UAS promoter, the activity of firefly luciferase, or a combination 
thereof. Further validation approaches have to be performed, for example, it 
should be addressed whether Albendazole has the potential to increase firefly 
luciferase activity when expressed under the control of the constitutively 






Figure 57: Validation Albendazole 
A) Extracted data from the screen showing a significant activation of Nrg1-ERBB4 
signalling caused by Albendazole in the co-culture assay. B) Renilla luciferase assay to 
test the toxicity of Albendazole. C) ERBB4/PIK3R1 co-culture assays activated with 1k, 5k, 
or 10k Nrg1-typeI cells. D) ERBB4/PIK3R1 single cell assay stimulated with 1ng EGFld. E) 
ERBB4/PIK3R1 single cell assay stimulated with 5ng EGFld. ERBB4 was fused to NTEV-
tevS-GV-2HA; Adapters were fused to CTEV-2HA. PC12 cells were stimulated with 
indicated numbers of Nrg1-typeI-expressing cells or indicated cell numbers of EGFld. F) 
GV/UAS-Fluc technical control assay showing the effect of Albendazole on relative 
luciferase activity. G) TM-TEV/TM-GV technical control assay showing the effect of 
Albendazole on TEV protease function. H) Comparison of the data shown from (B) to (I). 




5.8 Topotecan  
The NCC003 screen showed a significant reduction in firefly luciferase activity 
for 10µM Topotecan (brand name Hycamtin, GlaxoSmithKline 2007). 
Topotecan is a Topoisomerase I inhibitor used as a chemotherapeutic agent 
for the treatment of ovarian, cervical, and small cell lung cancer. 
 
Figure 58: Chemical structure of Topotecan  
Topotecan is a drug used as chemotherapeutic. It is a semi-synthetic 
derivative of the alkaloid Camptothecin, a substance from the bark or leaves 
of Camptotheca acuminate the Tibetian “Happy Tree”. Camptothecin is nearly 
insoluble in water and has to be modified to increase water solubility. One of 
these derivatives is Topotecan. It functions as a Topoisomerase I inhibitor, 
mimicking a DNA base pair, intercalating between the Topoisomerase 
(Arg364, Asp533, Asn 722) and the DNA (GC base pairs). This leads to a 
stalling of the rewinding process after the single strand break by stabilising the 
cleavage complex, and therefore causing double strand breaks that lead to 
cell cycle arrest in the S-phase, and terminal to apoptosis (Streltsov et al., 
2003; Streltsov et al., 2003; Takimoto and Arbuck, 1997a; O’Leary and 
Muggia, 1998a; Pommier, 2006; Pommier, 2004). 
Topotecan was FDA-approved in 2007 and is primarily used in the treatment 
of ovarian cancer and small cell lung cancer (Carol et al., 2010). It is also 
tested for brainstem gliomas and sarcomas (Houghton et al., 1995). 
In the NCC003 screen, Topotecan was found to decrease significant the 
luciferase activity (p=1,4*10e-10, two sided, two paired T-Test).  
5.8.1 Vertical validation for Topotecan  
The dose response to increasing concentrations of Topotecan showed an IC50 
of 0.5µM in the Nrg1-typeI ERBB4/PIK3R1 assay. Exchanging the Nrg1-typeI 
cells with EGFld lead to an IC50 of 0.4µM (Figure 59). 
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5.8.2 Technical controls  
5.8.2.1 Renilla luciferase 
The technical validation showed a strong toxic effect of Topotecan between 
3.3-100µM monitoring Renilla luciferase (Figure 60). All values above 10µM 
are excluded from the dose responses curves, because the decreased Renilla 
activity leads to false activation in the calculation of the relative luciferase 
units (RLU). 
5.8.2.2 Gal4-VP16 control 
In the first technical control assay, UAS-Fluc was co-transfected with GV only. 
There was no effect of Topotecan below 10µM on the GV/UAS-Fluc control 
assay. Above 10µM Topotecan PC12 cells were dead.  
5.8.2.3 TEV protease control 
The test showed a mild effect on the TM-TEV/TM-GV system (IC50 8.5µM) but 
data quality and toxic effects have to be taken into account as well (Figure 60). 
I can conclude that Topotecan has a strong toxic effect on the cells, but it 
neither seems to target the firefly luciferase itself, nor to interfere with TEV 
protease activity. 
5.8.2.4 Testing different adapter proteins  
The effect of Spironolactone on the recruitment of various other adapter 
proteins was analysed. The vertical validation of the adapters using the split 
TEV-based assay showed that the IC50 for PIK3R1 is at 0.5µM, for SRC 
kinase at 0.9µM, for GRB2 at 2.8µM, for STAT5A at 2.5µM, and for SHC1 at 
2.2µM. These data suggest that in particular the binding of the adapter 
molecules PIK3R1 and SRC to the ERBB4 receptor is inhibited by Topotecan, 
but the difference observed was not as strong as for Spironolactone (Figure 
61). 
5.8.3 Horizontal validation 
The horizontal validation showed no inhibitory effect of Topotecan on ERBB1 
and ERBB2 homodimers, and on ERBB1/ERBB2 heterodimers stimulated 
with 10ng/ml EGFld, as they are not activated (Figure 62). 
However, Topotecan showed an inhibitory effect on most ERBB 
homo/heterodimers, with an IC50 of 2.7µM for ERBB1/3, 2.0µM for ERBB1/4, 
0.9µM for ERBB2/3, 2.3µM for ERBB2/4, 2.3µM for ERBB3/3, 2.4µM 
ERBB3/4, and 1.0µM for ERBB4/4 (Figure 62). ERBB2/3 heterodimers and 
ERBB4 homodimers are of particular interest, displaying IC50 values of 0.9µM 
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and 1.0µM, thus having IC50 values that are within the range of the inhibitory 
effect for ERBB4/PIK3R1 and ERBB4/SRC assays (Figure 63). 
5.8.3.1 ERBB2/ERBB4 dimerisation and adapters  
To get further insight into Spironolactone’s specificity towards the potential 
inhibition of ERBB2/4, the adapter recruitment for ERBB2/4 heterodimers was 
analysed. The validation of ERBB2/4 adapter recruitment showed IC50 values 
of 0.6µM for ERBB2/4/SHC, 0.7µM for ERBB2/4/GRB2, 0.8µM for 
ERBB2/4/SRC, 2.1µM for ERBB2/4/PIK3R1, and 0.7µM for 
ERBB2/4/STAT5A (Figure 65).  
5.8.3.2 ERBB2/ERBB3 dimerisation and adapters 
Likewise, the adapter recruitment for ERBB2/3 heterodimers was measured. 
The validation of ERBB2/3 adapter recruitment showed IC50 values of 0.8µM 
for ERBB2/3/SHC1, 2.3µM for ERBB2/3/GRB2, 1.7µM ERBB2/3/SRC, 1.1µM 
for ERBB2/3/PIK3R1, and 0.8µM for ERBB2/3/STAT5A (Figure 64).  
Topotecan inhibits all measured ERBB homo and heterodimerisations within a 
comparable range. Therefore, Topotecan is not an ERBB4-specific inhibitor. 
5.8.4 Orthogonal validation  
5.8.4.1 ERBB1/ERBB1/EGF 
ERBB1/1 (EGFR-homodimerisation) stimulated with 1ng/ml EGF showed an 
inhibition of the homodimerisation at IC50 values of 0.5µM, but the inhibition 
seemed to be incomplete (Figure 67). 
5.8.4.2 FRB/FKBP model interaction induced by Rapamycin 
To address whether Topotecan is specific to the inhibition of ERBB receptor-
mediated signalling, I tested Topotecan’s effect in a another split TEV assay 
that used the Rapamycin-regulated model interaction of a membrane-targeted 
FRB fused to the NTEV moiety (TM-FRB-NTEV) and a cytosolic FKBP fused 
to the CTEV moiety (FKBP-CTEV).  
TM-FRB-NTEV and FKBP-CTEV were pre-stimulated with 10nM Rapamycin 
to ensure occurred interaction. Addition of Topotecan showed no effect, 
suggesting that it does not affect protein-protein interactions in general 
(Figure 68). 
5.8.4.3 ERBB4/PIK3R1 assay and effects caused by Irinotecan and SN38 
Irionotecan, a second-generation drug of Camptothecin (i.e. Topotecan 
derivative), was also present in the NCC003 library. Of interest, Irinotecan had 
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no effect on the ERBB4/PIK3R1 co-culture assay. Irinotecan is a pro-drug that 
has to be activated in the liver (Xie et al., 2003). As the co-culture assay 
cannot provide a metabolic functionality that is present in the liver, I tested the 
activated Irinotecan-metabolite SN38 (Chabot 1998). SN38 did not show any 
inhibitory or activatory activity in the ERBB4/PIK3R1 co-culture assay (Figure 
66). The analysis of Irinotecan and SN 38 suggests that the measured effect 
is Topotecan-specific and not a general effect of Camptothecin analogues. 
 
5.8.4.4 Summary validation Topotecan 
Technical validation  IC50 
  Rluc   n.c. 
  GV   n.c. 
TM-TEV TM-GV   8.5 
NTEV-tevS-GV CTEV   IC50 
ERBB4 ERBB4   1.0 
ERBB3 ERBB4   2.4 
  ERBB3   2.3 
ERBB2 ERBB4   2.3 
  ERBB3   0.9 
  ERBB2   n.c. 
ERBB1 ERBB4   2.0 
  ERBB3   2.7 
  ERBB2   n.c. 
  ERBB1   n.c. 
NTEV-tevS-GV CTEV    IC50 
ERBB4 
homodimerisation SHC1   2.2 
  GRB2   2.8 
  SRC   0.9 
  PIK3R1   0.4 
  STAT5A   2.5 
V5tag NTEV-tevs-GV CTEV  IC50 
ERBB2 ERBB3 SHC1 0.8 
  ERBB3 GRB2 2.3 
  ERBB3 SRC 1.7 
  ERBB3 PIK3R1 1.1 
  ERBB3 STAT5A 0.8 
        
ERBB2 ERBB4 SHC1 0.6 
  ERBB4 GRB2 0.7 
  ERBB4 SRC 0.8 
  ERBB4 PIK3R1 2.1 
  ERBB4 STAT5A 0.7 
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NTEV-tevS-GV CTEV  Drug   IC50 
ERBB1 ERBB1 EGF 0.5 
ERBB4 PIK3R1  co-culture assay  0.4 
ERBB4 PIK3R1 SN38 90.6 
Table 16: Summary of IC50 values 
 
From these data, Topotecan was found to be an inhibitor of ERBB 
dimerisation and adapter recruitment. Binding of Topotecan to ERBB 
receptors has to be further validated. However, the severe side effects of 
Topotecan, resulting from its anti-topoisomerase I effects, makes the usage of 
Topotecan for the treatment of psychiatric patients highly unlikely (Alimonti et 
al., 2004). To use the potential of Topotecan in this setting, an in-depth 
analysis of the underlying mechanisms related to the toxicity has to be 




Figure 59: ERBB4/PIK3R1 co-culture assay 
A) ERBB4 was fused to NTEV-tevS-GV-2HA; PIK3R1 was fused to CTEV-2HA. Cells 





Figure 60: Technical controls for Topotecan 
A) Data set from the NCC003 screen. Topotecan significantly inhibits Nrg1-typeI-
stimulated ERBB4/PIK3R1signalling. B) Renilla luciferase assay. Cells were transfected 
with 20ng/well TK-Rluc. C) GV control assay in PC12 cells. Cells were transfected with 
20ng/well CMV-GV, UAS-Fluc, and TK-Rluc. D) TM-TEV/TM-GV control assay in PC12 
cells. Cells were transfected with 20ng/well TM-TEV and TM-GV.E) Datasets shown from 





Figure 61: Vertical validation Topotecan ERBB4/adapter recruitment  
A) ERBB4/adapter recruitment. ERBB4 was fused to NTEV-tevS-GV-2HA; adapters were 
fused to CTEV-2HA. Cells were stimulated with 10ng/ml EGFld. B-F) ERBB4/adapter 
recruitment. ERBB4 was fused to NTEV-tevS-GV-2HA; adapters were fused to CTEV-
2HA. PC12 cells were stimulated with 10ng/ml EGFld. G) Comparison of ERBB4/adapter 
recruitment assays to ERBB4-PIK3R1 recruitment assay (red). ERBB/adapter recruitment 
for SHC1, GRB2, and STAT5A are less efficiently inhibited compared to the 







Figure 62: Homo and heterodimerisation of ERBB receptors 
A) ERBB homo- and heterodimerisation. ERBBx/ERBBy split TEV assay in PC12 cells. 
ERBBx was fused to NTEV-tevS-GV-2HA; ERBBy was fused to CTEV-2HA. Cells were 
stimulated with 10 ng/ml EGFld. B-K) ERBB homo- and heterodimerisations. ERBBx was 
fused to NTEV-tevS-GV-2HA; ERBBy was fused to CTEV-2HA. PC12 cells were 
stimulated with 10 ng/ml EGFld. L) Comparison of ERBB homo- and heterodimerisation 
assays to ERBB4-PIK3R1 recruitment. ERBB homo/heterodimerisations are less 








Figure 64: Horizontal validation ERBB2/ERBB3/adapters 
A) Schematic representation ERBB2/ERBB3 heterodimerisation. B) Assay performance. 
ERBB2/ERBB3 heterodimerise after stimulation with 10 ng/ml EGFld and recruit adapters 
as indicated. C) Comparison of the z’-factors obtained from the assays. D-H) 
ERBB2/ERBB3/various adapters. ERBB2 was fused to a V5 tag, ERBB3 was fused to 
NTEV-tevS-GV-2HA; adapters were fused to CTEV-2HA. PC12 cells were stimulated with 




Figure 65: Horizontal validation for Topotecan’s effect on ERBB2/ERBB4/adapters  
A) Schematic representation ERBB2/ERBB4 heterodimerisation. B) Assay performance. 
ERBB2/ERBB4 heterodimerise after stimulation with 10 ng/ml EGFld and recruit adapters 
as indicated. C) Comparison of the z’-factors obtained from the assays. D-H) 
ERBB2/ERBB4/various adapters. ERBB2 was fused to a V5 tag, ERBB4 was fused to 





Figure 66: Effect of Topotecan derivatives Irinotecan and SN38 on the 
ERBB4/PIK3R1 split TEV assay 
A) Comparison of the chemical structures of Camptothecin derivates. Chemical structures 
of Camptothecin, Topotecan, Irinotecan, SN38. B) Data set from the NCC003 screen.  
The difference between Topotecan and Irinotecan on the ERBB4/PIK3R1co-culture 
screen is shown. C-D) Individual effects of Topotecan (C) and SN38 (D). 
ERBB4 was fused to NTEV-tevS-GV-2HA; PIK3R1was fused to CTEV-2HA. Cells were 




Figure 67: Effect of Topotecan on ERBB1/1 dimerisation induced by EGF 
A) ERBB1 was fused to NTEV-tevS-GV-2HA; ERBB1 was fused to CTEV-2HA. PC12 cells 
were stimulated with 1 ng/ml EGF. B) Activation window of the EGF-induced ERBB1/1 
assay. Setup as in (A). 
 
 
Figure 68: Effect of Topotecan on the FRB/FKBP interaction induced by Rapamycin 
A) TM-FRB was fused to NTEV-tevS-GV, FKBP was fused to CTEV. PC12 cells were 
stimulated with 10nM Rapamycin. B) Activation window of the Rapamycin-induced 




5.9 Validation Mevastatin  
Mevastatin (Compactin penicillium) is an antifungal metabolite from 
Penicillium breviocompactum. It is an HMG-CoA reductase inhibitor 
(cholesterol biosynthesis) with multiple side effects, which prevent the 
therapeutic usage.  
 
Figure 69: Chemical structure of Mevastatin 
Mevastatin showed a significant activation of the firefly luciferase activity in 
the screen. In the ERBB4/PIK3R1 assay activated with 10ng/ml EGF-like 
domain it showed a 250% activation of the relative luciferase activity at an 
EC50 of 0.7µM. 
5.9.1 Technical controls for Mevastatin 
Renilla luciferase  
In the Renilla luciferase assay Mevastatin showed a toxic effect wit an IC50 of 
0.4µM. 
The comparison of both datasets indicate that the activation of the relative 
luciferase activity is reciprocal to the toxic effect of Mevastatin on the PC12 
cells e.g. the Renilla luciferase activity.  
Mevastatin has no specific effect on the ERBB4/PIK3R1 co culture assay. The 
Mevastatin dataset is an excellent example for the elimination of false positive 




Figure 70: Validation Mevastatin 
A) Data extracted from the screen. B) ERBB4/PIK3R1 10 ng/ml EGFld. ERBB4 was fused 
to NTEV-tevS-GV-2HA; PIK3R1 was fused to CTEV-2HA. PC12 Cells were stimulated 
with 10 ng/ml EGFld. C) Renilla luciferase assay to test the toxicity of Mevastatin. D). 
Comparison ERBB4/PIK3R1 and Renilla luciferase, the increment of growth of the RLU 




5.10 Validation CCPA 
2-chloro-N(6)-cyclopentyladenosine (CCPA) is a specific agonist for the 
Adenosin A1 receptor (Gao and Jacobson, 2002).  
 
Figure 71: Chemical structure of CCPA 
CCPA showed a significant activation of the firefly activity in a preliminary co-
culture screen witch did not reach a z’-factor of 0.5. CCPA showed a two fold 
activation of the firefly luciferase activity in the ERBB4/PIK3R1 co-culture 
assay.  
5.10.1 Technical controls for CCPA 
Renilla luciferase  
CCPA showed no toxic effect on the Renilla luciferase.  
The Gal4-VP16 control assay 
In the technical vallidation CCPA showed an two fold activation of the firefly 
activity. 
TEV protease control assay  
In the TM-TEV/TM-GV assay CCPA showed a two fold activation of the firefly 
activity.  
5.10.2 Vertical validation  
CCPA showed although a two fold activation of ERBB4/SHC adapter 
recruitment and a two fold activation of ERBB4 homodimerisation.  
As the technical controls indicate CCPA is not an activator of the NRG1-
ERBB4 system. It interfers unspecific with the firefly activity or cell activity, 




Figure 72: Validation CCPA 
A) Extracted data from the screen. B) Co culture assay Nrg1-typeI-ERBB4/PIK3R1. Split 
TEV assay in PC12 cells. ERBB4 was fused to NTEV-tevS-GV-2HA; PIK3R1 was fused to 
CTEV-2HA. C) Renilla luciferase assay to test the toxicity of CCPA. D) GV/ UAS-Fluc. E) 
TM-TEV/TM-GV.F) ERBB4/SHC split TEV assay in PC12 cells. ERBB4 was fused to 
NTEV-tevS-GV-2HA. SHC was fused to CTEV-2HA. Cells were stimulated with 10 ng/ml 
EGFld. G) ERBB4/ERBB4 split TEV assay in PC12 cells. ERBB4 was fused to NTEV-




5.11 Validation Vincristine, effects on Renilla luciferase  
Vindesine and Vincristine are vinca alkaloid derivatives from Catharanthus 
roseus. (Madagaskar Evergreen). They are antimitotic chemotherapeutics 
used in the treatment of cancer and as immunosuppressive drugs. The 
akaloids  interfere with the formation of tubulin into microtubules therby 
inhibiting cell division. Further effects are on RNA/DNA synthesis, lipid 
biosynthesis, cyclic nucleotide metabolism, glutathione metabolism and 
calmodulin-dependent CA2+-transport ATPase (Jordan et al., 1985). 
 
Figure 73: Chemical structure of Vincristine sulfat 
Vindesine and vincristine showed a minor significant activation of the firefly 
activity (p<0.009) in a preliminary co-culture screen that did not reach a z’-
factor of 0.5. Vinchristine was further analysed and showed a 10 fold 
activation of the firefly luciferase activity between 0.001µM and 1µM in the 
complete ERBB4/PIK3R1 co-culture assay. It showed a high toxic effect on 
the Renilla luciferase assay at an IC50 of 0.015µM reducing Renilla luciferase 
activity. In the technical vallidation Vincristine showed a ten fold activation of 
the GV/UAS-Fluc assay and a ten fold activation of the TM-TEV/TM-GV 
assay. Both increases in the relative luciferase values are due to the 90% 
decrease of Renilla luciferase activity. 
Vincristine showed although a ten fold activation of ERBB4/SHC and a ten 
fold activation of the ERBB4 homodimers.  
As the technical controls indicate Vincristine is not an activator of the Nrg1-
typeI-ERBB4 signalling system. It interfers with the Renilla activity, decreasing 
the Renilla activity with an IC50 of 0.015µM. The observed activation is a pure 
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mathematical artefact, resulting from the calculation of relative luciferase units 
(RLU). 
 
Figure 74: Validation Vincristine 
A) Extracted data from the screen. B) Co culture assay Nrg1-typeI-ERBB4/PIK3R. Split 
TEV assay in PC12 cells. ERBB4 was fused to NTEV-tevS-GV-2HA; PIK3R1 was fused to 
CTEV-2HA. C) Renilla luciferase assay to test the toxicity of Vincristine. D) GV/UAS-Fluc. 
E) TM-TEV/TM-GV. F) ERBB4/SHC split TEV assay in PC12 cells. ERBB4 was fused to 
NTEV-tevS-GV-2HA. SHC was fused to CTEV-2HA. Cells were stimulated with 10 ng/ml 
EGFld. G) ERBB4/ERBB4 split TEV assay in PC12 cells. ERBB4 was fused to NTEV-





5.12 Validation K252a 
The Indolocarbazole K252a is an alkaloid from Nocardiopsis spec. and a 
Staurosporin analogue. It is a highly specific CaM kinase and phosphorylase 
inhibitor (IC50 1.8 and 1.7nmol) and a serine/threonine protein kinase inhibitor 
(IC50 10 to 30nmol) (Borasio, 1990). 
 
Figure 75: Chemical structure of K252a 
K252a was described by Kuai (Kuai et al., 2010) to potentiate Nrg1 induced 
neuritogenesis in PC12 cells transfected with ERBB4. In addition, Kuai et al. 
showed that the effect of K252 depends on the potentiation of the localisation 
of ERBB4 receptors to the membrane and an elevation of ERBB4 receptors in 
the membrane due to altered endocytosis (Kuai et al., 2011). Therefore, I 
wished to test, whether K252a could activate NRG1-ERBB4 signalling using 
the split TEV ERBB4/PIK3R1 co-culture assay. However, K252a did not 
activate ERBB4 signalling, and proved only to be toxic for the cells.  
Surprisingly, K252a showed an inhibition of the relative luciferase activity in 
the ERBB4/PIK3R1 co-culture assay, with an IC50 of 0.7µM. The technical 
control Renilla luciferase showed an IC50 of 0.2µM K252a. Thus, the reduction 
in relative luciferase activity was not caused by a specific effect on NRG1-





Figure 76: Validation of K252a 
ERBB4/PIK3R1 10ng/ml EGFld. ERBB4/PIK3R1 split TEV assay in PC12 cells. ERBB4 
was fused to NTEV-tevS-GV-2HA. PIK3R1 was fused to CTEV-2HA. Cells were 
stimulated with 10ng/ml EGFld. Cells were harvested after 24h and luciferase data was 




6.1 Technical issues of cell-based assays 
6.1.1 Translational assays and using GWAS data to model SZ. 
Most of the findings gained from screening assays in animal models remain 
serendipitous. Animal models for SZ, which mimic the entire complexity of the 
disease, are not available for SZ (Nestler and Hyman, 2010). Therefore, the 
lack of construct validity in animal models favours simpler models, with one 
simple model covering one aspect/genetic trait of SZ. Those molecular 
isolated aspects of SZ may also be modelled in cell-based assays. Various 
pathways are known to be involved in SZ on a molecular level, which is 
consistent which the hypothesis that SZ is also seen as an umbrella term for 
various diseases with similar disease patterns (Pratt et al., 2012; Keshavan et 
al., 2008; Marín, 2012). 
Several genetic association studies revealed the relevance of malfunctions in 
the NRG1-ERBB4 signalling system for the development of (Stefansson et al., 
2003; Stefánsson et al., 2003; Stefansson et al., 2002; Buonanno, 2010; Li et 
al., 2004 Lu et al., 2010 Weickert et al., 2012). To address this signalling 
pathway in more detail, I designed a cell-based co-culture assay that could 
partially mimics the communication between two distinct neurons via Nrg1-
ERBB4. Hits resulting from this compound screen were shown to target the 
Nrg1-ERBB4 signalling pathway and could be used in the future to treat SZ 
mouse models to prove the hits’ in vivo relevance. 
6.1.2 Rational design of the assay workflow 
Critical to compound screenings are the time points of 
measurements(Macarron et al., 2011; Ohlmeyer and Zhou, 2010). Large 
screens imply the usage of huge substance libraries. These libraries are 
expensive in maintenance and the costly and laborious handling and storage 
forces the user to test an individual compound in a primary screen only once. 
Therefore, only a compound’s single effect of a single administration can be 
usually measured without exceeding available budgets. 
This requires assays of highest quality and reliability. Moreover, the handling 
of the cells and the screening time points have to be adjusted further to get an 
optimal window for the measurements. This includes several technical issues, 
such as enzyme activity, instrument availability, and manpower. The applied 
assay is a transcriptional-based assay with the activity of the firefly luciferase 
as readout. Firstly, the transfected cells need time to express the components 
required for the cell-based assay. In our cell-based assay, the cells need 12h 
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to sufficiently express the components. This is especially important for the 
correct localisation of the ERBB4 receptor. Secondly, after stimulation, the cell 
needs 12h time to express the reporter protein to get satisfying levels that can 
be measured. After testing various combinations and protocols, I decided to 
apply a 24h/24h measurement cycle, i.e. the cells were allowed to express the 
assay components for 24h, then stimulated with compounds and controls, and 
24h later they were lysed for luciferase assay analysis. This implies a 12h/12h 
measurement cycle. Also, measurement cycles are possible between 12h–
12h and 36h–36h. To integrate the screen in daily working hours a 24h-24h 
setup is most preferable.  
6.1.3 Selection of constructs 
Reaching construct validity for SZ is an ambitious goal and is so far not 
possible. It might be partially possible in the future, when patient-derived 
induced pluripotent stem cells (iPSC) could be instructed to relevant neirnal 
lineages and using these cells e.g. in phenotypic screen (Brennand et al., 
2011; Brennand and Gage, 2012; Brennand and Gage, 2011). The NRG1-
ERBB4 system signalling pathway itself is a proven target, but this signalling 
network is far more complex to be reflected used in one single assay (Mei and 
Xiong, 2008). NRG1 has a large number of isoforms (more than 30 are yet 
described). The isoforms differ in length, function, localisation, and processing 
properties (Fleck et al., 2011; Luo et al., 2011; Mei and Xiong, 2008; Meyer 
and Birchmeier, 1995).  
ERBB4 consists of four major isoforms (JM-a, JM-b, Cyt1, and Cyt-2)(Zeng et 
al., 2007a; Yarden and Pines, 2012). To this end it is unknown, which exact 
isoform(s), has/have what kind of impact on SZ, and in which cell types this 
may be cause a specific part in SZ. Tremendous effort has been done by the 
GWAS studies. However, they cannot deliver this kind of information. 
For the Nrg1-ERBB4 cell-based assay, I chose Nrg1.typeI-1a mainly for the 
reason of assay performance. The Nrg1-typeI containing cells delivered a far 
better measurement window than the Nrg1-typeIII (Figure 26). The most 
active part of all NRGs is the EGF like domain, which is encoded in NRG1-
typeI-1a but also in typeIII, and in the corresponding murine versions.   
For ERBB4 receptors, I chose the JM-a-Cyt1 variant, as it encodes a PI3K-
binding site that is necessary to integrate PI3K signalling given the importance 
of this downstream process in the context of SZ (Law et al., 2012). All 
adapters tested performed well when assaying for ERBB4 receptor activation. 
Importantly, the PI3K adapter protein PIK3R1 performed best, and was 
recently reported as a SZ target (Law et al., 2012).  
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The subset of Nrg1-typeI-1a/ERBB4-JMa-Cyt1/PIK3R1 was mainly chosen 
to meet the needs of assay performance and not as neccessarily being the 
most relevant for SZ. Nonetheless, SNPs enhancing the expression of the 
ERBB4-JMa-Cyt1 variant seems to associated with an elevated risk of SZ 
(Silberberg et al., 2006; Law et al., 2007).  
6.1.4 Artificial and tagged proteins in the cell-based assay  
The ERBB4 receptor and the adapter proteins that get recruited to the 
activated ERBB4 are modified (i.e. tagged) to make them applicable to the 
split TEV assay technique. For the split TEV system, it has been shown that 
the TEV fragments do not affect the function of the proteins under 
investigation (Wehr et al., 2008). However, it cannot be ruled out that some 
chemical compounds target the TEV fragments. Therefore, false positive hits 
that could be directed against artificial components of the cell-based assay 
had to be removed during the secondary analysis. 
6.1.5 In vitro screens vs. co-culture screening systems  
To date, many large-scale screens are done in in-vitro assays (Macarron et al., 
2011; Inglese et al., 2007). These screens deliver fast and specific binding 
data for substances that perform excellent against a single target. However, 
the absence of the biological context results in high attrition rates for 
compounds identified in in-vitro binding assays due to unanticipated off-target 
effects that are detected in later phases. For example, off-target effects can 
be caused by unspecific activation of non-desired signalling pathways that act 
opposite to the desired effects.  
Cell-based screens allow the integration of various signalling pathways into an 
overall cellular response, and toxic side effects and/or effects on downstream 
targets may be immediately measured (Lievens et al., 2012). However, 
limitations of cell-based assays are that usually only one or two different 
assay aspects can be addressed within a screen. Multiplexed cell-based 
assays, at least starting from the stage of hit-to-lead optimisation and later, 
may prove invaluable to increase information collected for a given compound. 
Therefore, the luciferase reporter has already been replaced successfully with 
encoded molecular barcodes that principally would allow monitoring of several 
cellulat parameters in parallel (Botvinnik et al., 2010). 
Cell-based screens utilising engineered cell lines or transiently transfected 
cells may prove equally well in screens. However, overexpressing proteins 
and alterations thereof to match the requirements of the cell-based assay 
have to be carefully tested to avoid any artificial effects. 
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The presented co-culture assays represent a technological progress over 
standard cell-based assays based on a single cell poulation. Such an assay is 
specifically designed to monitor the communication between two populations 
of cells and can monitor inter- as well as intracellular signalling (Wehr et al., 
2008a). These cells may be of different origin, where the first population may 
represent cells producing a signal-emitting ligand, and the second population 
may express a receptor that receives the signal. Ligands like NRG1 have to 
be expressed, processed, correctly localised and integrated into the plasma 
membrane, or even secreted to be fully functional (Falls, 2003). Likewise, the 
ERBB4 receptor can only signal correctly when specifically activated at the 
plasma membrane (Yarden and Pines, 2012). A co-culture assay using, firstly, 
a Nrg1-expressing and, secondly, an ERBB4-expressing cell population 
guarantees that the ERBB4 receptor is only activated at the plasma 
membrane, thereby best mimicking the natural situation. 
6.1.6 Limitations of co-culture systems vs. animal models 
Results obtained from cell-based assays, including co-culture assays, may 
have different degrees of implications for translational experiments planned 
thereafter in animal models. This is particularly true for cell-based assays 
designed to address neurobiological relevant mechanisms.  
In this compound screen, I have used PC12 cells, which are 
pheochromocytoma cells isolated from the rat adrenal medulla (Greene and 
Tischler, 1976). Therefore, these cells are neither neurons, nor organised in 
circuits, layers or tissues, and were not cultivated in a 3D format. PC12 cells 
were grown in flat-bottom 96-well plates for the assays performed. 
Compounds tested were pipetted onto the cells, and did not have to cross the 
blood-brain barrier, and compounds were also not degraded by liver functions. 
Nonetheless, compared to the hetelogous cell lines usually engaged for HTS 
campaigns (such as HEK293 or CHOk1 cell lines), PC12 cells seem to be 
more appropriate in a neurobiological context since closely related to the 
sympathoadrenergic lineage of neurons. 
Conversely, a given mouse model is a compromise between the very complex 
human brain and a rather simple cell-based co-culture assay. In addition, a 
mouse brain lacks several key features found in a human brain. This is 
particularly true for the ability to communicate in an abstract manner. For 
example, abnormal communication with other humans has been widely 
reported in SZ patients, and this phenotype can only be partially mimicked in 
mice, using the Open Field and other related tests (Pratt et al., 2012).  
Nevertheless, a well-developed cell-based assay may provide promising initial 
data that can be further corroborated using a suitable animal model. This 
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model, in turn, may offer opportunities to conclude signalling and wiring 
functions up to the human situation.  
6.1.7 Screening of compound libraries: The hit-to-lead process in 
drug discovery 
When screening large compound libraries, hit compounds are most likely 
clustered into sets of similar substances. These hits have to be confirmed 
using alternative assay. To enter the next phase, i.e. the hit-to-lead process, 
the isolated compounds have to be modified using medicinal chemistry, and 
the following lead structures will be analysed and further optimised towards 
improved signalling characteristics. Therefore, in a prospective manner, 
greatest care was taken to develop and test several secondary validation 
assays for robustness and fast applicability (see below). 
6.1.8 Screening of FDA approved drug libraries 
The NCC library is a collection of FDA-approved drugs that have a history of 
clinical usage, and important information such as toxicity, bioavailability, side 
effects etc. are well described. In addition, the safety, best way of application, 
and maximum dosage for humans is already known for the respective 
application. 
Therefore, using the NCC library is different from the screening of other 
compound libraries as putative hits are already FDA-approved drugs, which 
implies that a given hit could potentially be immediately used in patients. 
However, many drugs have a spectrum of side effects indicating that they 
have more targets than the one they were primarily designed for. A simple 
and straightforward approach is to test known drugs for yet undiscovered 
therapeutic potential. The NCC library was exactly designed for this purpose. 
All drugs in this library are well described and can be further tested investing 
little time and effort.  However, as these drugs are already on the market 
patent issues may prove complicated when a given drug from this library will 
be applied in a new context. Pharmaceutical companies have no interest to 
reassess patented drugs in new clinical trials. A solution to this could be a 
non-profit, government-financed consortium that takes over responsibilities. 
6.1.9 Transfer of the HTP screen to the LDC 
Problems in assay miniaturisation from a 96-well to a 384-well format  
For HTP screens of large libraries, such as for the library from LDC 
comprising more than 200,000 compounds, a miniaturisation of the assay is 
needed to optimise handling. For example, amounts of valuable drug portions 
should be reduced, and the number of data points per handling unit, such as a 
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cell culture plate, should be increased, also allowing for the generation of 
more data sets in less time. 
The assay presented in this thesis worked well in the 96-well format, with 
40,000 assay cells per well and 10,000 Nrg1-typeI cells added, with a z’ factor 
of >0.5 indicating a good separation window for the screen. Attempts to 
miniaturise the assay to a 384-well format caused problems in the assay’s 
stability, as indicated by a rather low z’ factor of around 0.3. Initial tests to 
simply downsize each component by a factor of four did not prove helpful. 
Colleagues at the LDC are now devoting much of their time and energy to get 
the assay working. Currently, it is expected that the large compound screen 
will be performed in a single cell assay including a stimulation using the EGF-
like domain. For secondary screening, however, it is planned to use the co-
culture assay in a 96-well format.  
6.1.10 Elimination of false positives 
Firefly luciferase activity was used as readout in the screen, and hits were 
scored for increased or reduced readings. A given drug may alter these 
readings by influencing the viability of the assay cells or by acting on the 
reporter proteins themselves, e.g. by changing their expression, efficient 
folding and sorting, or localisation, thereby leading to the identification of a 
false positive hit (Sink et al., 2010). For example, a given drug may promote 
or inhibit the firefly luciferase activity (Cheng and Inglese, 2012), or impinge 
on the correct functionality of the artificial co-transcriptional activator GV or 
the TEV protease. To eliminate these false positive hits, we implemented 
several measures in the screen itself and during the secondary screening 
process. For the screen, a second luciferase, the Renilla luciferase under the 
control of the constitutive TK-promoter was used to assay for viability. 
Therefore, all highly toxic substances can be excluded from the analysis as 
they strongly reduce Renilla readings. During the process of secondary 
screening, further tests were run to address a given drug’s effect related to 
the functionality of GV, the TEV protease, and the concomitant release of GV 
induced by TEV activity. To do this, I re-screened the entire library using (1) a 
setup of constitutive GV expression and the firefly luciferase reporter UAS-
Fluc and (2) a membrane-anchored TEV protease, a membrane-anchored GV, 
and the reporter UAS-Fluc. In summary, applying these controls helped to 
eliminate false positives. 
6.1.11 Elimination of false negatives  
The elimination of false negatives is less straight forward. For example, a 
given drug that has an effect on ERBB4 but does not score in the chosen cell-
based assay because of the chosen assay time point. For example, long-term 
effects of drugs cannot be monitored at the 24h time point, whereas 
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immediate and short-term effects may have already faded away. Each screen 
that we performed, however, was run in replicates, and complex statistical 
processing contributes to minimise false negatives. However, if the cell-based 
assay does not respond to a treatment, either due to a chosen readout or a 
given sensitivity, a selected assay time point, or a host cell, a potentially 
potent drug will not be recovered.  
6.1.12 Reproducibility of screening results 
The split TEV technique is a highly robust and sensitive method for cell-based 
assays (Capdevila-Nortes et al., 2012; Wehr et al., 2006; Wehr et al., 2008a, 
Djannatian et al., 2011) and was recently successfully used in an RNAi screen 
(Michael Wehr, personal communication). Here, the split TEV technique was 
applied for the first time in a compound screen, using the FDA-approved NCC 
library as template. For internal reasons, the NCC library was screened 
several times, i.e. to optimise protocols related to robotics and operational 
sequences. The library subset NCC201 was screened ten times in total, and 
Spironolactone was recovered each time as inhibitor of ERBB4 signalling. 
Other hits followed up upon in secondary screening, like Vincristin/Vindesine 
and CCPA scored in initial screens only, likely due to the setup process 
required to make the robotics unit fully functional (see table 16. for details).  
Name of drug  NCC subset Total times 
recovered  
State of validation 
Spironolactone 201-1-D06 10 animal model 
Topotecan 003-3-A04 5 stopped 
Vincristin 003-6-B02 1 toxic 
CCPA 003-6-B06 1 unspecific 
Albendazole 201-3-A03 2 unspecific 
Mevastatin 003-6-H04 1 toxic 
Table 16. Secondary screening and validated hits  
6.1.13 Binding assays and co-immunoprecipitations 
Drugs recovered from the screen need to be validated using alternative 
assays. For example, drug-protein binding assays are necessary to verify that 
a drug physically associates with its target protein. Various protein-drug 
binding assays like isothermal titration calorimetry, surface plasmon resonace 
system, plasma protein binding assays, X-ray christallography and nuclear 
magnetic resonance are available (Arkin and Wells, 2004). 
For the precise determination of protein-drug binding crystal structures and X-
ray crystallography or nuclear magnetic resonance can be used. As both 
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techniques are time-consuming an analysis using these methods is beyond 
the scope of this thesis. The following techniques are less time consuming.  
Surface plasmon resonance SPR (Huber, 2005) is a technique for the 
measurement of binding interactions. A surface bound immobilized molecule 
is probed against an analytic. Meassured is the change in refractive index of 
the surface after binding. 
Isothermal titration calorimetry is a physical technique (Freyer and Lewis, 
2008). Binding of small molecules to proteins can be measured using 
changes in Gibbs free energy and in entropy (Holdgate et al., 2010). This 
method has been used successfully for. ERBB Antibody binding was in 
addition profen by ITC (Castoldi et al., 2012). 
The overexpression and purification of large membrane proteins, such as the 
ERBB4 receptor, however, is difficult. To study ERBB4-drug binding affinities 
using these methods, the receptor may be separated into various functional 
subunits, such as the cytosolic, a transmembrane, and an extra-cellular part, 
thereby circumventing purification problems.  
In addition, the split TEV protein-protein interaction assay has to be 
complemented, i.e. by using a co-immunoprecipitation (co-IP) or a GST pull-
down assay. Currently, ERBB4 and PIK3R1 are cloned into co-IP compatible 
vectors, and these experiments will commence shortly. 
6.1.14 Testing compounds on unrelated targets 
To assess target specificity of the compounds, unrelated but also closely 
related targets were chosen using the same cell-based assay format. To 
ensure the specificity of the hit compounds and to get a broader 
understanding of additional effects a spectrum of selected PPI was tested. 
The selection contained Rapamycin induced FKBP-FRB (test of general effect 
on induced PPI), and a GPCR mediated interaction with -Arrestin2 
(Serotonin 5a Receptor). Further tests like NTRK1 (also known as TRKA)-
SHC (to study an effect on another receptor tyrosine kinase) and further 
kinases are scheduled to increase informations about target specificity.   
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6.2  Relevance for schizophrenia 
The potential applicability of the candidates identified from NRG1-ERBB4 
screens for treatment of SZ is unclear. NRG1-ERBB4 signalling plays a key 
role in the development of the brain, and this process takes place over 
decades (Mei and Xiong, 2008). Both, in the screen and in the dose response 
validation experiments end point effects are measured 24h after stimulation. It 
is unclear whether such an effect has an influence on brain architecture after 
many years post development. Nonetheless, each drug may be applied daily 
over long periods of time and may be functional even when half-life and on-
target effects are limited. Nonetheless, at least Spironolactone, which has a 
favourable tox-profile and is used in the clinic, might be applied in limited 
treatment trials at some point in patients. Before this might ever take place, 
several follow-up validations are essential. Most importantly, additional 
behavioral analyses with appropriate animal models need to be performed in 
the future, addressing working memory and social interaction tests for 
example. 
SZ is regularly diagnosed after puberty or in early adulthood. The most 
significant changes in brain architecture (early years and puberty) are 
occurring at this time point. Finding and then also applying a drug that affects 
brain or neuronal circuit architecture during the human childhood and puberty 
raises major questions. First, it is ethically inconceivable to treat a child with 
brain structure-modifying drugs to prevent the relatively small (1%) chance of 
contracting with SZ. Second, the severe side effects and unpredictable 
changes in the wiring of the brain do strictly bar this. In addition, to start a 
promising treatment scheme, a reliable biomarker that is present in children is 
needed, and a systematic analysis of a child’s brain wiring has to be initiated 
as well. However, as such a biomarker is still elusive, treating children in this 
perspective remains far in the future.  
Recent research shows (Nitsche et al., 2012; Lewis and González-Burgos, 
2008) that the neuroplasticity and the on-going change in brain architecture 
exhibit sufficient neuroplasticity to be a putative target for the effects induced 
by drugs. Hopefully, drugs modifying NRG1-ERBB4 signalling will help to 
specifically change the neuronal circuit of inhibitory chandelier and basket 
cells and activating principal neurons in adults, thus re-balancing the initially 
disturbed circuit architecture. However, this question cannot be answered 
without studies in humans. 
For the treatment of SZ, a moderate activator of NRG1-ERBB4 signalling is 
highly desired. In schizophrenia, reduced or potentially enhanced NRG1-
ERBB4 signalling (Weickert et al., 2012) leads to a loss of inhibition mediated 
by parvalbumin positive basket and chandelier cells (PV+ interneurons) on 
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principal pyramidal neurons, and an activator of NRG1-ERBB4 signalling 
could potentially alleviate symptoms related to this circuit architecture (Lewis 
and González-Burgos, 2008). However, no drug from the NCC library showed 
a specific activating effect on NRG1-ERBB4 signalling. Therefore, it is 
planned to use larger libraries of compounds to increase the chance to find an 
activator. For example, the analysis of the Spectrum collection (2320 
compounds (http://www.msdiscovery.com/spectrum.html) was successful 
used by (Kocisko et al., 2003; Weissmann and Aguzzi, 2005; Sun et al., 2006; 
Weisman et al., 2006; Stallings-Mann et al., 2006). Moreover, the 200,000  
compound library from the Lead Discovery Centre Dortmund is in progress 




6.3 NRG1-ERBB4 – Spironolactone  
The inhibitory effect of Spironolactone was several times recovered in the 
screen. In addition, dose-response assays for Spironolactone validated a 
clear concentration-dependent inhibition of NRG1-ERBB4 signalling. 
Spironolactone was originally described as an antagonist of the 
mineralocorticoid receptor MCR (Rogerson et al., 2003). MCR regulates salt 
homeostasis in the kidney (Brewster and Perazella, 2004), and 
Spironolactone is used as a diuretic in the clinics (Ogden et al., 1961). MCR 
plays also a role in the brain (in particular in the hippocampus)(Oyamada et 
al., 2008), heart vasculature (Oyamada et al., 2008), and adipose tissue 
(Marzolla et al., 2012). Mechanistically, Spironolactone binds to the 
aldosterone binding pocket of the MCR, thus preventing its translocation to 
the nucleus, where the MCR induces the transcription of target genes 
(Grossmann et al., 2012)  
For Spironolactone’s action on NRG1-ERBB4 signalling, I speculate that 
Spironolactone could prevent ERBB4 receptors from dimerising thus reducing 
downstream signalling, i.e. preventing activation of downstream kinases, such 
as PI3K and AKT. Importantly, treatment of Spironolactone showed reduced 
phosphorylation levels of pTyr1284 in ERBB4, concomitant with a mild 
decrease in phospho-AKT levels. However, this signalling needs to be 
addressed in more detail in the future, including other SZ-relevant kinases, 
such as GSK-3 (Emamian, 2012).  
6.3.1 Does Spironolactone physically bind to ERBB4 receptors?  
Spironolactone specifically inhibits NRG1-ERBB4 signalling. However, split 
TEV assays do not allow answering whether Spironolactone physically binds 
to ERBB4 to inhibit receptor activation. Other assays discussed above are 
necessary to address this question.  
6.3.2 Spironolactone derivates and metabolites  
The secomd generation drug of Spironolactone Eplerenone showed no effect 
on ERBB4/PIK3R1 co-culture assay. The metabolite Canterenone showed 
also no effect.  
This leads to the assumption that the thioketone (Acetylthio) group of 
Spironolactone is part of the mode of action. The entire description of the 
structure function relationship is beyond this thesis.  
The penetration of the blood-brain barrier (BBB) is vital for any drug used for 
psychiatric treatment. Until now it is not known if Spironolactone passes the 
BBB (Geerling and Loewy, 2009). 
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6.3.3 Preliminary validation in a mouse model 
An analysis of Spironolactone effects counteracting MK801 induced psychosis 
(see MK801 mouse model) showed that Spironolactone shows only a non-
significant tendency to reduce spontaneous locomotor activity. The 
administered Spironolactone concentration was 20 mg/kg, relatively high 
compared to concentrations in humans (20-200 mg/75kg (average human)). 
As the effects are measured in two hours, they are supposably not based on 
Spironolactone’s primary action against MCR and the resulting changes in 
gene expression (48h).  
The MK801 mouse model is not the perfect model to validate putative NRG1-
ERBB4 inhibitors. A mouse model constitutively overexpressing Nrg1-typeIII 
is in the validation phase and will soon be available ((Velanac et al., 2012) 
personal communication M. Schwab). 
The effect of Spironolactone on the mouse brain has also to be shown in 
Western-Blots on mouse brain lysates and will be performed as soon as the 




6.4 Topotecan shows strong toxic effects 
Topotecan is a semisynthetic variant of Camptothecin. Camptothecin is a 
pentacycline quinolone alkaloid found in the bark seeds, and fruits of the 
Chinese happy tree camptotheca acuminate (Xi Shu). Parts of the tree were 
regularly used in the treatment of different diseases in traditional Chinese 
medicine wheras no reports for the use in psychiatric treatments are available. 
In a screen for cancer therapeutics performed in 1966 by M. E. Wall and M. C. 
Wani camptothecin was isolated. It is not water-soluble and has severe side 
effects including unpredictable toxicity. Camptothecin acts as a 
topoisomerase I inhibitor (O’Leary and Muggia, 1998b; Redinbo et al., 1998; 
Morton, 1968).  
Topoisomerases are enzymes that are localised to the nucleus, and are 
responsible for the relaxation of positive and negative supercoiled DNA 
strands. Camptothecin inhibits the breakage re-joining reaction of DNA–
topoisomerase I. The inhibition is specific and results in the accumulation of 
reversible intermediate DNA-Camptothecin-topoisomerase I ternary 
complexes. Camptothecin only binds to the DNA-topoisomerase I complex, 
but not to DNA or the enzyme alone. (Gromova 1993, Hsiang 1989) 
(Gromova et al., 1993; Hsiang et al., 1989)  
Topotecan is made water-soluble by a basic chain at carbon 9. It is used 
against small lung cancer and ovarial cancers. It acts as Topoisomerase I 
inhibitor by stalling the DNA-topoisomerase I complex, and therefore acts 
cytostatic. For Topotecan, the penetration of the blood brain barrier, the 
localisation to the CNS, and cerebrospinal fluid concentrations of 32% in 
serum levels have been reported (Takimoto and Arbuck, 1997b)  
Irinotecan (FDA-approved in 1998) is a pro-drug and undergoes hydrolysis by 
carboxylesterase, primarily in the liver. This conversion results is SN-38, 
which is the biologically active form of Irinotecan, with an increased activity of 
1000-fold (Kawato et al., 1991; Redinbo et al., 1998; Kuhn, 1998; Zamboni et 
al., 1998). Irinotecan is used in the clinics to treat colorectal cancer. 
Irinotecan has severe side effects including diarrhoea associated with 
abdominal cramping, vomiting, flushing, and diaphoresis. This is mediated by 
increased cholinergic activity, and this is reversible with atropine (Abigerges et 





Figure 77: Immage. Campothecin derivatives (O’Leary and Muggia, 1998) 
Camptothecins are toxic to the bone marrow and cause mucositis and 
diarrhoea (Irinotecan) in humans (O’Leary and Muggia, 1998a). They are only 
used as chemotherapeutics in live-threatening cancers (Taguchi et al., 1990). 
Therefore, usage of Topotecan in psychiatric patients is not recommended 
unless a lead optimisation processes results in lead structure with reduced 
toxicity i.e. reduced DNA-Topoisomerase I binding. On a chemical basis, it 
has already shown that binding of an amino group at C12 abolishes 
topoisomerase I inhibiting function and that specific stereochemistry at C20 is 
necessary. Only the (S) isomer is active, racemic mixture shows 50% activity 
and the (R) isomer is completely inactive (O’Leary and Muggia, 1998a). This 
combined with the inactivity of SN 38 may serve as template for a putative 
starting point of a leadoptimisation process, given the modified compounds 
remain inhibitory to NRG1-ERBB4 signalling.  
Topotecan shows nicely the dilemma of the used co-culture assay systems. 
The time dimensions of an effect cannot be measured directly. Topotecan is 
strongly toxic for all fast-dividing cells, but the effect is not prominent in a 24h 
assay. Toxic effects can accumulate and strike over time and remain hidden 




Activators of NRG1-ERBB4 signalling are highly desired to compensate for 
SZ-induced loss of function phenotypes but remain elusive. The NCC library 
containing FDA-approved compounds was applied to address this issue. 
However, with Spironolactone and Topotecan, only inhibitors of NRG1-
ERBB4, were identified. As the NCC library only contains not far more than 
700 drugs, larger collections, such as the Spectrum Collection containing 
2300 compounds, will be used in the in the future. In addition, the LDC library, 
with more than 200,000 compounds, will be used to screen for activators of 
NRG1-ERBB4 signalling. Once an activator is identified, medicinal chemistry 
will be applied to generate new molecular entities in a lead optimisation 
process, with the aim to find a structure that activates NRG1-ERBB4 
signalling, is not toxic, and fulfils the requirements to proceed into the 





BACE Beta-site APP cleaving enzyme 
BRET Bioluminescence resonance energy transfer 
BBB Blood-brain-barrier 
Chr Chromosome 
CIP Calf intestinal alkaline phosphatase 
CMV Cytomegalovirus 
CNS Central nervous system 
CNV Copy number variations 
CO-IP Immunoprecipitation 
CRD Cystein rich domain 
DISC1 Disroupted in schizophrenia 
DMSO Dimethylsulfoxide 
DNA Desoxyribonuclein acid 
DSM IV Diagnostic and Statistical Manual of Mental Disorders 
DTT Dithiothreitol 
e.g. For example/exempli gratia 
ECL Enhanced chemiluminescens  
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
EGFP Enhanced green fluorescent protein 
ERBB4 
Receptor tyrosine-proteine kinase v-erb-a  
erythroblastic leukemia viral oncogene homolog 4 (avian) 
ERT2 Mutated Estrogen receptor domains  
f.c. Final concentration 
FDA Food and Drug Administeriation 
FRET Fluorescence Resonance Energy Transfer 
GABA Gamma-Aminobutyric acid 
GAD67 Glutamat acid decarboxylase 67kd 
GRB2 Growth factor receptor bound protein 2 
GV Galactose4.viral protein 16; artificial transcription factor 
GWAS Genome wide genetic association studies 
HTP High throughput  
i.e. That is/id est 
IQ Inteligence quotient 
k Kilo 
kb Kilo bases 
KO Knock out 
M Molar 
MAPK Mitogen activated protein kinases 
MDMA 3,4-methylenedioxy-N-methylamphetamine 
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MRI Magnetic Resonance imaging 
n Nano 
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PCR Polymerase chain reaction 
PI3K Phodphoinositide 3.kinase 
PLL Poly-L-Lysin 
PNS Peripheral nervous system 
PPI Protein-protein-interaction 
PTPRZ1 Receptor-type tyrosine-protein phosphatase zeta 
PV Parvalbumin 
RLU Relative luciferase units 
RTK Receptor tyrosine kinase 
SD Standard deviation 
sec Seconds 
SEM Standard error of the mean  
SHC1 SH2 domains containing transforming protein 
SNP Single nucleotide polymorphisms  
SRC Sarcoma tyrosine kinase 
STAT5A Signal transducer and activator of transcription 5a 
SV40 Simian virus 40 
SZ Schizophrenia 
TACE TNFalpha converting enzyme 
TEV Tobacco etch virus 
THC Tetra hydro canabinol 
TK Thymidine kinase 
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10  Apendix, List of Drugs NCC201/NCC003 
10.1.1 NIH1–NCC201 
NCC_SAMPLE Pl. Well Supplier NCC_STRUCTURE_SYNONYMS[2] 
SAM002264608 1 A02 LightBiologicals DOXEPIN HYDROCHLORIDE 
SAM002264609 1 B02 LightBiologicals DIPYRIDAMOLE 
SAM002264610 1 C02 LightBiologicals Propofol 
SAM002264611 1 D02 LightBiologicals ETHACRYNIC ACID 
SAM002264612 1 E02 LightBiologicals FLUTAMIDE 
SAM002264613 1 F02 LightBiologicals FENOFIBRATE 
SAM002264614 1 G02 LightBiologicals FUROSEMIDE 
SAM002264615 1 H02 LightBiologicals 5-FLUOROURACIL 
SAM002264616 1 A03 LightBiologicals Folic acid 
SAM002264617 1 B03 LightBiologicals HYDROCORTISONE 
SAM002264618 1 C03 LightBiologicals Cortell 
SAM002264619 1 D03 LightBiologicals IBUPROFEN 
SAM002264620 1 E03 LightBiologicals KETOPROFEN 
SAM002264621 1 F03 LightBiologicals MINOCYCLINE HYDROCHLORIDE 
SAM002264623 1 G03 LightBiologicals MICONAZOLE NITRATE 
SAM002297829 1 H03 LightBiologicals METYRAPONE 
SAM002264625 1 A04 LightBiologicals NORFLOXACIN 
SAM002264627 1 B04 LightBiologicals NADOLOL 
SAM002264628 1 C04 LightBiologicals Disipal 
SAM002264629 1 D04 LightBiologicals OFLOXACIN 
SAM002264631 1 E04 LightBiologicals PINDOLOL 
SAM002264632 1 F04 LightBiologicals PRAZIQUANTEL 
SAM002264634 1 G04 LightBiologicals Benzenebutanoic Acid 
SAM002264635 1 H04 LightBiologicals PREDNISOLONE ACETATE 
SAM002264636 1 A05 LightBiologicals Phenergan 
SAM002264637 1 B05 LightBiologicals PERPHENAZINE 
SAM002264639 1 C05 LightBiologicals Prednisolone 
SAM002264640 1 D05 LightBiologicals PRILOCAINE HYDROCHLORIDE 
SAM002264641 1 E05 LightBiologicals Prednisone 
SAM002264642 1 F05 LightBiologicals DL-PENICILLAMINE 
SAM002264643 1 G05 LightBiologicals PIPERACILLIN SODIUM SALT 
SAM002264644 1 H05 LightBiologicals Quinidine hydrochloride monohydrate 
SAM002264645 1 A06 LightBiologicals Ranitidine hydrochloride 
SAM002264646 1 B06 LightBiologicals RIFAMPICIN 
SAM002264647 1 C06 LightBiologicals Retinoic acid 
SAM002264648 1 D06 LightBiologicals Spironolactone 
SAM002264649 1 E06 LightBiologicals Trimethoprim 
SAM002264650 1 F06 LightBiologicals Tyzine 
SAM002264651 1 G06 LightBiologicals L-THYROXINE 
SAM002264652 1 H06 LightBiologicals Artane 
SAM002264653 1 A07 LightBiologicals URSODEOXYCHOLIC ACID 
SAM002554879 1 B07 LightBiologicals Dapsone 
SAM002554881 1 C07 LightBiologicals Symmetrel 
SAM002554882 1 D07 LightBiologicals WARFARIN SODIUM 
SAM002554883 1 E07 LightBiologicals Acetazolamide 
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SAM002554884 1 F07 LightBiologicals Allopurinol 
SAM002554885 1 G07 LightBiologicals ATROPINE 
SAM002554914 1 H07 LightBiologicals Nalidixic Acid 
"SAM003107539 1 A08 LightBiologicals ""3 
SAM002703134 1 B08 LightBiologicals HYDROFLUMETHIAZIDE 
SAM002554886 1 C08 LightBiologicals Annoyltin 
SAM002554887 1 D08 LightBiologicals Busulfan 
SAM002554888 1 E08 LightBiologicals Chlorzoxazone 
SAM002554891 1 F08 LightBiologicals Chlorothiazide 
SAM002554892 1 G08 LightBiologicals Cimetidine 
SAM002554889 1 H08 LightBiologicals Carisoprodol 
SAM002554890 1 A09 LightBiologicals Chlorpropamide 
"SAM002554894 1 B09 LightBiologicals Bentyl 
SAM002554895 1 C09 LightBiologicals Chloroxine 
SAM002554896 1 D09 LightBiologicals Diflunisal 
SAM002554898 1 E09 LightBiologicals Econazole Nitrate 
SAM002554899 1 F09 LightBiologicals Ethionamide 
SAM002554900 1 G09 LightBiologicals Methocarbamol 
SAM002554901 1 H09 LightBiologicals Hydrochlorothiazide 
SAM002554902 1 A10 LightBiologicals Vistaril Pamoate 
SAM002554903 1 B10 LightBiologicals Hexachlorophene 
SAM002554904 1 C10 LightBiologicals Isoniazid 
SAM002554905 1 D10 LightBiologicals Duvadilan 
SAM002554906 1 E10 LightBiologicals Isuprel 
SAM002554907 1 F10 LightBiologicals Triclosan 
SAM002554908 1 G10 LightBiologicals Mefenamic Acid 
"SAM002554910 1 H10 LightBiologicals Cantil 
SAM002554911 1 A11 LightBiologicals Maxolon 
SAM002554912 1 B11 LightBiologicals Methyldopa 
SAM002554913 1 C11 LightBiologicals NITROFURANTOIN 
SAM002554915 1 D11 LightBiologicals Pamelor 
SAM002554916 1 E11 LightBiologicals Albalon 
SAM002554917 1 F11 LightBiologicals Nicotinic Acid 
SAM002554918 1 G11 LightBiologicals Norflex 
SAM002554919 1 H11 LightBiologicals Oxytetracycline hydrochloride 
SAM002554920 2 A02 LightBiologicals Novocain 
SAM002554921 2 B02 LightBiologicals Pyrimethamine 
SAM002554922 2 C02 LightBiologicals Pro-Banthine 
SAM002554923 2 D02 LightBiologicals Probenecid 
SAM002554924 2 E02 LightBiologicals PYRIDINE-2-ALDOXIME METHOCHLORIDE 
SAM002554925 2 F02 LightBiologicals Primidone 
SAM002554926 2 G02 LightBiologicals Propylthiouracil 
SAM002554927 2 H02 LightBiologicals Pyrazinamide 
SAM002554928 2 A03 LightBiologicals Pronestyl 
SAM002554929 2 B03 LightBiologicals Sulfisoxazole 
SAM002554930 2 C03 LightBiologicals Sulfamethoxazole 
SAM002554931 2 D03 LightBiologicals Sulfacetamide 
SAM002554932 2 E03 LightBiologicals Sulfinpyrazone 
SAM002554933 2 F03 LightBiologicals Sulindac 
SAM002554934 2 G03 LightBiologicals TETRACYCLINE 
SAM002554935 2 H03 LightBiologicals Theophylline 
SAM002554936 2 A04 LightBiologicals Tolbutamide 
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"SAM002554937 2 B04 LightBiologicals Triamterene 
SAM002554938 2 C04 LightBiologicals Intropin 
SAM002564189 2 D04 LightBiologicals AMOXAPINE 
SAM002564191 2 E04 LightBiologicals Adenine 9-beta 
SAM002564193 2 F04 LightBiologicals ATENOLOL 
SAM002703133 2 G04 LightBiologicals Tamoxifen 
SAM002564195 2 H04 LightBiologicals BUMETANIDE 
SAM002564250 2 A05 LightBiologicals CLOBETASOL PROPIONATE 
SAM002564196 2 B05 LightBiologicals Sonazine 
SAM002564200 2 C05 LightBiologicals CEFAZOLIN SODIUM SALT 
SAM002564201 2 D05 LightBiologicals CAPTOPRIL 
SAM002564202 2 E05 LightBiologicals CHLORAMBUCIL 
SAM002564251 2 F05 LightBiologicals CEFOXITIN SODIUM SALT 
SAM002564203 2 G05 LightBiologicals DANAZOL 
SAM002564204 2 H05 LightBiologicals (+)-CIS-DILTIAZEM HYDROCHLORIDE 
SAM002564205 2 A06 LightBiologicals DIGOXIN 
SAM002564206 2 B06 LightBiologicals 17-BETA-ESTRADIOL 17-VALERATE 
SAM002564207 2 C06 LightBiologicals EDROPHONIUM CHLORIDE 
SAM002564208 2 D06 LightBiologicals FLUOCINOLONE ACETONIDE 
SAM002564209 2 E06 LightBiologicals Flurbiprofen 
SAM002564210 2 F06 LightBiologicals GLIPIZIDE 
SAM002564211 2 G06 LightBiologicals GEMFIBROZIL 
SAM002564212 2 H06 LightBiologicals Glyburide 
SAM002564213 2 A07 LightBiologicals HYDROCORTISONE HEMISUCCINATE 
SAM002564214 2 B07 LightBiologicals INDAPAMIDE 
SAM002564215 2 C07 LightBiologicals IPRATROPIUM BROMIDE MONOHYDRATE 
SAM002564216 2 D07 LightBiologicals Tofranil 
SAM002564217 2 E07 LightBiologicals LABETALOL HYDROCHLORIDE 
SAM002564218 2 F07 LightBiologicals Imodium 
SAM002564219 2 G07 LightBiologicals Pro-Amatine 
SAM002564220 2 H07 LightBiologicals Medroxyprogesterone 17-acetate 
SAM002564222 2 A08 LightBiologicals 19-NORETHINDRONE ACETATE 
SAM002564223 2 B08 LightBiologicals 19-Norethindrone 
SAM002564224 2 C08 LightBiologicals NICOTINE 
SAM002564254 2 D08 LightBiologicals Cardene 
SAM002564225 2 E08 LightBiologicals NABUMETONE 
SAM002564226 2 F08 LightBiologicals OXYBUTYNIN CHLORIDE 
SAM002564227 2 G08 LightBiologicals Mestinon 
SAM002564228 2 H08 LightBiologicals Rythmol 
SAM002564229 2 A09 LightBiologicals Pfizerpen 
SAM002564230 2 B09 LightBiologicals Valproic Acid 
SAM002564231 2 C09 LightBiologicals Kemadrin 
"SAM002564232 2 D09 LightBiologicals Proxymetacaine 
SAM002703137 2 E09 LightBiologicals NALOXONE HYDROCHLORIDE 
SAM002564233 2 F09 LightBiologicals SPECTINOMYCIN DIHYDROCHLORIDE PENTAHYDRATE 
SAM002564235 2 G09 LightBiologicals TROPICAMIDE 
SAM002564236 2 H09 LightBiologicals TOLAZAMIDE 
SAM002564237 2 A10 LightBiologicals TRIAMCINOLONE ACETONIDE 
SAM002564238 2 B10 LightBiologicals S(-)-Timolol maleate 
SAM002564239 2 C10 LightBiologicals THIABENDAZOLE 
SAM002564240 2 D10 LightBiologicals THIORIDAZINE HYDROCHLORIDE 
SAM002564241 2 E10 LightBiologicals Altretamine 
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SAM002564257 2 F10 LightBiologicals Phylloquinone 
SAM002564242 2 G10 LightBiologicals Eryped 
SAM002564244 2 H10 LightBiologicals Dibenzyline 
"SAM002564258 2 A11 LightBiologicals 6ALPHA-METHYL-11BETA-HYDROXYPROGESTERONE 
SAM002564245 2 B11 LightBiologicals Thalidomide 
SAM002589919 2 C11 LightBiologicals Aminolevulinic Acid 
SAM002589920 2 D11 LightBiologicals Carbinoxamine Maleate 
SAM002589921 2 E11 LightBiologicals Demeclocycline 
SAM002589925 2 F11 LightBiologicals Westcort 
SAM002589926 2 G11 LightBiologicals DEPRENALIN 
SAM002589927 2 H11 LightBiologicals 6-[2-ETHOXY-1-NAPHTHAMIDO]-PENICILLIN SODIUM SALT 
SAM002589929 3 A02 LightBiologicals Primaquine Diphosphate 
SAM002589930 3 B02 LightBiologicals Micropenin 
SAM002589932 3 C02 LightBiologicals DOXYCYCLINE 
"SAM002699895 3 D02 LightBiologicals Beclomethasone dipropionate 
SAM002589934 3 E02 LightBiologicals Cromolyn Sodium 
SAM002589935 3 F02 LightBiologicals Priscoline 
SAM002589937 3 G02 LightBiologicals Mercaptopurine 
SAM002589938 3 H02 LightBiologicals Azathioprine 
SAM002589939 3 A03 LightBiologicals Albendazole 
SAM002589940 3 B03 LightBiologicals Griseofulvin 
SAM002589936 3 C03 LightBiologicals Lincomycin hydrochloride 
SAM002589943 3 D03 LightBiologicals Methazolamide 
SAM002589944 3 E03 LightBiologicals Terbutaline Sulfate 
SAM002589979 3 F03 LightBiologicals Mupirocin 
SAM002589945 3 G03 LightBiologicals FLUOCINOLONE ACETONIDE 21-ACETATE 
SAM002699894 3 H03 LightBiologicals Mefloquine hydrochloride 
SAM002589947 3 A04 LightBiologicals Floxuridine 
SAM002699896 3 B04 LightBiologicals MITOXANTRONE 
SAM002699897 3 C04 LightBiologicals ENALAPRIL MALEATE 
SAM002699898 3 D04 LightBiologicals BUDESONIDE 
SAM002699899 3 E04 LightBiologicals RAMIPRIL 
SAM002699893 3 F04 LightBiologicals DEPO-MEDROL 
SAM002699901 3 G04 LightBiologicals (+/-)-NOREPINEPHRINE HYDROCHLORIDE 
SAM002699903 3 H04 LightBiologicals AMCINONIDE 
SAM002699904 3 A05 LightBiologicals Clomid 
SAM003107541 3 B05 LightBiologicals PHENTOLAMINE HCL 
SAM002548956 3 C05 Enamine FLUDARABINE 
SAM002548950 3 D05 Enamine Testosterone 
SAM002548955 3 E05 Enamine Isotretinoin 
SAM002548951 3 F05 Enamine Methimazole 
SAM002548957 3 G05 Enamine Zonisamide 
SAM002548958 3 H05 Enamine Brimonidine 
SAM002548959 3 A06 Enamine Mebendazole 
SAM002548969 3 B06 Enamine Duremesin 
SAM002548968 3 C06 Enamine Flecainide Acetate 
SAM002548966 3 D06 Enamine Dilantin 
SAM002548945 3 E06 Enamine Miochol 
SAM002703135 3 F06 LightBiologicals Dantrolene sodium salt 
SAM002548948 3 G06 Enamine Dexamethasone 
SAM002548938 3 H06 Enamine Cogentin Mesylate 
SAM002548936 3 A07 Enamine Ganciclovir 
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SAM002548937 3 B07 Enamine Mesna 
SAM002548942 3 C07 Enamine Meclomen 
SAM002589905 3 D07 Enamine Fluconazole 
SAM002548965 3 E07 Enamine Metaproterenol 
SAM002548974 3 F07 Enamine Methoxsalen 
SAM002548963 3 G07 Enamine Chloramphenicol 
SAM002548961 3 H07 Enamine Tizanidine hydrochloride 
SAM002548935 3 A08 Enamine Paroxetine 
SAM002548934 3 B08 Enamine mirtazapine 
SAM002548930 3 C08 Enamine Etomidate 
SAM002548933 3 D08 Enamine Moban 
SAM002548940 3 E08 Enamine fluvastatin 
SAM002548931 3 F08 Enamine Urecholine 
SAM002589901 3 G08 Enamine Cefuroxime 
SAM002548983 3 H08 Enamine Cytoxan 
SAM002548982 3 A09 Enamine Eszopiclone 
SAM002264598 3 B09 LightBiologicals Bendrofluazide 
SAM002548975 3 C09 Enamine Evista 
SAM002548971 3 D09 Enamine zidovudine 
SAM002548976 3 E09 Enamine Clozapine 
SAM002264590 3 F09 LightBiologicals Ampicillin Sodium 
SAM002264591 3 G09 LightBiologicals ACEBUTOLOL HYDROCHLORIDE 
SAM002264592 3 H09 LightBiologicals AMOXICILLIN CRYSTALLINE 
SAM002699891 3 A10 LightBiologicals (+/-)-Epinephrine hydrochloride 
SAM002264595 3 B10 LightBiologicals 5-Azacytidine 
SAM002264597 3 C10 LightBiologicals Buspar 
SAM002264596 3 D10 LightBiologicals Flumadine 
SAM002548978 3 E10 Enamine Podofilox 
SAM002264599 3 F10 LightBiologicals D-CYCLOSERINE 
SAM002264600 3 G10 LightBiologicals CORTISONE ACETATE 
SAM002264601 3 H10 LightBiologicals Anafranil 
SAM002264603 3 A11 LightBiologicals Carbamazepine 
SAM002699890 3 B11 LightBiologicals Memantine hydrochloride 
SAM002264605 3 C11 LightBiologicals Norpramin 
SAM002264606 3 D11 LightBiologicals Mexitil 
SAM002264607 3 E11 LightBiologicals Norpace 
SAM002589948 3 F11 LightBiologicals STAVUDINE 
SAM002589981 3 G11 LightBiologicals Doxazosin 
SAM002589949 3 H11 LightBiologicals Minoxidil 
SAM002699889 4 A02 LightBiologicals Inderal 
SAM002589951 4 B02 LightBiologicals Ribavirin 
SAM002589982 4 C02 LightBiologicals Terazosin 
SAM002589983 4 D02 LightBiologicals Chlorthalidone 
SAM002589984 4 E02 LightBiologicals METHYLPREDNISOLONE 
SAM002589985 4 F02 LightBiologicals Phenelzine 
SAM002589986 4 G02 LightBiologicals NALTREXONE HYDROCHLORIDE 
SAM002589987 4 H02 LightBiologicals Glycopyrrolate 
SAM002589988 4 A03 LightBiologicals Ethambutol 
SAM002589989 4 B03 LightBiologicals Cetirizine 
SAM002589990 4 C03 LightBiologicals DICLOXACILLIN SODIUM 
SAM002589991 4 D03 LightBiologicals Meloxicam 
SAM002589992 4 E03 LightBiologicals DAUNORUBICIN HYDROCHLORIDE 
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SAM002589953 4 F03 LightBiologicals RIFAPENTINE 
SAM002589954 4 G03 LightBiologicals Penicillin V 
SAM002589955 4 H03 LightBiologicals Gatifloxacin 
SAM002589956 4 A04 LightBiologicals clopidogrel 
SAM002643511 4 B04 LightBiologicals CEFOTAXIME SODIUM SALT 
SAM002589994 4 C04 LightBiologicals LAMIVUDINE 
SAM002589958 4 D04 LightBiologicals Ondansetron 
SAM002589959 4 E04 LightBiologicals Betamethasone 
SAM002589995 4 F04 LightBiologicals Celecoxib 
SAM002589996 4 G04 LightBiologicals 4-(AMINOMETHYL)BENZENESULFONAMIDE ACETATE 
SAM002589997 4 H04 LightBiologicals THIOTHIXENE 
SAM002589960 4 A05 LightBiologicals Citalopram 
SAM002589961 4 B05 LightBiologicals Azithromycin 
SAM002589963 4 C05 LightBiologicals Lovastatin 
SAM002589964 4 D05 LightBiologicals Aminoglutethimide 
SAM002589965 4 E05 LightBiologicals Prozac 
SAM002589966 4 F05 LightBiologicals FluniSOLIDe 
SAM002589967 4 G05 LightBiologicals Acyclovir 
SAM002589968 4 H05 LightBiologicals Etodolac 
SAM002589969 4 A06 LightBiologicals Simvastatin 
SAM002589970 4 B06 LightBiologicals Rifabutin 
SAM002589971 4 C06 LightBiologicals Felodipine 
SAM002589972 4 D06 LightBiologicals Quinapril  hydrochloride 
SAM002589973 4 E06 LightBiologicals Acitretin 
SAM002700173 4 F06 LightBiologicals Allegra 
SAM002700174 4 G06 LightBiologicals Fluorometholone 
SAM002700175 4 H06 LightBiologicals Sertraline 
SAM002703129 4 A07 LightBiologicals CARBIDOPA 
Table 9. NCC201 
10.1.2 NIH2-NCC003 
NCC_SAMPLE Pl. Well Supplier NCC_STRUCTURE_SYNONYMS[2] 
SAM001247063 1 A02 Tocris Bioscience Nalbuphine 
SAM001247072 1 B02 Tocris Bioscience Raclopride 
SAM001247069 1 C02 Tocris Bioscience Zacopride 
SAM001247068 1 D02 Tocris Bioscience SKF 83566 
SAM001246964 1 E02 Tocris Bioscience 3'-deoxydenosine 
SAM001246965 1 F02 Tocris Bioscience AM 404 
SAM001246962 1 G02 Tocris Bioscience PILOCARPINE HYDROCHLORIDE 
SAM001246963 1 H02 Tocris Bioscience NIFEDIPINE 
SAM001246961 1 A03 Tocris Bioscience Flurbiprofen 
SAM001247015 1 B03 Tocris Bioscience 3-HYDROXY-1,2-DIMETHYL-4(1H)-PYRIDONE 
SAM001247061 1 C03 Tocris Bioscience   
SAM001247062 1 D03 Tocris Bioscience d-3-Methoxy-N-methylmorphinan hydrobromide 
SAM001247059 1 E03 Tocris Bioscience Duloxetine 
SAM001247060 1 F03 Tocris Bioscience 
Glycine, N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-
,phenylmethyl ester [CAS] 
SAM001247057 1 G03 Tocris Bioscience 
Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 
monosodium salt [CAS] 
SAM001247039 1 H03 Tocris Bioscience PROGESTERONE 
SAM001247033 1 A04 Tocris Bioscience FAMOTIDINE 
SAM001246999 1 B04 Tocris Bioscience SR 57,227A 
SAM001247003 1 C04 Tocris Bioscience Pancuronium 
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SAM001247010 1 D04 Tocris Bioscience METRONIDAZOLE 
SAM001246967 1 E04 Tocris Bioscience 
Benzeneacetic acid, Alpha-(hydroxymethyl)-, 9-methyl-3-
oxa-9-azatricyclo[3.3.1.02,4]non-7-yl ester, [7(S)-
(1Alpha,2 ﾃｿ,4 ﾃｿ,5Alpha,7 ﾃｿ)]- [CAS] 
SAM001246968 1 F04 Tocris Bioscience 
Benzeneacetonitrile, Alpha-[3-[[2-(3,4-
dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-
dimethoxy-Alpha-(1-methylethyl)-, (R)- [CAS] 
SAM001246969 1 G04 Tocris Bioscience DEPRENALIN 
SAM001246970 1 H04 Tocris Bioscience Capsaicin 
SAM001246971 1 A05 Tocris Bioscience SALBUTAMOL SULFATE 
SAM001246972 1 B05 Tocris Bioscience (ｱ)-Vesamicol hydrochloride 
SAM001246993 1 C05 Tocris Bioscience Picrotin - Picrotoxinin 
SAM001247000 1 D05 Tocris Bioscience Terazosin 
SAM001247027 1 E05 Tocris Bioscience diphenylcyclopropenone 
SAM001247016 1 F05 Tocris Bioscience 4-Thiazolidinecarboxylic acid, 2-oxo-, (R)- [CAS] 
SAM001247051 1 G05 Tocris Bioscience Mesoridazine 
SAM001247053 1 H05 Tocris Bioscience 
3(2H)-Pyridazinone, 6-[4-(difluoromethoxy)-3-
methoxyphenyl]- [CAS] 
SAM001247054 1 A06 Tocris Bioscience 
10H-Phenothiazine, 2-chloro-10-[3-(4-methyl-1-
piperazinyl)propyl- [CAS] 
SAM001247055 1 B06 Tocris Bioscience 
1H-Cyclopenta[b]quinolin-9-amine, 2,3,5,6,7,8-
hexahydro-, monohydrochloride- [CAS] 
SAM001247056 1 C06 Tocris Bioscience CLOTRIMAZOLE 
SAM001246987 1 D06 Tocris Bioscience LORATADINE 
SAM001247037 1 E06 Tocris Bioscience PHENELZINE SULFATE SALT 
SAM001246997 1 F06 Tocris Bioscience Riluzole 
SAM001247004 1 G06 Tocris Bioscience Naltrindole 
SAM001247026 1 H06 Tocris Bioscience Nornicotine 
SAM001247052 1 A07 Tocris Bioscience Bifemelane 
SAM001246973 1 B07 Tocris Bioscience CGS 15943 
SAM001246974 1 C07 Tocris Bioscience Cinanserin 
SAM001246975 1 D07 Tocris Bioscience Cisapride 
SAM001246981 1 E07 Tocris Bioscience Indatraline 
SAM001247045 1 F07 Tocris Bioscience TRAZODONE HYDROCHLORIDE 
SAM001246995 1 G07 Tocris Bioscience Prazosin 
SAM001247001 1 H07 Tocris Bioscience URAPIDIL HYDROCHLORIDE 
SAM001247007 1 A08 Tocris Bioscience (-)-Cotinine 
SAM001247014 1 B08 Tocris Bioscience D-CYCLOSERINE 
SAM001246977 1 C08 Tocris Bioscience Fluvoxamine 
SAM001246976 1 D08 Tocris Bioscience Doxepin 
SAM001247046 1 E08 Tocris Bioscience   
SAM001247023 1 F08 Tocris Bioscience 
(+)-3-HYDROXY-N-METHYLMORPHINAN D-
TARTRATE 
SAM001247049 1 G08 Tocris Bioscience L-Ornithine, N5-[imino(methylamino)methyl]-[CAS] 
SAM001246989 1 H08 Tocris Bioscience Maprotilline HCl 
SAM001247038 1 A09 Tocris Bioscience Pizotyline 
SAM001247032 1 B09 Tocris Bioscience BETA-ESTRADIOL 
SAM001247019 1 C09 Tocris Bioscience N,N'-DIACETYL-1,6-DIAMINOHEXANE 
SAM001247024 1 D09 Tocris Bioscience Diphenhydramine hydrochloride 
SAM001246978 1 E09 Tocris Bioscience Galanthamine 
SAM001246980 1 F09 Tocris Bioscience Ifenprodil 
SAM001247028 1 G09 Tocris Bioscience TETRAETHYLTHIURAM DISULFIDE 
SAM001246994 1 H09 Tocris Bioscience Piribedil 
SAM001246983 1 A10 Tocris Bioscience   
SAM001247047 1 B10 Tocris Bioscience TRIPELENNAMINE HYDROCHLORIDE 





SAM001247002 1 D10 Tocris Bioscience 
9-AMINO-1,2,3,4-TETRAHYDROACRIDINE 
HYDROCHLORIDE 
SAM001247008 1 E10 Tocris Bioscience ETHYNYLESTRADIOL 
SAM001247012 1 F10 Tocris Bioscience 
2(1H)-Pyrimidinone, 4-amino-1- ﾃ ｿ -D-arabinofuranosyl- 
[CAS] 
SAM001246985 1 G10 Tocris Bioscience 
L-Glutamic acid, N-[4-[[(2,4-diamino-6-
pteridinyl)methyl]methylamino]benzoyl]- [CAS] 
SAM001247043 1 H10 Tocris Bioscience TFMPP 
SAM001247006 1 A11 Tocris Bioscience Pramipexole 
SAM001247018 1 B11 Tocris Bioscience LIDOCAINE 
SAM001246982 1 C11 Tocris Bioscience Indomethacin 
SAM001246988 1 D11 Tocris Bioscience LY 171883 
SAM001246991 1 E11 Tocris Bioscience Paroxetine 
SAM001247031 1 F11 Tocris Bioscience Epigallocatechin gallate 
SAM001247020 1 G11 Tocris Bioscience 5-Amino-2-hydroxy-benzoic acid 
SAM001247025 1 H11 Tocris Bioscience 
Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, 
ethyl ester- [CAS] 
SAM001246761 2 A02 Sequoia RP Ltd Cephalexin monohydrate 
SAM001246762 2 B02 Sequoia RP Ltd PIDOTIMOD 
SAM001246757 2 C02 Sequoia RP Ltd RAMIPRIL 
SAM001246642 2 D02 Sequoia RP Ltd FENPIVERINIUM BROMIDE 
SAM001246751 2 E02 Sequoia RP Ltd   
SAM001246752 2 F02 Sequoia RP Ltd NIZATIDINE 
SAM001246753 2 G02 Sequoia RP Ltd 5-FLUOROCYTOSINE 
SAM001246754 2 H02 Sequoia RP Ltd Trileptal 
SAM001246756 2 A03 Sequoia RP Ltd TROXIPIDE 
SAM001246647 2 B03 Sequoia RP Ltd ACTARIT 
SAM001246645 2 C03 Sequoia RP Ltd AZELASTINE HCl 
SAM001246759 2 D03 Sequoia RP Ltd TOCAINIDE 
SAM001246760 2 E03 Sequoia RP Ltd TAXIFOLIN-(+/-) 
SAM001246758 2 F03 Sequoia RP Ltd LEVOFLOXACIN 
SAM001246643 2 G03 Sequoia RP Ltd CEFATRIZINE PROPYLENE GLYCOL 
SAM001246700 2 H03 Sequoia RP Ltd IDEBENONE 
SAM001246703 2 A04 Sequoia RP Ltd LEVOSULPIRIDE 
SAM001246706 2 B04 Sequoia RP Ltd Pemoline 
SAM001246649 2 C04 Sequoia RP Ltd LETROZOLE 
SAM001246650 2 D04 Sequoia RP Ltd MEROPENEM 
SAM001246637 2 E04 Sequoia RP Ltd ORLISTAT 
SAM001246631 2 F04 Sequoia RP Ltd   
SAM001246694 2 G04 Sequoia RP Ltd LEVONORGESTREL 
SAM001246695 2 H04 Sequoia RP Ltd CETRAXATE HCl 
SAM001246696 2 A05 Sequoia RP Ltd Alprazolam 
SAM001246697 2 B05 Sequoia RP Ltd LAMOTRIGINE 
SAM001246702 2 C05 Sequoia RP Ltd N-Ethyl-o-crotonotoluidide 
SAM001246699 2 D05 Sequoia RP Ltd AMFEBUTAMONE HCl 
SAM001246638 2 E05 Sequoia RP Ltd ALFUZOSIN 
SAM001246639 2 F05 Sequoia RP Ltd Amisulpride 
SAM001246632 2 G05 Sequoia RP Ltd LOFEPRAMINE 
SAM001246688 2 H05 Sequoia RP Ltd PEROSPIRONE HCl 
SAM001246689 2 A06 Sequoia RP Ltd DOCETAXEL 
SAM001246690 2 B06 Sequoia RP Ltd HONOKIOL 
SAM001246691 2 C06 Sequoia RP Ltd TOLTERODINE TARTRATE 
SAM001246692 2 D06 Sequoia RP Ltd CARMOFUR 
SAM001246633 2 E06 Sequoia RP Ltd PAROXETINE 
Apendix 
 187 
SAM001246634 2 F06 Sequoia RP Ltd OLMESARTAN MEDOXOMIL 
SAM001246635 2 G06 Sequoia RP Ltd LOSARTAN Potassium 
SAM001246636 2 H06 Sequoia RP Ltd TEMOZOLOMIDE 
SAM001246682 2 A07 Sequoia RP Ltd Methyltestosterone 
SAM001246686 2 B07 Sequoia RP Ltd TOSUFLOXACIN TOSYLATE 
SAM001246687 2 C07 Sequoia RP Ltd MECILLINAM 
SAM001246626 2 D07 Sequoia RP Ltd ATOMOXETINE HCl 
SAM001246628 2 E07 Sequoia RP Ltd ARTESUNATE 
SAM001246679 2 F07 Sequoia RP Ltd ITRACONAZOLE 
SAM001246674 2 G07 Sequoia RP Ltd CEFPODOXIME PROXETIL 
SAM001246680 2 H07 Sequoia RP Ltd Buflomedil HCl 
SAM001246614 2 A08 Sequoia RP Ltd 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide 
SAM001246616 2 B08 Sequoia RP Ltd HALOMETASONE MONOHYDRATE 
SAM001246681 2 C08 Sequoia RP Ltd TRICLABENDAZOLE 
SAM001246617 2 D08 Sequoia RP Ltd ROFECOXIB 
SAM001246618 2 E08 Sequoia RP Ltd BISOPROLOL FUMARATE 
SAM001246623 2 F08 Sequoia RP Ltd EZETIMIBE 
SAM001246625 2 G08 Sequoia RP Ltd TIAGABINE HCl 
SAM001246676 2 H08 Sequoia RP Ltd IDARUBICIN HCl 
SAM001246685 2 A09 Sequoia RP Ltd FLUBENDAZOLE 
SAM001246677 2 B09 Sequoia RP Ltd TACROLIMUS 
SAM001246749 2 C09 Sequoia RP Ltd VALACICLOVIR HYDROCHLORIDE 
SAM001246748 2 D09 Sequoia RP Ltd CLARITHROMYCIN 
SAM001246750 2 E09 Sequoia RP Ltd ARIPIPRAZOLE 
SAM001246747 2 F09 Sequoia RP Ltd TRIMEBUTINE MALEATE 
SAM001246746 2 G09 Sequoia RP Ltd Mestanolone 
SAM001246719 2 H09 Sequoia RP Ltd NISOLDIPINE 
SAM001246720 2 A10 Sequoia RP Ltd PICEID 
SAM001246716 2 B10 Sequoia RP Ltd 1-(2-Methyl-5-nitro-imidazol-1-yl)-propan-2-ol 
SAM001246717 2 C10 Sequoia RP Ltd NIFEKALANT HCl 
SAM001246721 2 D10 Sequoia RP Ltd NATEGLINIDE 
SAM001246722 2 E10 Sequoia RP Ltd MEGESTROL ACETATE 
SAM001246728 2 F10 Sequoia RP Ltd ORMETOPRIM 
SAM001246738 2 G10 Sequoia RP Ltd ZILEUTON 
SAM001246729 2 H10 Sequoia RP Ltd STAVUDINE 
SAM001246730 2 A11 Sequoia RP Ltd   
SAM001246724 2 B11 Sequoia RP Ltd OXICONAZOLE NITRATE 
SAM001246731 2 C11 Sequoia RP Ltd KITASAMYCIN 
SAM001246732 2 D11 Sequoia RP Ltd FAMCICLOVIR 
SAM001246725 2 E11 Sequoia RP Ltd   
SAM001246726 2 F11 Sequoia RP Ltd RUFLOXACIN HCl 
SAM001246778 2 G11 Sequoia RP Ltd TAXIFOLIN-(+) 
SAM001246782 2 H11 Sequoia RP Ltd ALOSETRON HCl 
SAM001246723 3 A02 Sequoia RP Ltd BUPROPION HYDROCHLORIDE 
SAM001246718 3 B02 Sequoia RP Ltd IRSOGLADINE MALEATE 
SAM001246733 3 C02 Sequoia RP Ltd ACARBOSE 
SAM001246739 3 D02 Sequoia RP Ltd BENPROPERINE PHOSPHATE 
SAM001246740 3 E02 Sequoia RP Ltd PHENPROBAMATE 
SAM001246743 3 F02 Sequoia RP Ltd MEMANTINE HYDROCHLORIDE 
SAM001246736 3 G02 Sequoia RP Ltd Carvedilol 
SAM001246741 3 H02 Sequoia RP Ltd LOMIFYLLINE 
SAM001246742 3 A03 Sequoia RP Ltd PAZUFLOXACIN 
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SAM001246745 3 B03 Sequoia RP Ltd MIGLITOL 
SAM001246737 3 C03 Sequoia RP Ltd TRANILAST 
SAM001246652 3 D03 Sequoia RP Ltd OLANZAPINE 
SAM001246653 3 E03 Sequoia RP Ltd Nefazodone 
SAM001246654 3 F03 Sequoia RP Ltd MOXIFLOXACIN HCl 
SAM001246655 3 G03 Sequoia RP Ltd NELFINAVIR MESYLATE 
SAM001246656 3 H03 Sequoia RP Ltd PRAVASTATIN Sodium 
SAM001246651 3 A04 Sequoia RP Ltd TOPOTECAN HCL 
SAM001246539 3 B04 Sequoia RP Ltd LEVETIRACETAM 
SAM001246540 3 C04 Sequoia RP Ltd PRAMIPEXOLE HCl 
SAM001246595 3 D04 Sequoia RP Ltd RISPERIDONE 
SAM001246600 3 E04 Sequoia RP Ltd PIOGLITAZONE HCl 
SAM001246552 3 F04 Sequoia RP Ltd CILASTATIN Na 
SAM001246661 3 G04 Sequoia RP Ltd ARGATROBAN 
SAM001246603 3 H04 Sequoia RP Ltd VALDECOXIB 
SAM001246658 3 A05 Sequoia RP Ltd NAFTOPIDIL 
SAM001246662 3 B05 Sequoia RP Ltd Nobiletin 
SAM001246541 3 C05 Sequoia RP Ltd FINASTERIDE 
SAM001246549 3 D05 Sequoia RP Ltd ZOLPIDEM TARTRATE 
SAM001246551 3 E05 Sequoia RP Ltd Viramune 
SAM001246601 3 F05 Sequoia RP Ltd TOPIRAMATE 
SAM001246664 3 G05 Sequoia RP Ltd VORICONAZOLE 
SAM001246665 3 H05 Sequoia RP Ltd FENOLDOPAM MESYLATE 
SAM001246610 3 A06 Sequoia RP Ltd ROSIGLITAZONE MALEATE 
SAM001246668 3 B06 Sequoia RP Ltd ESCITALOPRAM OXALATE 
SAM001246609 3 C06 Sequoia RP Ltd ZERANOL 
SAM001246671 3 D06 Sequoia RP Ltd LATANOPROST 
SAM001246673 3 E06 Sequoia RP Ltd 2',3'-DIDEOXYINOSINE 
SAM001246666 3 F06 Sequoia RP Ltd Sertraline 
SAM001246670 3 G06 Sequoia RP Ltd CALCIPOTRIOL 
SAM001246559 3 H06 Sequoia RP Ltd EPIRUBICIN HYDROCHLORIDE 
SAM001246612 3 A07 Sequoia RP Ltd BICALUTAMIDE 
SAM001246672 3 B07 Sequoia RP Ltd BENIDIPINE HCl 
SAM001246669 3 C07 Sequoia RP Ltd AMLEXANOX 
SAM001246554 3 D07 Sequoia RP Ltd CERIVASTATIN Na 
SAM001246560 3 E07 Sequoia RP Ltd ICARIIN 
SAM001246562 3 F07 Sequoia RP Ltd METHYLANDROSTENEDIOL 
SAM001246553 3 G07 Sequoia RP Ltd TRIPTOLIDE 
SAM001246608 3 H07 Sequoia RP Ltd ROSIGLITAZONE HCl 
SAM001246561 3 A08 Sequoia RP Ltd FTORAFUR 
SAM001246769 3 B08 Sequoia RP Ltd OLIGOMYCIN C 
SAM001246712 3 C08 Sequoia RP Ltd BENAZEPRIL HCl 
SAM001246765 3 D08 Sequoia RP Ltd Oxymetholone 
SAM001246714 3 E08 Sequoia RP Ltd IPRIFLAVONE 
SAM001246770 3 F08 Sequoia RP Ltd OXAPROZIN 
SAM001246766 3 G08 Sequoia RP Ltd ROLIPRAM 
SAM001246713 3 H08 Sequoia RP Ltd MOSAPRIDE CITRATE 
SAM001246767 3 A09 Sequoia RP Ltd Isoquercitrin 
SAM001246763 3 B09 Sequoia RP Ltd FLUMAZENIL 
SAM001246593 3 C09 Sequoia RP Ltd   
SAM001246776 3 D09 Sequoia RP Ltd HYPEROSIDE 
SAM001246589 3 E09 Sequoia RP Ltd RIFABUTIN 
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SAM001246533 3 F09 Sequoia RP Ltd ESMOLOL HYDROCHLORIDE 
SAM001246586 3 G09 Sequoia RP Ltd TADALAFIL 
SAM001246587 3 H09 Sequoia RP Ltd Modafinil 
SAM001246768 3 A10 Sequoia RP Ltd DOXORUBICIN HYDROCHLORIDE 
SAM001246764 3 B10 Sequoia RP Ltd MOXONIDINE HCl 
SAM001246711 3 C10 Sequoia RP Ltd Nitrazepam 
SAM001246571 3 D10 Sequoia RP Ltd PEFLOXACIN MESYLATE 
SAM001246572 3 E10 Sequoia RP Ltd VENLAFAXINE HCl 
SAM001246591 3 F10 Sequoia RP Ltd PANTOPRAZOLE SODIUM SALT 
SAM001246583 3 G10 Sequoia RP Ltd FLUTICASONE PROPIONATE 
SAM001246588 3 H10 Sequoia RP Ltd INDINAVIR SULPHATE 
SAM001246585 3 A11 Sequoia RP Ltd MIDAZOLAM HCl 
SAM001246582 3 B11 Sequoia RP Ltd LAMIVUDINE 
SAM001246564 3 C11 Sequoia RP Ltd PROCARBAZINE HYDROCHLORIDE 
SAM001246538 3 D11 Sequoia RP Ltd ESOMEPRAZOLE Mg 
SAM001246530 3 E11 Sequoia RP Ltd SULFASALAZINE 
SAM001246567 3 F11 Sequoia RP Ltd TORASEMIDE 
SAM001246576 3 G11 Sequoia RP Ltd TROPISETRON HCl 
SAM001246534 3 H11 Sequoia RP Ltd Ranolazine dihydrochloride 
SAM001246531 4 A02 Sequoia RP Ltd NITRENDIPINE 
SAM001246578 4 B02 Sequoia RP Ltd SAQUINAVIR MESYLATE 
SAM001246775 4 C02 Sequoia RP Ltd BIFONAZOLE 
SAM001246579 4 D02 Sequoia RP Ltd SUMATRIPTAN SUCCINATE 
SAM001246574 4 E02 Sequoia RP Ltd EXEMESTANE 
SAM001246708 4 F02 Sequoia RP Ltd NITAZOXANIDE 
SAM001246536 4 G02 Sequoia RP Ltd Diazepam 
SAM001246777 4 H02 Sequoia RP Ltd QUETIAPINE HEMIFUMARATE 
SAM001246528 4 A03 Sequoia RP Ltd RUTIN 
SAM001246580 4 B03 Sequoia RP Ltd PENCICLOVIR 
SAM001246772 4 C03 Sequoia RP Ltd CALCITRIOL 
SAM001246532 4 D03 Sequoia RP Ltd DIPHENOXYLATE 
SAM001247005 4 E03 Tocris Bioscience Felbamate 
SAM001247013 4 F03 Tocris Bioscience DROPERIDOL 
SAM001247011 4 G03 Tocris Bioscience Pentoxifylline 
SAM001246596 4 H03 Sequoia RP Ltd   
SAM001246783 4 A04 Sequoia RP Ltd RITONAVIR 
SAM001246780 4 B04 Sequoia RP Ltd VINORELBINE BITATRATE 
SAM001246624 4 C04 Sequoia RP Ltd LINEZOLID 
SAM001246727 4 D04 Sequoia RP Ltd LOMERIZINE DiHCl 
SAM001246667 4 E04 Sequoia RP Ltd EFAVIRENZ 
SAM001246548 4 F04 Sequoia RP Ltd IRBESARTAN 
SAM001246546 4 G04 Sequoia RP Ltd REPAGLINIDE 
SAM001246555 4 H04 Sequoia RP Ltd Ethylestrenol 
SAM001246605 4 A05 Sequoia RP Ltd PTEROSTILBENE 
SAM001246547 4 B05 Sequoia RP Ltd ROXATIDINE ACETATE HCl 
SAM001246556 4 C05 Sequoia RP Ltd DEXBROMPHENIRAMINE MALEATE 
SAM001246604 4 D05 Sequoia RP Ltd ANAGRELIDE HCl 
SAM001246606 4 E05 Sequoia RP Ltd TEGASEROD MALEATE 
SAM001246611 4 F05 Sequoia RP Ltd MILRINONE 
SAM001246575 4 G05 Sequoia RP Ltd LEVOCETIRIZINE 
SAM001246599 4 H05 Sequoia RP Ltd   
SAM001246558 4 A06 Sequoia RP Ltd TICLOPIDINE HCl 
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SAM001246594 4 B06 Sequoia RP Ltd LOXOPROFEN SODIUM 
SAM001246577 4 C06 Sequoia RP Ltd ZAFIRLUKAST 
SAM001246565 4 D06 Sequoia RP Ltd TERBINAFINE HCl 
SAM001246584 4 E06 Sequoia RP Ltd ISRADIPINE 
SAM001246581 4 F06 Sequoia RP Ltd VALSARTAN 
SAM001247048 4 G06 Tocris Bioscience Piroxicam 
SAM001246629 4 H06 Sequoia RP Ltd Glycopyrrolate 
SAM001246992 4 A07 Tocris Bioscience Physostigmine 
SAM001247050 4 B07 Tocris Bioscience LOBELINE HYDROCHLORIDE 
SAM001247030 4 C07 Tocris Bioscience Doxylamine succinate salt 
SAM001247035 4 D07 Tocris Bioscience Milnacipran 
SAM001247017 4 E07 Tocris Bioscience 5-fluoro-2-pyrimidone 
SAM001247022 4 F07 Tocris Bioscience Chlorpheniramine 
SAM001246621 4 G07 Sequoia RP Ltd DOFETILIDE 
SAM001246675 4 H07 Sequoia RP Ltd FORMOTEROL FUMARATE DIHYDRATE 
SAM001246615 4 A08 Sequoia RP Ltd RIZATRIPTAN BENZOATE 
SAM001246620 4 B08 Sequoia RP Ltd RIFAPENTINE 
SAM001246630 4 C08 Sequoia RP Ltd LOTEPREDNOL ETABONATE 
SAM001246684 4 D08 Sequoia RP Ltd ENALAPRILAT 
SAM001246627 4 E08 Sequoia RP Ltd Donepezil 
SAM001246755 4 F08 Sequoia RP Ltd Nimetazepam 
SAM001246701 4 G08 Sequoia RP Ltd   
SAM001246602 4 H08 Sequoia RP Ltd TELMISARTAN 
SAM001246542 4 A09 Sequoia RP Ltd ITOPRIDE HCl 
SAM001246597 4 B09 Sequoia RP Ltd RIFAXIMIN 
SAM001246657 4 C09 Sequoia RP Ltd MONTELUKAST Na 
SAM001246779 4 D09 Sequoia RP Ltd 2',3'-DIDEOXYCYTIDINE 
SAM001247073 4 E09 Tocris Bioscience 
1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-
dihydro- [CAS] 








SAM001247074 4 H09 Tocris Bioscience 
1H-Imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl 
ester, (R)- [CAS] 
SAM001247078 4 A10 Tocris Bioscience 
Acetamide, 2-amino-N-(1-methyl-1,2-diphenylethyl)-, (+/-
)- [CAS] 
SAM001247080 4 B10 Tocris Bioscience Altanserin 
SAM001247084 4 C10 Tocris Bioscience   
SAM001246563 4 D10 Sequoia RP Ltd   
SAM001247082 4 E10 Tocris Bioscience Azasetron 
SAM001247087 4 F10 Tocris Bioscience GR 89696 
SAM001246897 4 G10 Sigma CC 
DELTA1-HYDROCORTISONE 21-HEMISUCCINATE 
SODIUM SALT 
SAM001246872 4 H10 Sigma CC DIAZOXIDE 
SAM001246886 4 A11 Sigma CC 2-CHLOROADENOSINE 
SAM001246873 4 B11 Sigma CC ORNIDAZOLE 
SAM001246914 4 C11 Sigma CC 1,1-DIMETHYL-4-PHENYLPIPERAZINIUM IODIDE 
SAM001246893 4 D11 Sigma CC PIRENPERONE 
SAM001246866 4 E11 Sigma CC MESTRANOL 
SAM001246867 4 F11 Sigma CC 2-(2-AMINOETHYL)PYRIDINE 
SAM001246868 4 G11 Sigma CC BENACTYZINE HYDROCHLORIDE 
SAM001246870 4 H11 Sigma CC DICHLOROACETIC ACID 
SAM001246806 5 A02 Sequoia RP Ltd BESTATIN 
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SAM001246774 5 B02 Sequoia RP Ltd TOREMIFENE CITRATE 
SAM001246784 5 C02 Sequoia RP Ltd GOSERELIN ACETATE 
SAM001246678 5 D02 Sequoia RP Ltd SECOISOLARICIRESINOL 
SAM001246796 5 E02 Sequoia RP Ltd RALTITREXED 
SAM001246792 5 F02 Sequoia RP Ltd DOXAPRAM HYDROCHLORIDE 
SAM001247095 5 G02 Tocris Bioscience RU 24969 
SAM001246865 5 H02 Sigma CC Brucine 
SAM001246862 5 A03 Sigma CC TRYPTOLINE 
SAM001246863 5 B03 Sigma CC   
SAM001246791 5 C03 Sequoia RP Ltd PALONOSETRON HCl 
SAM001246874 5 D03 Sigma CC NAPROXEN SODIUM 
SAM001246875 5 E03 Sigma CC MEPIVACAINE HYDROCHLORIDE 
SAM001246877 5 F03 Sigma CC 
3-[3,5-DIBROMO-4-HYDROXYBENZOYL]-2-
ETHYLBENZOFURAN 
SAM001246890 5 G03 Sigma CC NIMODIPINE 
SAM001246892 5 H03 Sigma CC ROLITETRACYCLINE 
SAM001246891 5 A04 Sigma CC MEPIRIZOLE 
SAM001246876 5 B04 Sigma CC 6-AZAURIDINE 
SAM001246889 5 C04 Sigma CC  
SAM001246894 5 D04 Sigma CC 3-PYRIDINEMETHANOL 
SAM001246979 5 E04 Tocris Bioscience Haloperidol 
SAM001247042 5 F04 Tocris Bioscience Stiripentol 
SAM001247034 5 G04 Tocris Bioscience Fluperlapine 
SAM001246887 5 H04 Sigma CC OXYPHENONIUM BROMIDE 
SAM001246869 5 A05 Sigma CC Homoveratrylamine 
SAM001246913 5 B05 Sigma CC TINIDAZOLE 
SAM001246912 5 C05 Sigma CC XANTHINOL NICOTINATE 
SAM001246896 5 D05 Sigma CC SYNEPHRINE 
SAM001246888 5 E05 Sigma CC Resveratrol 
SAM001246871 5 F05 Sigma CC 3-Hydroxy-2-methyl-4-pyrone 
SAM001246854 5 G05 Sigma CC 6-AMINOINDAZOLE 
SAM001246856 5 H05 Sigma CC ENROFLOXACIN 
SAM001246857 5 A06 Sigma CC DEHYDROCHOLIC ACID 
SAM001246884 5 B06 Sigma CC CEFACLOR 
SAM001246858 5 C06 Sigma CC 1-BENZYLIMIDAZOLE 
SAM001246523 5 D06 Sequoia RP Ltd DULOXETINE HCl 
SAM001246573 5 E06 Sequoia RP Ltd VARDENAFIL CITRATE 
SAM001246524 5 F06 Sequoia RP Ltd ROPIVACAINE HCl 
SAM001246525 5 G06 Sequoia RP Ltd ANASTROZOLE 
SAM001246984 5 H06 Tocris Bioscience KETOTIFEN FUMARATE 
SAM001246906 5 A07 Sigma CC MEDROXYPROGESTERONE 
SAM001246907 5 B07 Sigma CC Pinacidil monohydrate 
SAM001246908 5 C07 Sigma CC 7-NITROINDAZOLE 
SAM001246909 5 D07 Sigma CC 5-Methoxytryptamine 
SAM001246855 5 E07 Sigma CC PHENOTHIAZINE 
SAM001246526 5 F07 Sequoia RP Ltd 2-CHLORO-2'-DEOXYADENOSINE 
SAM001246527 5 G07 Sequoia RP Ltd GRANISETRON HCl 
SAM001247094 5 H07 Tocris Bioscience Rimcazole 
SAM001247092 5 A08 Tocris Bioscience Nafadotride 
SAM001246885 5 B08 Sigma CC DESOXIMETASONE 
SAM001246557 5 C08 Sequoia RP Ltd DEXCHLORPHENIRAMINE MALEATE 





SAM001247090 5 E08 Tocris Bioscience L-694,247 
SAM001247081 5 F08 Tocris Bioscience AM-251 
SAM001247089 5 G08 Tocris Bioscience HTMT 
SAM001247083 5 H08 Tocris Bioscience 
Benzo[a]phenanthridine-10,11-diol, 5,6,6a,7,8,12b-
hexahydro-, trans- [CAS] 




SAM001247076 5 B09 Tocris Bioscience 
2H-Indol-2-one, 1,3-dihydro-1-phenyl-3,3-bis(4-
pyridinylmethyl)- [CAS] 
SAM001246898 5 C09 Sigma CC Beclomethasone 
SAM001246900 5 D09 Sigma CC OMEPRAZOLE 
SAM001246842 5 E09 Sequoia RP Ltd DOLASETRON MESYLATE 
SAM001246841 5 F09 Sequoia RP Ltd Zolmitriptan 
SAM001246852 5 G09 Sequoia RP Ltd TREMULACIN 
SAM001246846 5 H09 Sequoia RP Ltd DACTINOMYCIN 
SAM001246847 5 A10 Sequoia RP Ltd Tramadol 
SAM001246815 5 B10 Sequoia RP Ltd CHLORDIAZEPOXIDE 
SAM001246816 5 C10 Sequoia RP Ltd CEFIXIME TRIHYDRATE 
SAM001246818 5 D10 Sequoia RP Ltd CEFDINIR 
SAM001246820 5 E10 Sequoia RP Ltd LOFEXIDINE HCl 
SAM001246804 5 F10 Sequoia RP Ltd BALSALAZIDE 
SAM001246802 5 G10 Sequoia RP Ltd OLOPATADINE HCl 
SAM001246803 5 H10 Sequoia RP Ltd ITAVASTATIN Ca 
SAM001246882 5 A11 Sigma CC CORTISONE 
SAM001246883 5 B11 Sigma CC   
SAM001246822 5 C11 Sequoia RP Ltd HOMOHARRINGTONINE 
SAM001246879 5 D11 Sigma CC CORTICOSTERONE 
SAM001246821 5 E11 Sequoia RP Ltd VECURONIUM BROMIDE 
SAM001246801 5 F11 Sequoia RP Ltd TIBOLONE 
SAM001246860 5 G11 Sigma CC NICOTINAMIDE 
SAM001246861 5 H11 Sigma CC NIALAMIDE 
SAM001246568 6 A02 Sequoia RP Ltd VINDESINE SULFATE 
SAM001246570 6 B02 Sequoia RP Ltd VINCRISTINE SULFATE 
SAM001246648 6 C02 Sequoia RP Ltd LACIDIPINE 
SAM001246659 6 D02 Sequoia RP Ltd MIRTAZAPINE 
SAM001246707 6 E02 Sequoia RP Ltd AMPIROXICAM 
SAM001246710 6 F02 Sequoia RP Ltd GLIMEPIRIDE 
SAM001246705 6 G02 Sequoia RP Ltd AMLODIPINE BASE 
SAM001246619 6 H02 Sequoia RP Ltd RABEPRAZOLE 
SAM001246878 6 A03 Sigma CC CLOFAZIMINE 
SAM001246598 6 B03 Sequoia RP Ltd IRINOTECAN HCl )trihydrate) 
SAM001246544 6 C03 Sequoia RP Ltd LANSOPRAZOLE 
SAM001246545 6 D03 Sequoia RP Ltd 
8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-
benzo[5,6]cyclohepta[1,2-b]pyridine 
SAM001246904 6 E03 Sigma CC 
1,3,5(10)-ESTRATRIEN-3-OL-17-ONE SULPHATE, 
SODIUM SALT 
SAM001246881 6 F03 Sigma CC MIFEPRISTONE 
SAM001246880 6 G03 Sigma CC   
SAM001247105 6 H03 Tocris Bioscience Sibutramine 
SAM001247107 6 A04 Tocris Bioscience Clobenpropit 
SAM001246851 6 B04 Sequoia RP Ltd HUPERZINE A 
SAM001246592 6 C04 Sequoia RP Ltd SIBUTRAMINE HCl 
SAM001246833 6 D04 Sequoia RP Ltd Lorazepam 






SAM001247106 6 F04 Tocris Bioscience Adenosine, N-(2-hydroxycyclopentyl)-, (1S-trans)- [CAS] 
SAM001246646 6 G04 Sequoia RP Ltd AMIODARONE HYDROCHLORIDE 
SAM001246644 6 H04 Sequoia RP Ltd mevastatin 
SAM001246622 6 A05 Sequoia RP Ltd IMATINIB MESYLATE 
SAM001247102 6 B05 Tocris Bioscience Metylperon 
SAM001246773 6 C05 Sequoia RP Ltd PARECOXIB Na 
SAM001247070 6 D05 Tocris Bioscience   
SAM001246793 6 E05 Sequoia RP Ltd ATRACURIUM BESYLATE 
SAM001246799 6 F05 Sequoia RP Ltd ARTEMETHER 
SAM001247071 6 G05 Tocris Bioscience EBSELEN 
SAM001247066 6 H05 Tocris Bioscience CGS 12066B 
SAM001246805 6 A06 Sequoia RP Ltd TELITHROMYCIN 
SAM001247065 6 B06 Tocris Bioscience CCPA 
SAM001247067 6 C06 Tocris Bioscience PD 81723 
SAM001246590 6 D06 Sequoia RP Ltd Stanozolol 
SAM001246641 6 E06 Sequoia RP Ltd Zaleplon 
SAM001246840 6 F06 Sequoia RP Ltd Prostaglandin E1 
SAM001246921 6 G06 Tocris Bioscience Testosterone 
SAM001246922 6 H06 Tocris Bioscience DEHYDROEPIANDROSTERONE 
SAM001247099 6 A07 Tocris Bioscience SDM25N 
SAM001247101 6 B07 Tocris Bioscience 
Thiophene, 5-bromo-2-(4-fluorophenyl)-3-[4-
(methylsulfonyl)phenyl]- [CAS] 
SAM001247103 6 C07 Tocris Bioscience 5-Nonyloxytryptamine 
SAM001247096 6 D07 Tocris Bioscience Salmeterol 
SAM001247097 6 E07 Tocris Bioscience SB 205607 
SAM001247098 6 F07 Tocris Bioscience R(+)-SCH-23390 hydrochloride 




Abigerges, D., Chabot, G.G., Armand, J.P., Hérait, P., Gouyette, A., and Gandia, D., 1995, 
Phase I and pharmacologic studies of the camptothecin analog irinotecan 
administered every 3 weeks in cancer patients: Journal of clinical oncology: official 
journal of the American Society of Clinical Oncology, v. 13, no. 1, p. 210–221. 
Adlkofer, K., and Lai, C., 2000, Role of neuregulins in glial cell development: Glia, v. 29, no. 2, 
p. 104–111. 
Akbarian, S., Kim, J.J., Potkin, S.G., Hagman, J.O., Tafazzoli, A., Bunney, W.E., Jr, and 
Jones, E.G., 1995, Gene expression for glutamic acid decarboxylase is reduced 
without loss of neurons in prefrontal cortex of schizophrenics: Archives of general 
psychiatry, v. 52, no. 4, p. 258–266. 
Aleman, A., Kahn, R.S., and Selten, J.-P., 2003, Sex differences in the risk of schizophrenia: 
evidence from meta-analysis: Archives of general psychiatry, v. 60, no. 6, p. 565–571, 
doi: 10.1001/archpsyc.60.6.565. 
Alimonti, A., Gelibter, A., Pavese, I., Satta, F., Cognetti, F., Ferretti, G., Rasio, D., Vecchione, 
A., and Di Palma, M., 2004, New approaches to prevent intestinal toxicity of 
irinotecan-based regimens: Cancer treatment reviews, v. 30, no. 6, p. 555–562, doi: 
10.1016/j.ctrv.2004.05.002. 
Allen, N.C., Bagade, S., McQueen, M.B., Ioannidis, J.P.A., Kavvoura, F.K., Khoury, M.J., 
Tanzi, R.E., and Bertram, L., 2008, Systematic meta-analyses and field synopsis of 
genetic association studies in schizophrenia: the SzGene database: Nature genetics, 
v. 40, no. 7, p. 827–834, doi: 10.1038/ng.171. 
Allen, R.M., and Young, S.J., 1978, Phencyclidine-induced psychosis: The American journal 
of psychiatry, v. 135, no. 9, p. 1081–1084. 
Arkin, M.R., and Wells, J.A., 2004, Small-molecule inhibitors of protein–protein interactions: 
progressing towards the dream: Nature Reviews Drug Discovery, v. 3, no. 4, p. 301–
317, doi: 10.1038/nrd1343. 
Arnold, S.E., and Trojanowski, J.Q., 1996, Recent advances in defining the neuropathology of 
schizophrenia: Acta neuropathologica, v. 92, no. 3, p. 217–231. 
Arnt, J., 1998, Pharmacological differentiation of classical and novel antipsychotics: 
International clinical psychopharmacology, v. 13 Suppl 3, p. S7–14. 
Auger, K.R., Serunian, L.A., Soltoff, S.P., Libby, P., and Cantley, L.C., 1989, PDGF-
dependent tyrosine phosphorylation stimulates production of novel 
polyphosphoinositides in intact cells: Cell, v. 57, no. 1, p. 167–175. 
Ayhan, Y., Sawa, A., Ross, C.A., and Pletnikov, M.V., 2009, Animal models of gene-
environment interactions in schizophrenia: Behavioural brain research, v. 204, no. 2, 
p. 274–281, doi: 10.1016/j.bbr.2009.04.010. 
Literature 
 195 
Barr, M.S., Farzan, F., Tran, L.C., Chen, R., Fitzgerald, P.B., and Daskalakis, Z.J., 2010, 
Evidence for excessive frontal evoked gamma oscillatory activity in schizophrenia 
during working memory: Schizophrenia research, v. 121, no. 1-3, p. 146–152, doi: 
10.1016/j.schres.2010.05.023. 
de Bartolomeis, A., Sarappa, C., Magara, S., and Iasevoli, F., 2012, Targeting glutamate 
system for novel antipsychotic approaches: relevance for residual psychotic 
symptoms and treatment resistant schizophrenia: European journal of pharmacology, 
v. 682, no. 1-3, p. 1–11, doi: 10.1016/j.ejphar.2012.02.033. 
Bayer, T.A., Falkai, P., and Maier, W., 1999, Genetic and non-genetic vulnerability factors in 
schizophrenia: the basis of the “two hit hypothesis:” Journal of psychiatric research, v. 
33, no. 6, p. 543–548. 
Becker, V., 2005, [Rokitansky and Virchow: throes about the scientific term of disease]: 
Wiener medizinische Wochenschrift (1946), v. 155, no. 19-20, p. 463–467, doi: 
10.1007/s10354-005-0217-x. 
Belforte, J.E., Zsiros, V., Sklar, E.R., Jiang, Z., Yu, G., Li, Y., Quinlan, E.M., and Nakazawa, 
K., 2010, Postnatal NMDA receptor ablation in corticolimbic interneurons confers 
schizophrenia-like phenotypes: Nature neuroscience, v. 13, no. 1, p. 76–83, doi: 
10.1038/nn.2447. 
Berganza, C.E., Mezzich, J.E., and Pouncey, C., 2005, Concepts of disease: their relevance 
for psychiatric diagnosis and classification: Psychopathology, v. 38, no. 4, p. 166–170, 
doi: 10.1159/000086084. 
Bertani, G., 1951, Studies on lysogenesis. I. The mode of phage liberation by lysogenic 
Escherichia coli: Journal of bacteriology, v. 62, no. 3, p. 293–300. 
Bian, S.-Z., Zhang, J., Liu, W.-L., Sun, Z.-H., Gu, Z.-L., and Jiang, X.-G., 2009, [Receptor 
antagonist of NMDA and animal models of schizophrenia]: Fa yi xue za zhi, v. 25, no. 
6, p. 443–446. 
Biedermann, F., and Fleischhacker, W.W., 2009, Antipsychotics in the early stage of 
development: Current opinion in psychiatry, v. 22, no. 3, p. 326–330, doi: 
10.1097/YCO.0b013e328329cd73. 
Birnboim, H.C., and Doly, J., 1979, A rapid alkaline extraction procedure for screening 
recombinant plasmid DNA: Nucleic acids research, v. 7, no. 6, p. 1513–1523. 
Bjarnadottir, M., Misner, D.L., Haverfield-Gross, S., Bruun, S., Helgason, V.G., Stefansson, H., 
Sigmundsson, A., Firth, D.R., Nielsen, B., Stefansdottir, R., Novak, T.J., Stefansson, 
K., Gurney, M.E., and Andresson, T., 2007, Neuregulin1 (NRG1) signaling through 
Fyn modulates NMDA receptor phosphorylation: differential synaptic function in 
NRG1+/- knock-outs compared with wild-type mice: The Journal of neuroscience: the 
official journal of the Society for Neuroscience, v. 27, no. 17, p. 4519–4529, doi: 
10.1523/JNEUROSCI.4314-06.2007. 
Borasio, G.D., 1990, Differential effects of the protein kinase inhibitor K-252a on the in vitro 




Botvinnik, A., Wichert, S.P., Fischer, T.M., and Rossner, M.J., 2010, Integrated analysis of 
receptor activation and downstream signaling with EXTassays: Nature methods, v. 7, 
no. 1, p. 74–80, doi: 10.1038/nmeth.1407. 
Boute, N., Jockers, R., and Issad, T., 2002, The use of resonance energy transfer in high-
throughput screening: BRET versus FRET: Trends in pharmacological sciences, v. 
23, no. 8, p. 351–354. 
Braun, I., Genius, J., Grunze, H., Bender, A., Möller, H.-J., and Rujescu, D., 2007, Alterations 
of hippocampal and prefrontal GABAergic interneurons in an animal model of 
psychosis induced by NMDA receptor antagonism: Schizophrenia research, v. 97, no. 
1-3, p. 254–263, doi: 10.1016/j.schres.2007.05.005. 
Brennand, K.J., and Gage, F.H., 2011, Concise review: the promise of human induced 
pluripotent stem cell-based studies of schizophrenia: Stem cells (Dayton, Ohio), v. 29, 
no. 12, p. 1915–1922, doi: 10.1002/stem.762. 
Brennand, K.J., and Gage, F.H., 2012, Modeling psychiatric disorders through 
reprogramming: Disease models & mechanisms, v. 5, no. 1, p. 26–32, doi: 
10.1242/dmm.008268. 
Brennand, K.J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N., Sangar, S., Li, Y., Mu, Y., 
Chen, G., Yu, D., McCarthy, S., Sebat, J., and Gage, F.H., 2011, Modelling 
schizophrenia using human induced pluripotent stem cells: Nature, v. 473, no. 7346, 
p. 221–225, doi: 10.1038/nature09915. 
Brewster, U.C., and Perazella, M.A., 2004, The renin-angiotensin-aldosterone system and the 
kidney: effects on kidney disease: The American journal of medicine, v. 116, no. 4, p. 
263–272, doi: 10.1016/j.amjmed.2003.09.034. 
Brinkmann, B.G., Agarwal, A., Sereda, M.W., Garratt, A.N., Müller, T., Wende, H., Stassart, 
R.M., Nawaz, S., Humml, C., Velanac, V., Radyushkin, K., Goebbels, S., Fischer, 
T.M., Franklin, R.J., et al., 2008, Neuregulin-1/ErbB signaling serves distinct functions 
in myelination of the peripheral and central nervous system: Neuron, v. 59, no. 4, p. 
581–595, doi: 10.1016/j.neuron.2008.06.028. 
Brockes, J.P., Lemke, G.E., and Balzer, D.R., Jr, 1980, Purification and preliminary 
characterization of a glial growth factor from the bovine pituitary: The Journal of 
biological chemistry, v. 255, no. 18, p. 8374–8377. 
Buonanno, A., 2010, The neuregulin signaling pathway and schizophrenia: from genes to 
synapses and neural circuits: Brain research bulletin, v. 83, no. 3-4, p. 122–131, doi: 
10.1016/j.brainresbull.2010.07.012. 
Burgess, A.W., Cho, H.-S., Eigenbrot, C., Ferguson, K.M., Garrett, T.P.J., Leahy, D.J., 
Lemmon, M.A., Sliwkowski, M.X., Ward, C.W., and Yokoyama, S., 2003, An open-
and-shut case? Recent insights into the activation of EGF/ErbB receptors: Molecular 
cell, v. 12, no. 3, p. 541–552. 
Cantor-Graae, E., and Selten, J.-P., 2005, Schizophrenia and migration: a meta-analysis and 




Capdevila-Nortes, X., López-Hernández, T., Ciruela, F., and Estévez, R., 2012, A 
modification of the split-tobacco etch virus method for monitoring interactions 
between membrane proteins in mammalian cells: Analytical biochemistry, v. 423, no. 
1, p. 109–118, doi: 10.1016/j.ab.2012.01.022. 
Carlén, M., Meletis, K., Siegle, J.H., Cardin, J.A., Futai, K., Vierling-Claassen, D., Rühlmann, 
C., Jones, S.R., Deisseroth, K., Sheng, M., Moore, C.I., and Tsai, L.-H., 2012, A 
critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm 
induction and behavior: Molecular psychiatry, v. 17, no. 5, p. 537–548, doi: 
10.1038/mp.2011.31. 
Carlsson, A., Waters, N., and Carlsson, M.L., 1999, Neurotransmitter interactions in 
schizophrenia-therapeutic implications: European archives of psychiatry and clinical 
neuroscience, v. 249 Suppl 4, p. 37–43. 
Carol, H., Houghton, P.J., Morton, C.L., Kolb, E.A., Gorlick, R., Reynolds, C.P., Kang, M.H., 
Maris, J.M., Keir, S.T., Watkins, A., Smith, M.A., and Lock, R.B., 2010, Initial Testing 
of Topotecan by the Pediatric Preclinical Testing Program: Pediatric blood & cancer, 
v. 54, no. 5, p. 707–715, doi: 10.1002/pbc.22352. 
Carpenter, G., 2003, ErbB-4: mechanism of action and biology: Experimental cell research, v. 
284, no. 1, p. 66–77. 
Carraway, K.L., 3rd, Sliwkowski, M.X., Akita, R., Platko, J.V., Guy, P.M., Nuijens, A., Diamonti, 
A.J., Vandlen, R.L., Cantley, L.C., and Cerione, R.A., 1994, The erbB3 gene product 
is a receptor for heregulin: The Journal of biological chemistry, v. 269, no. 19, p. 
14303–14306. 
Castoldi, R., Jucknischke, U., Pradel, L.P., Arnold, E., Klein, C., Scheiblich, S., Niederfellner, 
G., and Sustmann, C., 2012, Molecular characterization of novel trispecific ErbB-
cMet-IGF1R antibodies and their antigen-binding properties: Protein Engineering 
Design and Selection,, doi: 10.1093/protein/gzs048. 
Chen, Y.-J.J., Johnson, M.A., Lieberman, M.D., Goodchild, R.E., Schobel, S., Lewandowski, 
N., Rosoklija, G., Liu, R.-C., Gingrich, J.A., Small, S., Moore, H., Dwork, A.J., 
Talmage, D.A., and Role, L.W., 2008, Type III neuregulin-1 is required for normal 
sensorimotor gating, memory-related behaviors, and corticostriatal circuit 
components: The Journal of neuroscience: the official journal of the Society for 
Neuroscience, v. 28, no. 27, p. 6872–6883, doi: 10.1523/JNEUROSCI.1815-08.2008. 
Chen, S.-K., Tvrdik, P., Peden, E., Cho, S., Wu, S., Spangrude, G., and Capecchi, M.R., 
2010, Hematopoietic origin of pathological grooming in Hoxb8 mutant mice: Cell, v. 
141, no. 5, p. 775–785, doi: 10.1016/j.cell.2010.03.055. 
Cheng, K.C.-C., and Inglese, J., 2012, A coincidence reporter-gene system for high-
throughput screening: Nature methods, v. 9, no. 10, p. 937, doi: 10.1038/nmeth.2170. 
Clower, W.T., and Finger, S., 2001, Discovering trepanation: the contribution of Paul Broca: 
Neurosurgery, v. 49, no. 6, p. 1417–1425; discussion 1425–1426. 
Davis, K.L., Kahn, R.S., Ko, G., and Davidson, M., 1991, Dopamine in schizophrenia: a 




Desbonnet, L.,  addington, J.L., and O’Tuathaigh, C.M.P., 2009, Mutant models for genes 
associated with schizophrenia: Biochemical Society transactions, v. 37, no. Pt 1, p. 
308–312, doi: 10.1042/BST0370308. 
Djannatian, M.S., Galinski, S., Fischer, T.M., and Rossner, M.J., 2011, Studying G protein-
coupled receptor activation using split-tobacco etch virus assays: Analytical 
biochemistry, v. 412, no. 2, p. 141–152, doi: 10.1016/j.ab.2011.01.042. 
Eaton, W.W., Hall, A.L.F., Macdonald, R., and McKibben, J., 2007, Case identification in 
psychiatric epidemiology: a review: International review of psychiatry (Abingdon, 
England), v. 19, no. 5, p. 497–507, doi: 10.1080/09540260701564906. 
Eitner, K., and Koch, U., 2009, From fragment screening to potent binders: strategies for 
fragment-to-lead evolution: Mini reviews in medicinal chemistry, v. 9, no. 8, p. 956–
961. 
Elenius, K., Choi, C.J., Paul, S., Santiestevan, E., Nishi, E., and Klagsbrun, M., 1999, 
Characterization of a naturally occurring ErbB4 isoform that does not bind or activate 
phosphatidyl inositol 3-kinase: Oncogene, v. 18, no. 16, p. 2607–2615, doi: 
10.1038/sj.onc.1202612. 
Ellard, J., 1987, Did schizophrenia exist before the eighteenth century?: The Australian and 
New Zealand journal of psychiatry, v. 21, no. 3, p. 306–318. 
Emamian, E.S., 2012, AKT/GSK3 signaling pathway and schizophrenia: Frontiers in 
molecular neuroscience, v. 5, p. 33, doi: 10.3389/fnmol.2012.00033. 
Eyjolfsson, E.M., Brenner, E., Kondziella, D., and Sonnewald, U., 2006, Repeated injection of 
MK801: an animal model of schizophrenia?: Neurochemistry international, v. 48, no. 
6-7, p. 541–546, doi: 10.1016/j.neuint.2005.11.019. 
Fagart, J., Hillisch, A., Huyet, J., Bärfacker, L., Fay, M., Pleiss, U., Pook, E., Schäfer, S., 
Rafestin-Oblin, M.-E., and Kolkhof, P., 2010, A new mode of mineralocorticoid 
receptor antagonism by a potent and selective nonsteroidal molecule: The Journal of 
biological chemistry, v. 285, no. 39, p. 29932–29940, doi: 10.1074/jbc.M110.131342. 
Falls, D.L., 2003, Neuregulins: functions, forms, and signaling strategies: Experimental cell 
research, v. 284, no. 1, p. 14–30. 
Fazzari, P., Paternain, A.V., Valiente, M., Pla, R., Luján, R., Lloyd, K., Lerma, J., Marín, O., 
and Rico, B., 2010, Control of cortical GABA circuitry development by Nrg1 and 
ErbB4 signalling: Nature, v. 464, no. 7293, p. 1376–1380, doi: 10.1038/nature08928. 
Ferentinos, P., and Dikeos, D., 2012, Genetic correlates of medical comorbidity associated 
with schizophrenia and treatment with antipsychotics: Current opinion in psychiatry, v. 
25, no. 5, p. 381–390, doi: 10.1097/YCO.0b013e3283568537. 
Di Fiore, P.P., Segatto, O., Lonardo, F., Fazioli, F., Pierce, J.H., and Aaronson, S.A., 1990, 
The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert 
different regulatory effects on intrinsic receptor tyrosine kinase function and 
transforming activity: Molecular and cellular biology, v. 10, no. 6, p. 2749–2756. 
Literature 
 199 
Fisahn, A., Neddens, J., Yan, L., and Buonanno, A., 2009, Neuregulin-1 modulates 
hippocampal gamma oscillations: implications for schizophrenia: Cerebral cortex 
(New York, N.Y.: 1991), v. 19, no. 3, p. 612–618, doi: 10.1093/cercor/bhn107. 
Fishman, M.C., and Porter, J.A., 2005, Pharmaceuticals: a new grammar for drug discovery: 
Nature, v. 437, no. 7058, p. 491–493, doi: 10.1038/437491a. 
Flames, N., Long, J.E., Garratt, A.N., Fischer, T.M., Gassmann, M., Birchmeier, C., Lai, C., 
Rubenstein, J.L.R., and Marín, O., 2004, Short- and long-range attraction of cortical 
GABAergic interneurons by neuregulin-1: Neuron, v. 44, no. 2, p. 251–261, doi: 
10.1016/j.neuron.2004.09.028. 
Fleck, D., Garratt, A.N., Haass, C., and Willem, M., 2011, BACE1 Dependent Neuregulin 
Proteolysis: Current Alzheimer research,. 
Flores, C., and Coyle, J.T., 2003, Regulation of glutamate carboxypeptidase II function in 
corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine: 
Neuropsychopharmacology: official publication of the American College of 
Neuropsychopharmacology, v. 28, no. 7, p. 1227–1234, doi: 10.1038/sj.npp.1300129. 
Fornito, A., Zalesky, A., Pantelis, C., and Bullmore, E.T., 2012, Schizophrenia, neuroimaging 
and connectomics: NeuroImage, v. 62, no. 4, p. 2296–2314, doi: 
10.1016/j.neuroimage.2011.12.090. 
Freyer, M.W., and Lewis, E.A., 2008, Isothermal titration calorimetry: experimental design, 
data analysis, and probing macromolecule/ligand binding and kinetic interactions: 
Methods in cell biology, v. 84, p. 79–113, doi: 10.1016/S0091-679X(07)84004-0. 
Fried, K., Risling, M., Tidcombe, H., Gassmann, M., and Lillesaar, C., 2002, Expression of 
ErbB3, ErbB4, and neuregulin-1 mRNA during tooth development: Developmental 
dynamics: an official publication of the American Association of Anatomists, v. 224, 
no. 3, p. 356–360, doi: 10.1002/dvdy.10114. 
Fuller, P.J., Yao, Y., Yang, J., and Young, M.J., 2012, Mechanisms of ligand specificity of the 
mineralocorticoid receptor: The Journal of endocrinology, v. 213, no. 1, p. 15–24, doi: 
10.1530/JOE-11-0372. 
Gao, Z., and Jacobson, K.A., 2002, 2-Chloro-N(6)-cyclopentyladenosine, adenosine A(1) 
receptor agonist, antagonizes the adenosine A(3) receptor: European journal of 
pharmacology, v. 443, no. 1-3, p. 39–42. 
Gaunitz, F., and Papke, M., 1998, Gene transfer and expression: Methods in molecular 
biology (Clifton, N.J.), v. 107, p. 361–370, doi: 10.1385/0-89603-519-0:361. 
Geerling, J.C., and Loewy, A.D., 2009, Aldosterone in the brain: American journal of 
physiology. Renal physiology, v. 297, no. 3, p. F559–576, doi: 
10.1152/ajprenal.90399.2008. 
Goff, D.C., and Coyle, J.T., 2001, The emerging role of glutamate in the pathophysiology and 
treatment of schizophrenia: The American journal of psychiatry, v. 158, no. 9, p. 
1367–1377. 
Goldman-Rakic, P.S., Castner, S.A., Svensson, T.H., Siever, L.J., and Williams, G.V., 2004, 
Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive 
Literature 
 200 
dysfunction: Psychopharmacology, v. 174, no. 1, p. 3–16, doi: 10.1007/s00213-004-
1793-y. 
Greene, L.A., and Tischler, A.S., 1976, Establishment of a noradrenergic clonal line of rat 
adrenal pheochromocytoma cells which respond to nerve growth factor: Proceedings 
of the National Academy of Sciences of the United States of America, v. 73, no. 7, p. 
2424–2428. 
Gromova, I.I., Kjeldsen, E., Svejstrup, J.Q., Alsner, J., Christiansen, K., and Westergaard, O., 
1993, Characterization of an altered DNA catalysis of a camptothecin-resistant 
eukaryotic topoisomerase I: Nucleic acids research, v. 21, no. 3, p. 593–600. 
Grossmann, C., Ruhs, S., Langenbruch, L., Mildenberger, S., Strätz, N., Schumann, K., and 
Gekle, M., 2012, Nuclear shuttling precedes dimerization in mineralocorticoid 
receptor signaling: Chemistry & biology, v. 19, no. 6, p. 742–751, doi: 
10.1016/j.chembiol.2012.04.014. 
Grossmann, K.S., Wende, H., Paul, F.E., Cheret, C., Garratt, A.N., Zurborg, S., Feinberg, K., 
Besser, D., Schulz, H., Peles, E., Selbach, M., Birchmeier, W., and Birchmeier, C., 
2009, The tyrosine phosphatase Shp2 (PTPN11) directs Neuregulin-1/ErbB signaling 
throughout Schwann cell development: Proceedings of the National Academy of 
Sciences of the United States of America, v. 106, no. 39, p. 16704–16709, doi: 
10.1073/pnas.0904336106. 
Grunze, H.C., Rainnie, D.G., Hasselmo, M.E., Barkai, E., Hearn, E.F., McCarley, R.W., and 
Greene, R.W., 1996, NMDA-dependent modulation of CA1 local circuit inhibition: The 
Journal of neuroscience: the official journal of the Society for Neuroscience, v. 16, no. 
6, p. 2034–2043. 
Gunduz-Bruce, H., 2009, The acute effects of NMDA antagonism: from the rodent to the 
human brain: Brain research reviews, v. 60, no. 2, p. 279–286, doi: 
10.1016/j.brainresrev.2008.07.006. 
Haenschel, C., Bittner, R.A., Waltz, J., Haertling, F., Wibral, M., Singer, W., Linden, D.E.J., 
and Rodriguez, E., 2009, Cortical oscillatory activity is critical for working memory as 
revealed by deficits in early-onset schizophrenia: The Journal of neuroscience: the 
official journal of the Society for Neuroscience, v. 29, no. 30, p. 9481–9489, doi: 
10.1523/JNEUROSCI.1428-09.2009. 
Hall, J., Whalley, H.C., Job, D.E., Baig, B.J., McIntosh, A.M., Evans, K.L., Thomson, P.A., 
Porteous, D.J., Cunningham-Owens, D.G., Johnstone, E.C., and Lawrie, S.M., 2006, 
A neuregulin 1 variant associated with abnormal cortical function and psychotic 
symptoms: Nature neuroscience, v. 9, no. 12, p. 1477–1478, doi: 10.1038/nn1795. 
Hancock, M.L., Canetta, S.E., Role, L.W., and Talmage, D.A., 2008, Presynaptic type III 
neuregulin1-ErbB signaling targets alpha7 nicotinic acetylcholine receptors to axons: 
The Journal of general physiology, v. 131, no. 6, p. i4, doi: 10.1085/JGP1316OIA4. 
Hanisch, U.-K., and Kettenmann, H., 2007, Microglia: active sensor and versatile effector 
cells in the normal and pathologic brain: Nature neuroscience, v. 10, no. 11, p. 1387–
1394, doi: 10.1038/nn1997. 
Literature 
 201 
Harrison, P.J., and Weinberger, D.R., 2005, Schizophrenia genes, gene expression, and 
neuropathology: on the matter of their convergence: Molecular psychiatry, v. 10, no. 1, 
p. 40–68; image 5, doi: 10.1038/sj.mp.4001558. 
Hartley, J.L., Temple, G.F., and Brasch, M.A., 2000, DNA cloning using in vitro site-specific 
recombination: Genome research, v. 10, no. 11, p. 1788–1795. 
Hashimoto, T., Volk, D.W., Eggan, S.M., Mirnics, K., Pierri, J.N., Sun, Z., Sampson, A.R., and 
Lewis, D.A., 2003, Gene expression deficits in a subclass of GABA neurons in the 
prefrontal cortex of subjects with schizophrenia: The Journal of neuroscience: the 
official journal of the Society for Neuroscience, v. 23, no. 15, p. 6315–6326. 
Höistad, M., Segal, D., Takahashi, N., Sakurai, T., Buxbaum, J.D., and Hof, P.R., 2009, 
Linking white and grey matter in schizophrenia: oligodendrocyte and neuron 
pathology in the prefrontal cortex: Frontiers in neuroanatomy, v. 3, p. 9, doi: 
10.3389/neuro.05.009.2009. 
Holdgate, G.A., Anderson, M., Edfeldt, F., and Geschwindner, S., 2010, Affinity-based, 
biophysical methods to detect and analyze ligand binding to recombinant proteins: 
matching high information content with high throughput: Journal of structural biology, 
v. 172, no. 1, p. 142–157, doi: 10.1016/j.jsb.2010.06.024. 
Holsboer, F., 1999, The rationale for corticotropin-releasing hormone receptor (CRH-R) 
antagonists to treat depression and anxiety: Journal of psychiatric research, v. 33, no. 
3, p. 181–214. 
Homayoun, H., and Moghaddam, B., 2007, NMDA Receptor Hypofunction Produces Opposite 
Effects on Prefrontal Cortex Interneurons and Pyramidal Neurons: The Journal of 
Neuroscience, v. 27, no. 43, p. 11496–11500, doi: 10.1523/JNEUROSCI.2213-
07.2007. 
Honea, R.A., Meyer-Lindenberg, A., Hobbs, K.B., Pezawas, L., Mattay, V.S., Egan, M.F., 
Verchinski, B., Passingham, R.E., Weinberger, D.R., and Callicott, J.H., 2008, Is gray 
matter volume an intermediate phenotype for schizophrenia? A voxel-based 
morphometry study of patients with schizophrenia and their healthy siblings: 
Biological psychiatry, v. 63, no. 5, p. 465–474, doi: 10.1016/j.biopsych.2007.05.027. 
Hong, L.E., Wonodi, I., Stine, O.C., Mitchell, B.D., and Thaker, G.K., 2008, Evidence of 
missense mutations on the neuregulin 1 gene affecting function of prepulse inhibition: 
Biological psychiatry, v. 63, no. 1, p. 17–23, doi: 10.1016/j.biopsych.2007.05.011. 
Houghton, P.J., Cheshire, P.J., Hallman, J.D., 2nd, Lutz, L., Friedman, H.S., Danks, M.K., 
and Houghton, J.A., 1995, Efficacy of topoisomerase I inhibitors, topotecan and 
irinotecan, administered at low dose levels in protracted schedules to mice bearing 
xenografts of human tumors: Cancer chemotherapy and pharmacology, v. 36, no. 5, 
p. 393–403. 
Hsiang, Y.H., Liu, L.F., Wall, M.E., Wani, M.C., Nicholas, A.W., Manikumar, G., 
Kirschenbaum, S., Silber, R., and Potmesil, M., 1989, DNA topoisomerase I-mediated 
DNA cleavage and cytotoxicity of camptothecin analogues: Cancer research, v. 49, 
no. 16, p. 4385–4389. 
Literature 
 202 
Huber, W., 2005, A new strategy for improved secondary screening and lead optimization 
using high-resolution SPR characterization of compound-target interactions: Journal 
of molecular recognition: JMR, v. 18, no. 4, p. 273–281, doi: 10.1002/jmr.744. 
Hudepohl, N.S., and Nasrallah, H.A., 2012, Antipsychotic drugs: Handbook of clinical 
neurology / edited by P.J. Vinken and G.W. Bruyn, v. 106, p. 657–667, doi: 
10.1016/B978-0-444-52002-9.00039-5. 
Hudis, C.A., 2007, Trastuzumab--mechanism of action and use in clinical practice: The New 
England journal of medicine, v. 357, no. 1, p. 39–51, doi: 10.1056/NEJMra043186. 
Inglese, J., Johnson, R.L., Simeonov, A., Xia, M., Zheng, W., Austin, C.P., and Auld, D.S., 
2007, High-throughput screening assays for the identification of chemical probes: 
Nature chemical biology, v. 3, no. 8, p. 466–479, doi: 10.1038/nchembio.2007.17. 
Ishii, R., Takahashi, H., Kurimoto, R., Aoki, Y., Ikeda, S., Hata, M., Ikezawa, K., Canuet, L., 
Nakahachi, T., Iwase, M., and Takeda, M., 2012, [Endophenotypes in schizophrenia: 
a review of electrophysiological studies]: Seishin shinkeigaku zasshi = Psychiatria et 
neurologia Japonica, v. 114, no. 6, p. 629–646. 
Jaaro-Peled, H., Hayashi-Takagi, A., Seshadri, S., Kamiya, A., Brandon, N.J., and Sawa, A., 
2009, Neurodevelopmental mechanisms of schizophrenia: understanding disturbed 
postnatal brain maturation through neuregulin-1-ErbB4 and DISC1: Trends in 
neurosciences, v. 32, no. 9, p. 485–495, doi: 10.1016/j.tins.2009.05.007. 
Javitt, D.C., and Zukin, S.R., 1991, Recent advances in the phencyclidine model of 
schizophrenia: The American journal of psychiatry, v. 148, no. 10, p. 1301–1308. 
Jeste, D.V., del Carmen, R., Lohr, J.B., and Wyatt, R.J., 1985, Did schizophrenia exist before 
the eighteenth century?: Comprehensive psychiatry, v. 26, no. 6, p. 493–503. 
Jia, P., Sun, J., Guo, A.Y., and Zhao, Z., 2010, SZGR: a comprehensive schizophrenia gene 
resource: Molecular psychiatry, v. 15, no. 5, p. 453–462, doi: 10.1038/mp.2009.93. 
Jones, R.B., Gordus, A., Krall, J.A., and MacBeath, G., 2006, A quantitative protein 
interaction network for the ErbB receptors using protein microarrays: Nature, v. 439, 
no. 7073, p. 168–174, doi: 10.1038/nature04177. 
Jordan, M.A., Himes, R.H., and Wilson, L., 1985, Comparison of the effects of vinblastine, 
vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in 
vitro: Cancer research, v. 45, no. 6, p. 2741–2747. 
Kang, E., Burdick, K.E., Kim, J.Y., Duan, X., Guo, J.U., Sailor, K.A., Jung, D.-E., Ganesan, S., 
Choi, S., Pradhan, D., Lu, B., Avramopoulos, D., Christian, K., Malhotra, A.K., et al., 
2011, Interaction between FEZ1 and DISC1 in regulation of neuronal development 
and risk for schizophrenia: Neuron, v. 72, no. 4, p. 559–571, doi: 
10.1016/j.neuron.2011.09.032. 
Karam, C.S., Ballon, J.S., Bivens, N.M., Freyberg, Z., Girgis, R.R., Lizardi-Ortiz, J.E., Markx, 
S., Lieberman, J.A., and Javitch, J.A., 2010, Signaling pathways in schizophrenia: 
emerging targets and therapeutic strategies: Trends in pharmacological sciences, v. 
31, no. 8, p. 381–390, doi: 10.1016/j.tips.2010.05.004. 
Literature 
 203 
Karaman, M.W., Herrgard, S., Treiber, D.K., Gallant, P., Atteridge, C.E., Campbell, B.T., 
Chan, K.W., Ciceri, P., Davis, M.I., Edeen, P.T., Faraoni, R., Floyd, M., Hunt, J.P., 
Lockhart, D.J., et al., 2008, A quantitative analysis of kinase inhibitor selectivity: 
Nature biotechnology, v. 26, no. 1, p. 127–132, doi: 10.1038/nbt1358. 
Kato, T., Kasai, A., Mizuno, M., Fengyi, L., Shintani, N., Maeda, S., Yokoyama, M., Ozaki, M., 
and Nawa, H., 2010, Phenotypic characterization of transgenic mice overexpressing 
neuregulin-1: PloS one, v. 5, no. 12, p. e14185, doi: 10.1371/journal.pone.0014185. 
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K., 1991, Intracellular roles of SN-38, 
a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-
11: Cancer research, v. 51, no. 16, p. 4187–4191. 
Keely, S.J., Calandrella, S.O., and Barrett, K.E., 2000, Carbachol-stimulated transactivation 
of epidermal growth factor receptor and mitogen-activated protein kinase in T(84) 
cells is mediated by intracellular ca(2+), PYK-2, and p60(src): The Journal of 
biological chemistry, v. 275, no. 17, p. 12619–12625. 
Kellendonk, C., Simpson, E.H., and Kandel, E.R., 2009, Modeling cognitive endophenotypes 
of schizophrenia in mice: Trends in neurosciences, v. 32, no. 6, p. 347–358, doi: 
10.1016/j.tins.2009.02.003. 
Keshavan, M.S., Tandon, R., Boutros, N.N., and Nasrallah, H.A., 2008, Schizophrenia, “just 
the facts”: what we know in 2008 Part 3: neurobiology: Schizophrenia research, v. 
106, no. 2-3, p. 89–107, doi: 10.1016/j.schres.2008.07.020. 
Kibbe, W.A., 2007, OligoCalc: an online oligonucleotide properties calculator: Nucleic acids 
research, v. 35, no. Web Server issue, p. W43–46, doi: 10.1093/nar/gkm234. 
Kirkbride, J.B., Fearon, P., Morgan, C., Dazzan, P., Morgan, K., Tarrant, J., Lloyd, T., 
Holloway, J., Hutchinson, G., Leff, J.P., Mallett, R.M., Harrison, G.L., Murray, R.M., 
and Jones, P.B., 2006, Heterogeneity in incidence rates of schizophrenia and other 
psychotic syndromes: findings from the 3-center AeSOP study: Archives of general 
psychiatry, v. 63, no. 3, p. 250–258, doi: 10.1001/archpsyc.63.3.250. 
Kisseleva, T., Bhattacharya, S., Braunstein, J., and Schindler, C.W., 2002, Signaling through 
the JAK/STAT pathway, recent advances and future challenges: Gene, v. 285, no. 1-
2, p. 1–24. 
Kleinman, J.E., Law, A.J., Lipska, B.K., Hyde, T.M., Ellis, J.K., Harrison, P.J., and Weinberger, 
D.R., 2011, Genetic neuropathology of schizophrenia: new approaches to an old 
question and new uses for postmortem human brains: Biological psychiatry, v. 69, no. 
2, p. 140–145, doi: 10.1016/j.biopsych.2010.10.032. 
Klosterkötter, J., 2008, Indicated prevention of schizophrenia: Deutsches Ärzteblatt 
international, v. 105, no. 30, p. 532–539, doi: 10.3238/arztebl.2008.0532. 
Kocisko, D.A., Baron, G.S., Rubenstein, R., Chen, J., Kuizon, S., and Caughey, B., 2003, 
New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs 
and natural products: Journal of virology, v. 77, no. 19, p. 10288–10294. 
Kodesh, A., Goldshtein, I., Gelkopf, M., Goren, I., Chodick, G., and Shalev, V., 2012, 
Epidemiology and comorbidity of severe mental illnesses in the community: findings 
Literature 
 204 
from a computerized mental health registry in a large Israeli health organization: 
Social psychiatry and psychiatric epidemiology,, doi: 10.1007/s00127-012-0478-9. 
Konradi, C., Yang, C.K., Zimmerman, E.I., Lohmann, K.M., Gresch, P., Pantazopoulos, H., 
Berretta, S., and Heckers, S., 2011, Hippocampal interneurons are abnormal in 
schizophrenia: Schizophrenia research, v. 131, no. 1-3, p. 165–173, doi: 
10.1016/j.schres.2011.06.007. 
Kraepelin, E. 1896: Psychiatrie: Ein Lehrbuch für Studierende und Ärzte.  
Fünfte, vollständig umgearbeitete Auflage. Leipzig. 
 
Kuai, L., Ong, S.-E., Madison, J.M., Wang, X., Duvall, J.R., Lewis, T.A., Luce, C.J., Conner, 
S.D., Pearlman, D.A., Wood, J.L., Schreiber, S.L., Carr, S.A., Scolnick, E.M., and 
Haggarty, S.J., 2011, AAK1 identified as an inhibitor of neuregulin-1/ErbB4-
dependent neurotrophic factor signaling using integrative chemical genomics and 
proteomics: Chemistry & biology, v. 18, no. 7, p. 891–906, doi: 
10.1016/j.chembiol.2011.03.017. 
Kuai, L., Wang, X., Madison, J.M., Schreiber, S.L., Scolnick, E.M., and Haggarty, S.J., 2010, 
Chemical genetics identifies small-molecule modulators of neuritogenesis involving 
neuregulin-1/ErbB4 signaling: ACS chemical neuroscience, v. 1, no. 4, p. 325–342, 
doi: 10.1021/cn900046a. 
Kuhn, J.G., 1998, Pharmacology of irinotecan: Oncology (Williston Park, N.Y.), v. 12, no. 8 
Suppl 6, p. 39–42. 
Kwon, O.B., Paredes, D., Gonzalez, C.M., Neddens, J., Hernandez, L., Vullhorst, D., and 
Buonanno, A., 2008, Neuregulin-1 regulates LTP at CA1 hippocampal synapses 
through activation of dopamine D4 receptors: Proceedings of the National Academy 
of Sciences of the United States of America, v. 105, no. 40, p. 15587–15592, doi: 
10.1073/pnas.0805722105. 
Law, A.J., Kleinman, J.E., Weinberger, D.R., and Weickert, C.S., 2007, Disease-associated 
intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant 
expression in the brain in schizophrenia: Human molecular genetics, v. 16, no. 2, p. 
129–141, doi: 10.1093/hmg/ddl449. 
Law, A.J., ang, Y., Sei, Y., O’Donnell, P., Piantadosi, P., Papaleo, F., Straub, R.E., Huang, 
W., Thomas, C.J., Vakkalanka, R., Besterman, A.D., Lipska, B.K., Hyde, T.M., 
Harrison, P.J., et al., 2012b, Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and 
phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy: 
Proceedings of the National Academy of Sciences of the United States of America,, 
doi: 10.1073/pnas.1206118109. 
Leevers, S.J., Vanhaesebroeck, B., and Waterfield, M.D., 1999, Signalling through 
phosphoinositide 3-kinases: the lipids take centre stage: Current opinion in cell 
biology, v. 11, no. 2, p. 219–225. 
Lewis, D.A., and González-Burgos, G., 2008, Neuroplasticity of neocortical circuits in 
schizophrenia: Neuropsychopharmacology: official publication of the American 




Lewis, D.A., Hashimoto, T., and Volk, D.W., 2005, Cortical inhibitory neurons and 
schizophrenia: Nature reviews. Neuroscience, v. 6, no. 4, p. 312–324, doi: 
10.1038/nrn1648. 
Lewis, D.A., and Levitt, P., 2002, Schizophrenia as a disorder of neurodevelopment: Annual 
review of neuroscience, v. 25, p. 409–432, doi: 
10.1146/annurev.neuro.25.112701.142754. 
Lewis, D.A., and Lieberman, J.A., 2000, Catching up on schizophrenia: natural history and 
neurobiology: Neuron, v. 28, no. 2, p. 325–334. 
Li, D., Collier, D.A., and He, L., 2006, Meta-analysis shows strong positive association of the 
neuregulin 1 (NRG1) gene with schizophrenia: Human molecular genetics, v. 15, no. 
12, p. 1995–2002, doi: 10.1093/hmg/ddl122. 
Li, T., Stefansson, H., Gudfinnsson, E., Cai, G., Liu, X., Murray, R.M., Steinthorsdottir, V., 
Januel, D., Gudnadottir, V.G., Petursson, H., Ingason, A., Gulcher, J.R., Stefansson, 
K., and Collier, D.A., 2004, Identification of a novel neuregulin 1 at-risk haplotype in 
Han schizophrenia Chinese patients, but no association with the Icelandic/Scottish 
risk haplotype: Molecular psychiatry, v. 9, no. 7, p. 698–704, doi: 
10.1038/sj.mp.4001485. 
Lievens, S., Caligiuri, M., Kley, N., and Tavernier, J., 2012, The use of mammalian two-hybrid 
technologies for high-throughput drug screening: Methods (San Diego, Calif.),, doi: 
10.1016/j.ymeth.2012.08.003. 
Liu, P., Cleveland, T.E., 4th, Bouyain, S., Byrne, P.O., Longo, P.A., and Leahy, D.J., 2012, A 
single ligand is sufficient to activate EGFR dimers: Proceedings of the National 
Academy of Sciences of the United States of America, v. 109, no. 27, p. 10861–
10866, doi: 10.1073/pnas.1201114109. 
Liu, X., Robinson, G.W., Wagner, K.U., Garrett, L., Wynshaw-Boris, A., and Hennighausen, L., 
1997, Stat5a is mandatory for adult mammary gland development and lactogenesis: 
Genes & development, v. 11, no. 2, p. 179–186. 
Lodge, D., and Anis, N.A., 1982, Effects of phencyclidine on excitatory amino acid activation 
of spinal interneurones in the cat: European journal of pharmacology, v. 77, no. 2-3, p. 
203–204. 
Lonardo, F., Di Marco, E., King, C.R., Pierce, J.H., Segatto, O., Aaronson, S.A., and Di Fiore, 
P.P., 1990, The normal erbB-2 product is an atypical receptor-like tyrosine kinase 
with constitutive activity in the absence of ligand: The New biologist, v. 2, no. 11, p. 
992–1003. 
Lu, C.-L., Wang, Y.-C., Chen, J.-Y., Lai, I.-C., and Liou, Y.-J., 2010, Support for the 
involvement of the ERBB4 gene in schizophrenia: a genetic association analysis: 
Neuroscience letters, v. 481, no. 2, p. 120–125, doi: 10.1016/j.neulet.2010.06.067. 
LUBY, E.D., COHEN, B.D., ROSENBAUM, G., GOTTLIEB, J.S., and KELLEY, R., 1959, 
Study of a new schizophrenomimetic drug; sernyl: A.M.A. archives of neurology and 
psychiatry, v. 81, no. 3, p. 363–369. 
Luo, X., Prior, M., He, W., Hu, X., Tang, X., Shen, W., Yadav, S., Kiryu-Seo, S., Miller, R., 
Trapp, B.D., and Yan, R., 2011, Cleavage of neuregulin-1 by BACE1 or ADAM10 
Literature 
 206 
protein produces differential effects on myelination: The Journal of biological 
chemistry, v. 286, no. 27, p. 23967–23974, doi: 10.1074/jbc.M111.251538. 
Macarron, R., Banks, M.N., Bojanic, D., Burns, D.J., Cirovic, D.A., Garyantes, T., Green, 
D.V.S., Hertzberg, R.P., Janzen, W.P., Paslay, J.W., Schopfer, U., and Sittampalam, 
G.S., 2011, Impact of high-throughput screening in biomedical research: Nature 
reviews. Drug discovery, v. 10, no. 3, p. 188–195, doi: 10.1038/nrd3368. 
Man, H.-Y., Wang, Q., Lu, W.-Y., Ju,  ., Ahmadian, G., Liu, L., D’Souza, S.,  ong, T.P., 
Taghibiglou, C., Lu, J., Becker, L.E., Pei, L., Liu, F., Wymann, M.P., et al., 2003, 
Activation of PI3-kinase is required for AMPA receptor insertion during LTP of 
mEPSCs in cultured hippocampal neurons: Neuron, v. 38, no. 4, p. 611–624. 
Maniatis,T., Fritsch, E.F., Sambrook, J., 1982, Molecular cloning : a laboratory manual, Cold                                            
Spring Harbour Laboratory 
 
Marín, O., 2012, Interneuron dysfunction in psychiatric disorders: Nature Reviews 
Neuroscience, v. 13, no. 2, p. 107–120, doi: 10.1038/nrn3155. 
Marmor, M.D., Skaria, K.B., and Yarden, Y., 2004, Signal transduction and oncogenesis by 
ErbB/HER receptors: International journal of radiation oncology, biology, physics, v. 
58, no. 3, p. 903–913, doi: 10.1016/j.ijrobp.2003.06.002. 
Marzolla, V., Armani, A., Zennaro, M.-C., Cinti, F., Mammi, C., Fabbri, A., Rosano, G.M.C., 
and Caprio, M., 2012, The role of the mineralocorticoid receptor in adipocyte biology 
and fat metabolism: Molecular and cellular endocrinology, v. 350, no. 2, p. 281–288, 
doi: 10.1016/j.mce.2011.09.011. 
Maynard, T.M., Sikich, L., Lieberman, J.A., and LaMantia, A.S., 2001, Neural development, 
cell-cell signaling, and the “two-hit” hypothesis of schizophrenia: Schizophrenia 
bulletin, v. 27, no. 3, p. 457–476. 
McGrath, J.J., 2007, The surprisingly rich contours of schizophrenia epidemiology: Archives 
of general psychiatry, v. 64, no. 1, p. 14–16, doi: 10.1001/archpsyc.64.1.14. 
McIntosh, A.M., Moorhead, T.W.J., Job, D., Lymer, G.K.S., Muñoz Maniega, S., McKirdy, J., 
Sussmann, J.E.D., Baig, B.J., Bastin, M.E., Porteous, D., Evans, K.L., Johnstone, 
E.C., Lawrie, S.M., and Hall, J., 2008, The effects of a neuregulin 1 variant on white 
matter density and integrity: Molecular psychiatry, v. 13, no. 11, p. 1054–1059, doi: 
10.1038/sj.mp.4002103. 
Medina, P.J., and Goodin, S., 2008, Lapatinib: a dual inhibitor of human epidermal growth 
factor receptor tyrosine kinases: Clinical therapeutics, v. 30, no. 8, p. 1426–1447, doi: 
10.1016/j.clinthera.2008.08.008. 
Mei, L., and Xiong, W.-C., 2008, Neuregulin 1 in neural development, synaptic plasticity and 
schizophrenia: Nature reviews. Neuroscience, v. 9, no. 6, p. 437–452, doi: 
10.1038/nrn2392. 
Meyer, D., and Birchmeier, C., 1995, Multiple essential functions of neuregulin in 
development: Nature, v. 378, no. 6555, p. 386–390, doi: 10.1038/378386a0. 
Meyer-Lindenberg, A., 2011, Neuroimaging and the question of neurodegeneration in 




Mezler, M., Geneste, H., Gault, L., and Marek, G.J., 2010, LY-2140023, a prodrug of the 
group II metabotropic glutamate receptor agonist LY-404039 for the potential 
treatment of schizophrenia: Current opinion in investigational drugs (London, 
England: 2000), v. 11, no. 7, p. 833–845. 
Michailov, G.V., Sereda, M.W., Brinkmann, B.G., Fischer, T.M., Haug, B., Birchmeier, C., 
Role, L., Lai, C., Schwab, M.H., and Nave, K.-A., 2004, Axonal neuregulin-1 
regulates myelin sheath thickness: Science (New York, N.Y.), v. 304, no. 5671, p. 
700–703, doi: 10.1126/science.1095862. 
Millar, J.K., Wilson-Annan, J.C., Anderson, S., Christie, S., Taylor, M.S., Semple, C.A., Devon, 
R.S., St Clair, D.M., Muir, W.J., Blackwood, D.H., and Porteous, D.J., 2000, 
Disruption of two novel genes by a translocation co-segregating with schizophrenia: 
Human molecular genetics, v. 9, no. 9, p. 1415–1423. 
Missios, S., 2007, Hippocrates, Galen, and the uses of trepanation in the ancient classical 
world: Neurosurgical focus, v. 23, no. 1, p. E11, doi: 10.3171/foc.2007.23.1.11. 
Mohit, A., 2001, Mental health and psychiatry in the Middle East: historical development: 
Eastern Mediterranean health journal = La revue de santé de la Méditerranée 
orientale = al-Majallah al-ṣiḥḥīyah li-sharq al-mutawassiṭ, v. 7, no. 3, p. 336–347. 
Monji, A., Kato, T., and Kanba, S., 2009, Cytokines and schizophrenia: Microglia hypothesis 
of schizophrenia: Psychiatry and clinical neurosciences, v. 63, no. 3, p. 257–265. 
Morton, J.F., 1968, Medicinal plants--old and new: Bulletin of the Medical Library Association, 
v. 56, no. 2, p. 161–167. 
Mülhardt, C., 2003, Der Experimentator, Molekularbiologie/Genomics, 
Spektrum  
 
Mullis, K.B., and Faloona, F.A., 1987, Specific synthesis of DNA in vitro via a polymerase-
catalyzed chain reaction: Methods in enzymology, v. 155, p. 335–350. 
Mullis, K., Faloona, F., Scharf, S., Saiki, R., Horn, G., and Erlich, H., 1992, Specific enzymatic 
amplification of DNA in vitro: the polymerase chain reaction. 1986: Biotechnology 
(Reading, Mass.), v. 24, p. 17–27. 
Munafò, M.R., Thiselton, D.L., Clark, T.G., and Flint, J., 2006, Association of the NRG1 gene 
and schizophrenia: a meta-analysis: Molecular psychiatry, v. 11, no. 6, p. 539–546, 
doi: 10.1038/sj.mp.4001817. 
Nayak, A., Gayen, P., Saini, P., Maitra, S., and Sinha Babu, S.P., 2011, Albendazole induces 
apoptosis in adults and microfilariae of Setaria cervi: Experimental parasitology, v. 
128, no. 3, p. 236–242, doi: 10.1016/j.exppara.2011.03.005. 
Neddens, J., and Buonanno, A., 2011, Expression of the neuregulin receptor ErbB4 in the 
brain of the rhesus monkey (Macaca mulatta): PloS one, v. 6, no. 11, p. e27337, doi: 
10.1371/journal.pone.0027337. 
Neddens, J., and Buonanno, A., 2010, Selective populations of hippocampal interneurons 
express ErbB4 and their number and distribution is altered in ErbB4 knockout mice: 
Hippocampus, v. 20, no. 6, p. 724–744, doi: 10.1002/hipo.20675. 
Literature 
 208 
Neddens, J., Fish, K.N., Tricoire, L., Vullhorst, D., Shamir, A., Chung, W., Lewis, D.A., 
McBain, C.J., and Buonanno, A., 2011, Conserved interneuron-specific ErbB4 
expression in frontal cortex of rodents, monkeys, and humans: implications for 
schizophrenia: Biological psychiatry, v. 70, no. 7, p. 636–645, doi: 
10.1016/j.biopsych.2011.04.016. 
Nestler, E.J., and Hyman, S.E., 2010, Animal models of neuropsychiatric disorders: Nature 
neuroscience, v. 13, no. 10, p. 1161–1169, doi: 10.1038/nn.2647. 
Ni, C.Y., Murphy, M.P., Golde, T.E., and Carpenter, G., 2001, gamma -Secretase cleavage 
and nuclear localization of ErbB-4 receptor tyrosine kinase: Science (New York, N.Y.), 
v. 294, no. 5549, p. 2179–2181, doi: 10.1126/science.1065412. 
Nicodemus, K.K., Marenco, S., Batten, A.J., Vakkalanka, R., Egan, M.F., Straub, R.E., and 
Weinberger, D.R., 2008, Serious obstetric complications interact with hypoxia-
regulated/vascular-expression genes to influence schizophrenia risk: Molecular 
psychiatry, v. 13, no. 9, p. 873–877, doi: 10.1038/sj.mp.4002153. 
Nilsson, M., Carlsson, A., Markinhuhta, K.R., Sonesson, C., Pettersson, F., Gullme, M., and 
Carlsson, M.L., 2004, The dopaminergic stabiliser ACR16 counteracts the 
behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: 
implications for cognition: Progress in neuro-psychopharmacology & biological 
psychiatry, v. 28, no. 4, p. 677–685, doi: 10.1016/j.pnpbp.2004.05.004. 
Nitsche, M.A., Müller-Dahlhaus, F., Paulus, W., and Ziemann, U., 2012, The pharmacology of 
neuroplasticity induced by non-invasive brain stimulation: building models for the 
clinical use of CNS active drugs: The Journal of physiology,, doi: 
10.1113/jphysiol.2012.232975. 
O’Leary, J., and Muggia, F.M., 1998a, Camptothecins: a review of their development and 
schedules of administration: European journal of cancer (Oxford, England: 1990), v. 
34, no. 10, p. 1500–1508. 
Oda, K., Matsuoka, Y., Funahashi, A., and Kitano, H., 2005, A comprehensive pathway map 
of epidermal growth factor receptor signaling: Molecular Systems Biology, v. 1, p. 
2005.0010, doi: 10.1038/msb4100014. 
Ogden, D.A., Scherr, L., Spritz, N., and Rubin, A.L., 1961, A comparison of the properties of 
chlorothiazide, spironolactone and a combination of both as diuretic agents: The New 
England journal of medicine, v. 265, p. 358–362, doi: 
10.1056/NEJM196108242650802. 
Ohlmeyer, M., and Zhou, M.-M., 2010, Integration of small-molecule discovery in academic 
biomedical research: The Mount Sinai journal of medicine, New York, v. 77, no. 4, p. 
350–357, doi: 10.1002/msj.20197. 
Okasha, A., 2001, Egyptian contribution to the concept of mental health: Eastern 
Mediterranean health journal = La revue de santé de la Méditerranée orientale = al-
Majallah al-ṣiḥḥīyah li-sharq al-mutawassiṭ, v. 7, no. 3, p. 377–380. 
Okasha, A., 1999, Mental health in the Middle East: an Egyptian perspective: Clinical 
psychology review, v. 19, no. 8, p. 917–933. 
Literature 
 209 
Olayioye, M.A., Beuvink, I., Horsch, K., Daly, J.M., and Hynes, N.E., 1999, ErbB receptor-
induced activation of stat transcription factors is mediated by Src tyrosine kinases: 
The Journal of biological chemistry, v. 274, no. 24, p. 17209–17218. 
Olney, J.W., and Farber, N.B., 1995, NMDA antagonists as neurotherapeutic drugs, 
psychotogens, neurotoxins, and research tools for studying schizophrenia: 
Neuropsychopharmacology: official publication of the American College of 
Neuropsychopharmacology, v. 13, no. 4, p. 335–345, doi: 10.1016/0893-
133X(95)00079-S. 
Oyamada, N., Sone, M., Miyashita, K., Park, K., Taura, D., Inuzuka, M., Sonoyama, T., 
Tsujimoto, H., Fukunaga, Y., Tamura, N., Itoh, H., and Nakao, K., 2008, The role of 
mineralocorticoid receptor expression in brain remodeling after cerebral ischemia: 
Endocrinology, v. 149, no. 8, p. 3764–3777, doi: 10.1210/en.2007-1770. 
Ozaki, M., Sasner, M., Yano, R., Lu, H.S., and Buonanno, A., 1997, Neuregulin-beta induces 
expression of an NMDA-receptor subunit: Nature, v. 390, no. 6661, p. 691–694, doi: 
10.1038/37795. 
Pelicci, G., Lanfrancone, L., Grignani, F., McGlade, J., Cavallo, F., Forni, G., Nicoletti, I., 
Grignani, F., Pawson, T., and Pelicci, P.G., 1992, A novel transforming protein (SHC) 
with an SH2 domain is implicated in mitogenic signal transduction: Cell, v. 70, no. 1, p. 
93–104. 
Penzes, P., Cahill, M.E., Jones, K.A., VanLeeuwen, J.-E., and Woolfrey, K.M., 2011, 
Dendritic spine pathology in neuropsychiatric disorders: Nature neuroscience, v. 14, 
no. 3, p. 285–293, doi: 10.1038/nn.2741. 
Pippal, J.B., and Fuller, P.J., 2008, Structure-function relationships in the mineralocorticoid 
receptor: Journal of molecular endocrinology, v. 41, no. 6, p. 405–413, doi: 
10.1677/JME-08-0093. 
Plowman, G.D., Culouscou, J.M., Whitney, G.S., Green, J.M., Carlton, G.W., Foy, L., 
Neubauer, M.G., and Shoyab, M., 1993, Ligand-specific activation of 
HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family: 
Proceedings of the National Academy of Sciences of the United States of America, v. 
90, no. 5, p. 1746–1750. 
Pommier, Y., 2004, Camptothecins and topoisomerase I: a foot in the door. Targeting the 
genome beyond topoisomerase I with camptothecins and novel anticancer drugs: 
importance of DNA replication, repair and cell cycle checkpoints: Current medicinal 
chemistry. Anti-cancer agents, v. 4, no. 5, p. 429–434. 
Pommier, Y., 2006, Topoisomerase I inhibitors: camptothecins and beyond: Nature reviews. 
Cancer, v. 6, no. 10, p. 789–802, doi: 10.1038/nrc1977. 
Pratt, J., Winchester, C., Dawson, N., and Morris, B., 2012, Advancing schizophrenia drug 
discovery: optimizing rodent models to bridge the translational gap: Nature reviews. 
Drug discovery, v. 11, no. 7, p. 560–579, doi: 10.1038/nrd3649. 
Ravichandran, K.S., 2001, Signaling via Shc family adapter proteins: Oncogene, v. 20, no. 44, 
p. 6322–6330, doi: 10.1038/sj.onc.1204776. 
Literature 
 210 
Redinbo, M.R., Stewart, L., Kuhn, P., Champoux, J.J., and Hol, W.G., 1998, Crystal 
structures of human topoisomerase I in covalent and noncovalent complexes with 
DNA: Science (New York, N.Y.), v. 279, no. 5356, p. 1504–1513. 
Rio, C., Buxbaum, J.D., Peschon, J.J., and Corfas, G., 2000, Tumor necrosis factor-alpha-
converting enzyme is required for cleavage of erbB4/HER4: The Journal of biological 
chemistry, v. 275, no. 14, p. 10379–10387. 
Rogerson, F.M., Yao, Y.-Z., Smith, B.J., Dimopoulos, N., and Fuller, P.J., 2003, Determinants 
of spironolactone binding specificity in the mineralocorticoid receptor: Journal of 
molecular endocrinology, v. 31, no. 3, p. 573–582. 
van Rossum, J.M., 1967, [The effect of psychostimulants on the central and autonomic 
nervous system]: Schweizerische Zeitschrift für Sportmedizin, v. 15, no. 1, p. 26–40. 
van Rossum, J.M., 1966, The significance of dopamine-receptor blockade for the mechanism 
of action of neuroleptic drugs: Archives internationales de pharmacodynamie et de 
thérapie, v. 160, no. 2, p. 492–494. 
Rowinsky, E.K., Adjei, A., Donehower, R.C., Gore, S.D., Jones, R.J., Burke, P.J., Cheng, 
Y.C., Grochow, L.B., and Kaufmann, S.H., 1994, Phase I and pharmacodynamic 
study of the topoisomerase I-inhibitor topotecan in patients with refractory acute 
leukemia: Journal of clinical oncology: official journal of the American Society of 
Clinical Oncology, v. 12, no. 10, p. 2193–2203. 
Rund, B.R., 2009, Is there a degenerative process going on in the brain of people with 
Schizophrenia?: Frontiers in human neuroscience, v. 3, p. 36, doi: 
10.3389/neuro.09.036.2009. 
Russel, J., Cohn, R., History of schizophrenia, Bookvika publishing  
 
Rumsey, D., 2010, Statistik für Dummies, Wiley 
 
Saha, S., Chant, D., Welham, J., and McGrath, J., 2005, A systematic review of the 
prevalence of schizophrenia: PLoS medicine, v. 2, no. 5, p. e141, doi: 
10.1371/journal.pmed.0020141. 
Sams-Dodd, F., Lipska, B.K., and Weinberger, D.R., 1997, Neonatal lesions of the rat ventral 
hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood: 
Psychopharmacology, v. 132, no. 3, p. 303–310. 
Sanyal, S., and Van Tol, H.H., 1997, Review the role of dopamine D4 receptors in 
schizophrenia and antipsychotic action: Journal of psychiatric research, v. 31, no. 2, p. 
219–232. 
Sato, K., Kimoto, M., Kakumoto, M., Horiuchi, D., Iwasaki, T., Tokmakov, A.A., and Fukami, 
Y., 2000, Adaptor protein Shc undergoes translocation and mediates up-regulation of 
the tyrosine kinase c-Src in EGF-stimulated A431 cells: Genes to cells: devoted to 
molecular & cellular mechanisms, v. 5, no. 9, p. 749–764. 
van Schalkwyk, P.C., Geyser, T.L., Récio, M., and Erasmus, F.P., 1979, The anthelmintic 
efficacy of albendazole against gastrointestinal roundworms, tapeworms, lungworms 
Literature 
 211 
and liverflukes in sheep: Journal of the South African Veterinary Association, v. 50, 
no. 1, p. 31–35. 
Schulze, W.X., Deng, L., and Mann, M., 2005, Phosphotyrosine interactome of the ErbB-
receptor kinase family: Molecular systems biology, v. 1, p. 2005.0008, doi: 
10.1038/msb4100012. 
Sebat, J., Levy, D.L., and McCarthy, S.E., 2009, Rare structural variants in schizophrenia: 
one disorder, multiple mutations; one mutation, multiple disorders: Trends in 
genetics: TIG, v. 25, no. 12, p. 528–535, doi: 10.1016/j.tig.2009.10.004. 
Seeman, P., and Lee, T., 1975, Antipsychotic drugs: direct correlation between clinical 
potency and presynaptic action on dopamine neurons: Science (New York, N.Y.), v. 
188, no. 4194, p. 1217–1219. 
Silberberg, G., Darvasi, A., Pinkas-Kramarski, R., and Navon, R., 2006, The involvement of 
ErbB4 with schizophrenia: association and expression studies: American journal of 
medical genetics. Part B, Neuropsychiatric genetics: the official publication of the 
International Society of Psychiatric Genetics, v. 141B, no. 2, p. 142–148, doi: 
10.1002/ajmg.b.30275. 
Sink, R., Gobec, S., Pečar, S., and Zega, A., 2010, False positives in the early stages of drug 
discovery: Current medicinal chemistry, v. 17, no. 34, p. 4231–4255. 
Slichenmyer, W.J., Elliott, W.L., and Fry, D.W., 2001, CI-1033, a pan-erbB tyrosine kinase 
inhibitor: Seminars in oncology, v. 28, no. 5 Suppl 16, p. 80–85. 
Snyder, S.H., 1980, Phencyclidine: Nature, v. 285, no. 5764, p. 355–356. 
St Clair, D., Blackwood, D., Muir, W., Carothers, A., Walker, M., Spowart, G., Gosden, C., 
and Evans, H.J., 1990, Association within a family of a balanced autosomal 
translocation with major mental illness: Lancet, v. 336, no. 8706, p. 13–16. 
Stagljar, I., Korostensky, C., Johnsson, N., and te Heesen, S., 1998, A genetic system based 
on split-ubiquitin for the analysis of interactions between membrane proteins in vivo: 
Proceedings of the National Academy of Sciences of the United States of America, v. 
95, no. 9, p. 5187–5192. 
Stallings-Mann, M., Jamieson, L., Regala, R.P., Weems, C., Murray, N.R., and Fields, A.P., 
2006, A novel small-molecule inhibitor of protein kinase Ciota blocks transformed 
growth of non-small-cell lung cancer cells: Cancer research, v. 66, no. 3, p. 1767–
1774, doi: 10.1158/0008-5472.CAN-05-3405. 
Stefansson, H., Sarginson, J., Kong, A., Yates, P., Steinthorsdottir, V., Gudfinnsson, E., 
Gunnarsdottir, S., Walker, N., Petursson, H., Crombie, C., Ingason, A., Gulcher, J.R., 
Stefansson, K., and St Clair, D., 2003, Association of neuregulin 1 with schizophrenia 
confirmed in a Scottish population: American journal of human genetics, v. 72, no. 1, 
p. 83–87. 
Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, 
S., Brynjolfsson, J., Gunnarsdottir, S., Ivarsson, O., Chou, T.T., Hjaltason, O., 
Birgisdottir, B., Jonsson, H., Gudnadottir, V.G., et al., 2002, Neuregulin 1 and 
Literature 
 212 
susceptibility to schizophrenia: American journal of human genetics, v. 71, no. 4, p. 
877–892, doi: 10.1086/342734. 
Stefánsson, H., Thorgeirsson, T.E., Gulcher, J.R., and Stefánsson, K., 2003, Neuregulin 1 in 
schizophrenia: out of Iceland: Molecular psychiatry, v. 8, no. 7, p. 639–640, doi: 
10.1038/sj.mp.4001384. 
Steurer, J., Bachmann, L.M., and Miettinen, O.S., 2006, Etiology in a taxonomy of illnesses: 
European journal of epidemiology, v. 21, no. 2, p. 85–89, doi: 10.1007/s10654-005-
5925-4. 
Streltsov, S., Oleinikov, V., Ermishov, M., Mochalov, K., Sukhanova, A., Nechipurenko, Y., 
Grokhovsky, S., Zhuze, A., Pluot, M., and Nabiev, I., 2003, Interaction of clinically 
important human DNA topoisomerase I poison, topotecan, with double-stranded 
DNA: Biopolymers, v. 72, no. 6, p. 442–454, doi: 10.1002/bip.10479. 
Stryer,L., Berg,M., Tymoczko, L., 2007 Biochemie, Spektrum Akademischer  
Verlag 
 
Sui, Y., and Wu, Z., 2007, Alternative statistical parameter for high-throughput screening 
assay quality assessment: Journal of biomolecular screening, v. 12, no. 2, p. 229–
234, doi: 10.1177/1087057106296498. 
Sullivan, P.F., Kendler, K.S., and Neale, M.C., 2003, Schizophrenia as a complex trait: 
evidence from a meta-analysis of twin studies: Archives of general psychiatry, v. 60, 
no. 12, p. 1187–1192, doi: 10.1001/archpsyc.60.12.1187. 
Sun, H., Liu, X., Xiong, Q., Shikano, S., and Li, M., 2006, Chronic inhibition of cardiac Kir2.1 
and HERG potassium channels by celastrol with dual effects on both ion conductivity 
and protein trafficking: The Journal of biological chemistry, v. 281, no. 9, p. 5877–
5884, doi: 10.1074/jbc.M600072200. 
Taguchi, T., Wakui, A., Hasegawa, K., Niitani, H., Furue, H., Ohta, K., and Hattori, T., 1990, 
[Phase I clinical study of CPT-11. Research group of CPT-11]: Gan to kagaku ryoho. 
Cancer & chemotherapy, v. 17, no. 1, p. 115–120. 
Takimoto, C.H., and Arbuck, S.G., 1997a, Clinical status and optimal use of topotecan: 
Oncology (Williston Park, N.Y.), v. 11, no. 11, p. 1635–1646; discussion 1649–1651, 
1655–1657. 
Takimoto, C.H., and Arbuck, S.G., 1997b, Clinical status and optimal use of topotecan: 
Oncology (Williston Park, N.Y.), v. 11, no. 11, p. 1635–1646; discussion 1649–1651, 
1655–1657. 
Tandon, R., Keshavan, M.S., and Nasrallah, H.A., 2008a, Schizophrenia, “just the facts” what 
we know in 2008. 2. Epidemiology and etiology: Schizophrenia research, v. 102, no. 
1-3, p. 1–18, doi: 10.1016/j.schres.2008.04.011. 
Tandon, R., Keshavan, M.S., and Nasrallah, H.A., 2008b, Schizophrenia, “Just the Facts”: 
What we know in 2008: Part 1: Overview: Schizophrenia Research, v. 100, no. 1–3, p. 
4–19, doi: 10.1016/j.schres.2008.01.022. 
Literature 
 213 
Tandon, R., Nasrallah, H.A., and Keshavan, M.S., 2009, Schizophrenia, “just the facts” 4. 
Clinical features and conceptualization: Schizophrenia research, v. 110, no. 1-3, p. 1–
23, doi: 10.1016/j.schres.2009.03.005. 
Tandon, R., Nasrallah, H.A., and Keshavan, M.S., 2010, Schizophrenia, “just the facts” 5. 
Treatment and prevention. Past, present, and future: Schizophrenia research, v. 122, 
no. 1-3, p. 1–23, doi: 10.1016/j.schres.2010.05.025. 
Taniguchi, C.M., Emanuelli, B., and Kahn, C.R., 2006, Critical nodes in signalling pathways: 
insights into insulin action: Nature reviews. Molecular cell biology, v. 7, no. 2, p. 85–
96, doi: 10.1038/nrm1837. 
Taveggia, C., Thaker, P., Petrylak, A., Caporaso, G.L., Toews, A., Falls, D.L., Einheber, S., 
and Salzer, J.L., 2008, Type III neuregulin-1 promotes oligodendrocyte myelination: 
Glia, v. 56, no. 3, p. 284–293, doi: 10.1002/glia.20612. 
Taveggia, C., Zanazzi, G., Petrylak, A., Yano, H., Rosenbluth, J., Einheber, S., Xu, X., Esper, 
R.M., Loeb, J.A., Shrager, P., Chao, M.V., Falls, D.L., Role, L., and Salzer, J.L., 2005, 
Neuregulin-1 type III determines the ensheathment fate of axons: Neuron, v. 47, no. 5, 
p. 681–694, doi: 10.1016/j.neuron.2005.08.017. 
Tidcombe, H., Jackson-Fisher, A., Mathers, K., Stern, D.F., Gassmann, M., and Golding, J.P., 
2003, Neural and mammary gland defects in ErbB4 knockout mice genetically 
rescued from embryonic lethality: Proceedings of the National Academy of Sciences 
of the United States of America, v. 100, no. 14, p. 8281–8286, doi: 
10.1073/pnas.1436402100. 
Ting, A.K., Chen, Y., Wen, L., Yin, D.-M., Shen, C., Tao, Y., Liu, X., Xiong, W.-C., and Mei, L., 
2011, Neuregulin 1 promotes excitatory synapse development and function in 
GABAergic interneurons: The Journal of neuroscience: the official journal of the 
Society for Neuroscience, v. 31, no. 1, p. 15–25, doi: 10.1523/JNEUROSCI.2538-
10.2011. 
Towbin, H., Staehelin, T., and Gordon, J., 1992, Electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979: 
Biotechnology (Reading, Mass.), v. 24, p. 145–149. 
Tsai, G., and Coyle, J.T., 2002, Glutamatergic mechanisms in schizophrenia: Annual review 
of pharmacology and toxicology, v. 42, p. 165–179, doi: 
10.1146/annurev.pharmtox.42.082701.160735. 
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B.J., 
and Yarden, Y., 1996, A hierarchical network of interreceptor interactions determines 
signal transduction by Neu differentiation factor/neuregulin and epidermal growth 
factor: Molecular and cellular biology, v. 16, no. 10, p. 5276–5287. 
Uetz, P., and Hughes, R.E., 2000, Systematic and large-scale two-hybrid screens: Current 
opinion in microbiology, v. 3, no. 3, p. 303–308. 
Uhlhaas, P.J., and Singer, W., 2010, Abnormal neural oscillations and synchrony in 




Velanac, V., Unterbarnscheidt, T., Hinrichs, W., Gummert, M.N., Fischer, T.M., Rossner, M.J., 
Trimarco, A., Brivio, V., Taveggia, C., Willem, M., Haass, C., Möbius, W., Nave, K.-A., 
and Schwab, M.H., 2012, Bace1 processing of NRG1 type III produces a myelin-
inducing signal but is not essential for the stimulation of myelination: Glia, v. 60, no. 2, 
p. 203–217, doi: 10.1002/glia.21255. 
Vidal, G.A., Naresh, A., Marrero, L., and Jones, F.E., 2005, Presenilin-dependent gamma-
secretase processing regulates multiple ERBB4/HER4 activities: The Journal of 
biological chemistry, v. 280, no. 20, p. 19777–19783, doi: 10.1074/jbc.M412457200. 
Vigano, D., Guidali, C., Petrosino, S., Realini, N., Rubino, T., Di Marzo, V., and Parolaro, D., 
2009, Involvement of the endocannabinoid system in phencyclidine-induced cognitive 
deficits modelling schizophrenia: The international journal of 
neuropsychopharmacology / official scientific journal of the Collegium Internationale 
Neuropsychopharmacologicum (CINP), v. 12, no. 5, p. 599–614, doi: 
10.1017/S1461145708009371. 
Wehr, M.C., Laage, R., Bolz, U., Fischer, T.M., Grünewald, S., Scheek, S., Bach, A., Nave, 
K.-A., and Rossner, M.J., 2006, Monitoring regulated protein-protein interactions 
using split TEV: Nature methods, v. 3, no. 12, p. 985–993, doi: 10.1038/nmeth967. 
Wehr, M.C., Reinecke, L., Botvinnik, A., and Rossner, M.J., 2008a, Analysis of transient 
phosphorylation-dependent protein-protein interactions in living mammalian cells 
using split-TEV: BMC biotechnology, v. 8, p. 55, doi: 10.1186/1472-6750-8-55. 
Weickert, C.S., Tiwari, Y., Schofield, P.R., Mowry, B.J., and Fullerton, J.M., 2012, 
Schizophrenia-associated HapICE haplotype is associated with increased NRG1 type 
III expression and high nucleotide diversity: Translational Psychiatry, v. 2, no. 4, p. 
e104, doi: 10.1038/tp.2012.25. 
Weisman, J.L., Liou, A.P., Shelat, A.A., Cohen, F.E., Guy, R.K., and DeRisi, J.L., 2006, 
Searching for new antimalarial therapeutics amongst known drugs: Chemical biology 
& drug design, v. 67, no. 6, p. 409–416, doi: 10.1111/j.1747-0285.2006.00391.x. 
Weissmann, C., and Aguzzi, A., 2005, Approaches to therapy of prion diseases: Annual 
review of medicine, v. 56, p. 321–344, doi: 10.1146/annurev.med.56.062404.172936. 
Wen, L., Lu, Y.-S., Zhu, X.-H., Li, X.-M., Woo, R.-S., Chen, Y.-J., Yin, D.-M., Lai, C., Terry, 
A.V., Jr, Vazdarjanova, A., Xiong, W.-C., and Mei, L., 2010, Neuregulin 1 regulates 
pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons: 
Proceedings of the National Academy of Sciences of the United States of America, v. 
107, no. 3, p. 1211–1216, doi: 10.1073/pnas.0910302107. 
Wexler, E.M., and Geschwind, D.H., 2011, DISC1: a schizophrenia gene with multiple 
personalities: Neuron, v. 72, no. 4, p. 501–503, doi: 10.1016/j.neuron.2011.10.023. 
Whalley, H.C., Papmeyer, M., Sprooten, E., Lawrie, S.M., Sussmann, J.E., and McIntosh, 
A.M., 2012, Review of functional magnetic resonance imaging studies comparing 
bipolar disorder and schizophrenia: Bipolar disorders, v. 14, no. 4, p. 411–431, doi: 
10.1111/j.1399-5618.2012.01016.x. 
Williams, C.C., Allison, J.G., Vidal, G.A., Burow, M.E., Beckman, B.S., Marrero, L., and Jones, 
F.E., 2004, The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by 
Literature 
 215 
functioning as a STAT5A nuclear chaperone: The Journal of cell biology, v. 167, no. 3, 
p. 469–478, doi: 10.1083/jcb.200403155. 
Williams, R., Berndt, A., Miller, S., Hon, W.-C., and Zhang, X., 2009, Form and flexibility in 
phosphoinositide 3-kinases: Biochemical Society transactions, v. 37, no. Pt 4, p. 615–
626, doi: 10.1042/BST0370615. 
Williamson, P, 2005, Mind Brain and Schiziophrenia, Oxford University Press 
Winterer, G., Konrad, A., Vucurevic, G., Musso, F., Stoeter, P., and Dahmen, N., 2008, 
Association of 5’ end neuregulin-1 (NRG1) gene variation with subcortical medial 
frontal microstructure in humans: NeuroImage, v. 40, no. 2, p. 712–718, doi: 
10.1016/j.neuroimage.2007.12.041. 
Woo, T.U., Whitehead, R.E., Melchitzky, D.S., and Lewis, D.A., 1998, A subclass of prefrontal 
gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia: 
Proceedings of the National Academy of Sciences of the United States of America, v. 
95, no. 9, p. 5341–5346. 
Xie, M., Yang, D., Wu, M., Xue, B., and Yan, B., 2003, Mouse liver and kidney 
carboxylesterase (M-LK) rapidly hydrolyzes antitumor prodrug irinotecan and the N-
terminal three quarter sequence determines substrate selectivity: Drug metabolism 
and disposition: the biological fate of chemicals, v. 31, no. 1, p. 21–27. 
Yap, T.A., Garrett, M.D., Walton, M.I., Raynaud, F., de Bono, J.S., and Workman, P., 2008, 
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises: Current 
opinion in pharmacology, v. 8, no. 4, p. 393–412, doi: 10.1016/j.coph.2008.08.004. 
Yarden, Y., and Pines, G., 2012, The ERBB network: at last, cancer therapy meets systems 
biology: Nature Reviews. Cancer, v. 12, no. 8, p. 553–563, doi: 10.1038/nrc3309. 
Yarden, Y., and Sliwkowski, M.X., 2001, Untangling the ErbB signalling network: Nature 
reviews. Molecular cell biology, v. 2, no. 2, p. 127–137, doi: 10.1038/35052073. 
Zamboni, W.C., Houghton, P.J., Thompson, J., Cheshire, P.J., Hanna, S.K., Richmond, L.B., 
Lou, X., and Stewart, C.F., 1998, Altered irinotecan and SN-38 disposition after 
intravenous and oral administration of irinotecan in mice bearing human 
neuroblastoma xenografts: Clinical cancer research: an official journal of the 
American Association for Cancer Research, v. 4, no. 2, p. 455–462. 
Zeng, F., Zhang, M.-Z., Singh, A.B., Zent, R., and Harris, R.C., 2007a, ErbB4 isoforms 
selectively regulate growth factor induced Madin-Darby canine kidney cell 
tubulogenesis: Molecular biology of the cell, v. 18, no. 11, p. 4446–4456, doi: 
10.1091/mbc.E07-03-0223. 
Zhang, X.D., 2008, Novel analytic criteria and effective plate designs for quality control in 
genome-scale RNAi screens: Journal of biomolecular screening, v. 13, no. 5, p. 363–
377, doi: 10.1177/1087057108317062. 
Zhang, Chung, and Oldenburg, 1999, A Simple Statistical Parameter for Use in Evaluation 
and Validation of High Throughput Screening Assays: Journal of biomolecular 
screening, v. 4, no. 2, p. 67–73. 
Literature 
 216 
Zhang, X.D., Espeseth, A.S., Johnson, E.N., Chin, J., Gates, A., Mitnaul, L.J., Marine, S.D., 
Tian, J., Stec, E.M., Kunapuli, P., Holder, D.J., Heyse, J.F., Strulovici, B., and Ferrer, 
M., 2008, Integrating experimental and analytic approaches to improve data quality in 
genome-wide RNAi screens: Journal of biomolecular screening, v. 13, no. 5, p. 378–
389, doi: 10.1177/1087057108317145. 
 
